

## Part 2, M-Z

- M**
- Ma BBY, *see* Chan ATC
- Ma BBY, Chan ATC. In Reply (correspondence), 7758
- Ma CX, Nair S, Thomas S, Mandrekar SJ, Nikcevich DA, Rowland KM, Fitch TR, Windschitl HE, Hillman SL, Schild SE, Jett JR, Obasaju C, Adjei AA. Randomized Phase II Trial of Three Schedules of Pemetrexed and Gemcitabine As Front-Line Therapy for Advanced Non-Small-Cell Lung Cancer, 5929
- Ma E, *see* Au WY
- Ma ESK, *see* Chim CS  
*see* Hon C
- Ma J, *see* Chua DTT
- Maadani F, *see* Khouri IF
- Maas CP, *see* Marijnen CAM
- Maas R, *see* Kempf-Bielack B
- Mabbott DJ, Spiegler BJ, Greenberg ML, Rutka JT, Hyder DJ, Bouffet E. Serial Evaluation of Academic and Behavioral Outcome After Treatment With Cranial Radiation in Childhood, 2256
- Macann A, *see* Rischin D
- Macapinlac H, *see* Sasaki R
- Macbeth F, Stephens R, Hoskin P. Radiation Dose in Spinal Cord Compression (correspondence), 8270
- Maccario R, *see* Comoli P
- Macchiarella A, *see* Boccardo F.
- Macdonald JS, *see* Berger AC  
*see* Haller DG  
*see* Poplin EA
- MacDonald N, *see* Menon U
- Mace JR, *see* Chugh R
- Macedo A, *see* Herrinton LJ
- MacGregor-Cortelli B, *see* O'Connor OA
- MacGregore-Cortelli B, *see* Kelly WK
- MacGrogan G, de Maascarel I, Sierankowski G, Mauriac L, Debled M, Durand M, Tunon de Lara C, Avril A, Picot V, Mathoulin-Pélissier S. Time for Reappraisal of Progesterone-Receptor Testing in Breast Cancer Management (correspondence), 2870
- Machin D, *see* Wee J
- Machover D, *see* Ulusakarya A
- Machtay M, *see* Bradley JD  
*see* Ettinger DS  
*see* Movsas B
- Mack JW, Hilden JM, Watterson J, Moore C, Turner B, Grier HE, Weeks JC, Wolfe J. Parent and Physician Perspectives on Quality of Care at the End of Life in Children With Cancer, 9155
- Mack WJ, *see* Meeske KA
- MacKenzie M, *see* Hotte TJ
- MacKenzie MA, *see* van Imhoff GW
- MacKey JR, *see* Verma S
- MacKinlay G, *see* Aronson DC
- Mackinnon S, *see* Tauro S
- Macklis R, *see* Grundy PE
- MacLennan KA, *see* Johnson PWM
- MacLeod C, *see* Hagerty RG
- MacLeod D, *see* Couban S
- MacNeil M, *see* Butts C
- Macon WR, *see* Ghobrial IM
- MacPherson N, *see* Sehn LH
- Macrae FA, *see* Southey MC
- Macro M, *see* Fermand J-P
- Madalinska JB, Hollenstein J, Bleiker E, van Beurden M, Valdimarsdottir HB, Massuger LF, Gaarenstroom KN, Mourits MJE, Verheijen RHM, van Dorst EBL, van der Putten H, van der Velden K, Boonstra H, Aaronson NK. Quality-of-Life Effects of Prophylactic Salpingo-Oophorectomy Versus Gynecologic Screening Among Women At Increased Risk of Hereditary Ovarian Cancer, 6890
- Madero L, *see* Ortega JJ
- Madewell JE, *see* Hamaoka T
- Madhusudan S, Muthuramalingam SR, Braybrooke JP, Wilner S, Kaur K, Han C, Hoare S, Balkwill F, Ganesan TS. Study of Etanercept, a Tumor Necrosis Factor-Alpha Inhibitor, in Recurrent Ovarian Cancer, 5950
- Maeda E, *see* Iwao-Koizumi K
- Maeda M, *see* Igarashi S
- Maestu I, *see* Sastre J
- Maffioli M, *see* Malcovati L
- Maggino T, Gadducci A
- Maggioni A, Gadducci A
- Magherini E, *see* Conroy T  
*see* Scotté F
- Maghfoor I, *see* Akhtar S
- Magnani M, *see* Graziano F
- Magyarosy E, *see* Pession A
- Maharaj D, *see* Baker KS
- Maharry K, *see* Marcucci G
- Mahendra P, *see* Tauro S
- Maher VE, *see* Carbone DP
- Mahfouz T, Micali MH, Saghafifar F, Stroud S, Jones-Jackson L, Walker R, Graziutti ML, Purnell G, Fassas A, Tricot G, Barlogie B, Anaissie E. <sup>18</sup>F-Fluorodeoxyglucose Positron Emission Tomography Contributes to the Diagnosis and Management of Infections in Patients With Multiple Myeloma: A Study of 165 Infectious Episodes, 7857
- Mahoney J, *see* Stadler WM
- Mahoney MR, *see* Alberts SR  
*see* Okuno S  
*see* Philip PA
- Mahoney MR, Sargent DJ, O'Connell MJ, Goldberg RM, Schaefer P, Buckner JC. Dealing With a Deluge of Data: An Assessment of Adverse Event Data on North Central Cancer Treatment Group Trials, 9275
- Mai H-Q, *see* Chua DTT
- Maiello E, *see* Colucci G
- Maiello MR, *see* Normanno N
- Mailliard JA, *see* Sun W  
*see* Witzig TE
- Maingon P, *see* Bosset J-F
- Maione P, Perrone F, Gallo C, Manzione L, Piantedosi F, Barbera S, Cigolari S, Rosetti F, Piazza E, Robbiati SF, Bertetto O, Novello S,

- Migliorino MR, Favaretto A, Spatafora M, Ferrau F, Frontini L, Bearz A, Repetto L, Gridelli C. Pretreatment Quality of Life and Functional Status Assessment Significantly Predict Survival of Elderly Patients With Advanced Non-Small-Cell Lung Cancer Receiving Chemotherapy: A Prognostic Analysis of the Multicenter Italian Lung Cancer in the Elderly Study, 6865
- Maiorana A, *see* Rossi G
- Maiseri H, *see* Lutgendorf SK
- Maisonneuve P, *see* Colleoni M
- Maitra A, *see* Hansel DE
- Majlis A, *see* Ajani JA
- Major P, *see* Coleman RE
- Majunke P, *see* Shimabukuro-Vornhagen A
- Makarski J, *see* Browman GP
- Maker AV, *see* Attia P
- Makhson A, *see* Leyland-Jones B
- Maki RG, *see* D'Adamo DR  
*see* Garcia-Carbonero R  
*see* Kortmansky J  
*see* Traina TA
- Maksymiuk A, *see* Butts C
- Mala C, *see* Brouwers AH
- Malcovati L, Della Porta MG, Pascutto C, Invernizzi R, Boni M, Travaglino E, Passamonti F, Arcaini L, Maffioli M, Bernasconi P, Lazzarino M, Cazzola M. Prognostic Factors and Life Expectancy in Myelodysplastic Syndromes Classified According to WHO Criteria: A Basis for Clinical Decision Making, 7594
- Maldonado A, *see* Pozo-Rodríguez F
- Maldonado J, *see* Zapatero A
- Malhi S, *see* Mekhail TM  
*see* Sup SJ
- Malin JL, Keating NL. The Cost-Quality Trade-Off: Need for Data Quality Standards for Studies That Impact Clinical Practice and Health Policy, 4581
- Malka D, Pacault V, De Baere T, Ducreux M, Boige V. Antitumoral Effect of Celecoxib in Hepatocellular Carcinoma (correspondence), 4805
- Malkin D, *see* Wunder JS
- Malogolowkin M, *see* Grundy PE
- Maloney A, *see* Banerji U
- Maloney DG, *see* Baron F  
*see* Fisher RI  
*see* Sorrow ML  
*see* Treon SP
- Maloney DG. Immunotherapy for Non-Hodgkin's Lymphoma: Monoclonal Antibodies and Vaccines, 6421
- Maltoni M, Caraceni A, Brunelli C, Broeckaert B, Christakis N, Eychmueller S, Glare P, Nabal M, Viganó A, Larkin P, De Conno F, Hanks G, Kaasa S. Prognostic Factors in Advanced Cancer Patients: Evidence-Based Clinical Recommendations—A Study by the Steering Committee of the European Association for Palliative Care, 6240
- Malvey J, *see* Puig S
- Malzoni C, *see* Buda A
- Mamon HJ, Yeap BY, Jänne PA, Reblando J, Shrager S, Jaklitsch MT, Mentzer S, Lukanich JM, Sugarbaker DJ, Baldini EH, Berman S, Skarin A, Bueno R. High Risk of Brain Metastases in Surgically Staged IIIA Non-Small-Cell Lung Cancer Patients Treated With Surgery, Chemotherapy, and Radiation, 1530
- Mamounas EP, *see* Levine MN  
*see* Tan-Chiu E  
*see* Winer EP
- Mamounas EP, Brown A, Anderson S, Julian T, Miller B, Bear HD, Caldwell CB, Walker AP, Mikkelsen WM, Stauffer JS, Robidoux A, Theoret Heather, Fisher B, Wickerham DL, Wolmark N. Sentinel Node Biopsy After Neoadjuvant Chemotherapy in Breast Cancer: Results From National Surgical Adjuvant Breast and Bowel Project Protocol B-27, 2694
- Mamounas EP, Bryant J, Lembersky B, Fehrenbacher L, Sedlacek SM, Fisher B, Wickerham DL, Yothers G, Soran A, Wolmark N. Paclitaxel After Doxorubicin Plus Cyclophosphamide As Adjuvant Chemotherapy for Node-Positive Breast Cancer: Results From NSABP B-28, 3686
- Mamounas EP. Continuing Evolution in Breast Cancer Surgical Management (editorial), 1603
- Man AK, *see* Spector NL
- Manabe A, *see* Igarashi S
- Mandala M, *see* Ferretti G
- Mandalà M, *see* Curigliano G
- Mandalia S, *see* Bower M  
*see* Stebbing J
- Mandel M, *see* Weitzen R
- Mandelblatt J, *see* Kimmick GG
- Mandenhall NP, *see* Gordan LN
- Mandrekar SJ, *see* Ma CX
- Mañé JM, *see* Fernández-Rodríguez R
- Manegold C, *see* Bell DW  
*see* Gridelli C  
*see* van Meerbeeck JP
- Manera R, *see* Nagda SN
- Manganelli A, *see* Boccardo F.
- Mangel L, *see* Schwab R
- Mangham DC, *see* Wunder JS
- Mangiameli DP, *see* Dudley ME
- Mangioni C, *see* Buda A
- Mangum S, *see* Burris HA III  
*see* Spector NL
- Mani A, Gelmann EP. The Ubiquitin-Proteasome Pathway and Its Role in Cancer, 4776
- Manikhas G, *see* Leyland-Jones B
- Mankin HJ, Hornicek FJ, Ortiz-Cruz E, Villafuerte J, Gebhardt MC. Aneurysmal Bone Cyst: A Review of 150 Patients, 6756
- Mann G, *see* Einsiedel HG  
*see* Schellong G
- Mann GB, *see* Lim L
- Mann GB, Buchanan MR. In Reply (correspondence), 8918
- Mann GB, Fahey VD, Feleppa F, Buchanan MR. Reliance on Hormone Receptor Assays of Surgical Specimens May Compromise Outcome in Patients With Breast Cancer, 5148
- Mann JR, *see* Dannenberg AJ
- Mann RB, *see* Keegan THM
- Mannan N, *see* Low JA
- Manne S. Our Invisible Patients (editorial), 7375
- Manne V, *see* Tabernero J
- Manning JA, *see* Tabernero J
- Manning JT, *see* Khouri IF
- Manola J, *see* Garcia-Carbonero R
- Manon R, O'Neill A, Knisely J, Werner-Wasik M, Lazarus HM, Wagner H, Gilbert M, Mehta M. Phase II Trial of Radiosurgery for One to Three Newly Diagnosed Brain Metastases From Renal Cell Carcinoma, Melanoma, and Sarcoma: An Eastern Cooperative Oncology Group Study (E 6397), 8870
- Mansfield P, *see* Petrelli NJ
- Mansfield PF, *see* Ajani JA  
*see* Cormier JN  
*see* Yao JC
- Mansi J, *see* Butts C
- Mansi JL, *see* Evans TRJ
- Mantha S, Jacobs MI, Savage DG. Unusual Leukemia Presentations: Type I IgG $\lambda$  Cryoglobulinemia Associated With Chronic Lymphocytic Leukemia, 5841

## AUTHOR INDEX

- Manuel J, *see* Avis NE
- Manziona L, *see* Colucci G  
*see* Maione P
- Manzitti C, Tomá P, Rizzo A, Gambini C, Garaventa A. Problems in Colon Cancer and a Child With Renal Lymphoma. Mature B-Cell Renal Lymphoma Presenting As a Single Osseous Mass in a Child, 5257
- Manzo J, *see* Wright J
- Manzoni S, *see* Noberasco C
- Maples WJ, *see* Okuno S
- Mar Fan HG, Houédé-Tchen N, Yi Q-L, Chemerynsky I, Downie FP, Sabate K, Tannock IF. Fatigue, Menopausal Symptoms, and Cognitive Function in Women After Adjuvant Chemotherapy for Breast Cancer: 1- and 2-Year Follow-Up of a Prospective Controlled Study, 8025
- Maragoudakis E, *see* Athanassiou H
- Marani SK, *see* Gritz ER
- Maraninchi D, *see* Jourdan E  
*see* Marty M  
*see* van Baren N
- Maranzano E, Bellavita R, Rossi R, De Angelis V, Frattegiani A, Bagnoli R, Mignogna M, Beneventi S, Lupattelli M, Ponticelli P, Biti GP, Latini P. Short-Course Versus Split-Course Radiotherapy in Metastatic Spinal Cord Compression: Results of a Phase III, Randomized, Multicenter Trial, 3358
- Maranzano E, Bellavita R, Rossi R. Radiotherapy Alone or Surgery in Spinal Cord Compression? The Choice Depends on Accurate Patient Selection (correspondence), 8270
- Marasca R, *see* Vallisa D
- Marcellin L, *see* Entz-Werlé N
- Marchand M, *see* van Baren N
- Marchetti A, Barassi F, Felicioni L, Martella C, Salvatore S, Mezzetti A, Cuccurullo F, Buttitta F, Chella A, Campese PP, Iarussi T, Mucilli F, Sacco R. In Reply (correspondence), 5848
- Marchetti A, Martella C, Felicioni L, Barassi F, Salvatore S, Chella A, Campese PP, Iarussi T, Mucilli F, Mezzetti A, Cuccurullo F, Sacco R, Buttitta F. *EGFR* Mutations in Non-Small-Cell Lung Cancer: Analysis of a Large Series of Cases and Development of a Rapid and Sensitive Method for Diagnostic Screening With Potential Implications on Pharmacologic Treatment, 857
- Marchetti M, *see* Massa M
- Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C, Marilus, Villegas A, Tognoni G, Barbui T. Vascular and Neoplastic Risk in a Large Cohort of Patients With Polycythemia Vera, 2224
- Marchioni A, *see* Rossi G
- Marcom PK, *see* Burris HA III  
*see* Miller KD  
*see* Spector NL
- Marcucci G, Baldus CD, Ruppert AS, Radmacher MD, Mrózek K, Whitman SP, Kolitz JE, Edwards CG, Vardiman JW, Powell BL, Baer MR, Moore JO, Perrotti D, Caligiuri MA, Carroll AJ, Larson RA, de La Chapelle A, Bloomfield CD. Overexpression of the ETS-Related Gene, *ERG*, Predicts a Worse Outcome in Acute Myeloid Leukemia With Normal Karyotype: A Cancer and Leukemia Group B Study, 9234
- Marcucci G, Mrózek K, Ruppert AS, Maharry K, Kolitz JE, Moore JO, Mayer RJ, Pettenati MJ, Powell BL, Edwards CG, Sterling LJ, Vardiman JW, Schiffer CA, Carroll AJ, Larson RA, Bloomfield CD. Prognostic Factors and Outcome of Core Binding Factor Acute Myeloid Leukemia Patients with t(8;21) Differ From Those of Patients With inv(16): A Cancer and Leukemia Group B Study, 5705
- Marcucci G, Stock W, Dai G, Klisovic RB, Liu S, Klisovic MI, Blum W, Kefauver C, Sher DA, Green M, Moran M, Maharry K, Novick S, Bloomfield CD, Zwiebel JA, Larson RA, Grever MR, Chan KK, Byrd JC. Phase I Study of Oblimersen Sodium, an Antisense to Bcl-2, in Untreated Older Patients With Acute Myeloid Leukemia: Pharmacokinetics, Pharmacodynamics, and Clinical Activity, 3404
- Marcuello E, *see* Sastre J
- Marcus BH, *see* Pinto BM
- Marcus R, *see* Pappo AS
- Margolin KA, *see* McDermott DF
- Margolis J, *see* Bolaños-Meade J
- Maria del Campo J, *see* Tabertero J
- Mariani G, *see* Gianni L
- Mariani L, *see* Bajetta E  
*see* Ferrari A  
*see* Fiore M  
*see* Gronchi A
- Mariette X, *see* Femand J-P
- Marijnen CAM, *see* Nagtegaal ID  
*see* Peeters KCMJ
- Marijnen CAM, van de Velde CJH, Putter G, van den Brink M, Maas CP, Martijn H, Rutten HJ, Wiggers T, Kranenbarg EK, Leer J-WH, Stiggelbout AM. Impact of Short-Term Preoperative Radiotherapy on Health-Related Quality of Life and Sexual Functioning in Primary Rectal Cancer: Report of a Multicenter Randomized Trial, 1847
- Marilus C, *see* Marchioli R
- Marimón I, *see* Baselga J  
*see* Tabertero J
- Marina N, Meyers PA. High-Dose Therapy and Stem-Cell Rescue for Ewing's Family of Tumors in Second Remission (editorial), 4262
- Marion S, *see* Kondagunta GV  
*see* Ronnen EA
- Mariotti J, *see* Corradini P
- Maris JM, *see* George RE  
*see* London WB  
*see* Schmidt ML
- Maris MB, *see* Baron F  
*see* Sorrow ML
- Marit G, *see* Jourdan E
- Markman M. Chemosensitivity and Chemoresistance Testing (correspondence), 7363
- Markman M. Use of Positron Emission Tomography Scans in Ovarian Cancer: A Diagnostic Technique in Search of an Indication (editorial), 7385
- Marks DI, *see* Baker KS
- Marks JR, *see* Petros WP
- Marks LB, *see* Peters WP  
*see* Prosnitz RG
- Marks PA, *see* Kelly WK
- Marks RS, *see* Niell HB
- Markus P, *see* Liersch T
- Markwalder R, *see* Fleischmann A
- Marolla P, *see* Papaldo P
- Maroto P, *see* Aparicio J
- Marsan S, *see* Scotté F
- Marsden D, *see* Paramasivan S
- Marsden HB, *see* Stevens MCG
- Marsh J, *see* Tauro S
- Marshall E, *see* Butts C
- Marshall GM, *see* Laughton SJ
- Marshall JL, Gulley JL, Arlen PM, Beetham PK, Tsang K-Y, Slack R, Hodge JW, Doren S, Grosenbach DW, Hwang J, Fox E, Odogwu L, Park S, Panicali D, Schlom J. Phase I Study of Sequential Vaccinations with Fowlpox-CEA(6D)-TRICOM Alone and Sequentially With Vaccinia-CEA(6D)-TRICOM, With and Without Granulocyte-Macrophage Colony-Stimulating Factor, in Patients With Carcinoembryonic Antigen-Expressing Carcinomas, 720
- Marsili S, *see* Correale P
- Marsoni S, *see* Sessa C
- Martel CL, *see* Lara PN Jr

AUTHOR INDEX

- Martel-Lafay I, *see* Arpin D  
 Martella C, *see* Marchetti A  
 Martelli H, *see* Stevens MCG  
 Martelli MF, *see* Aversa F  
 Martelli MP, *see* Aversa F  
 Martí JL, *see* Hitt R  
 Marti R, *see* Puig S  
 Martijn H, *see* Marijnen CAM  
     *see* Peeters KCMJ  
 Martin-Aresti J, *see* Montalbán C  
 Martín de Nicolás JL, *see* Pozo-Rodríguez F  
 Martín-Escribano P, *see* Pozo-Rodríguez F  
 Martín G, *see* Ortega JJ  
 Martín-García I, *see* Pozo-Rodríguez F  
 Martín J, Poveda A, Llombart-Bosch A, Ramos R, López-Guerrero JA, García del Muro J, Maurel J, Calabuig S, Gutiérrez A, González de Sande JL, Martínez J, De Juan A, Laínez N, Losa F, Alija V, Escudero P, Casado A, García P, Blanco R, Buesa JM. Deletions Affecting Codons 557–558 of the *c-KIT* Gene Indicate a Poor Prognosis in Patients With Completely Resected Gastrointestinal Stromal Tumors: A Study by the Spanish Group for Sarcoma Research (GEIS), 6190  
 Martin JAL, *see* Faivre S  
 Martin PJ, *see* Syrjala KL  
 Martin S, *see* Lenz G  
 Martin WG, Ristow KM, Habermann TM, Colgan JP, Witzig TE, Ansell SM. Bleomycin Pulmonary Toxicity Has a Negative Impact on the Outcome of Patients With Hodgkin's Lymphoma, 7614  
 Martin WMC, *see* Rudd RM  
 Martinelli G, *see* Laszlo D  
     *see* Soverini S  
 Martinelli G, Laszlo D, Ferreri AJM, Pruneri G, Ponzoni M, Conconi A, Crosta C, Pedrinis E, Bertoni F, Calabrese L, Zucca E. Clinical Activity of Rituximab in Gastric Marginal Zone Non-Hodgkin's Lymphoma Resistant to or Not Eligible for Anti-*Helicobacter Pylori* Therapy, 1979  
 Martínez B, *see* Espinosa E  
 Martínez J, *see* Martín J  
 Martínez SR, *see* Mori T  
 Martínez-Trufero J, *see* Hitt R  
 Martinka M, *see* Dai DL  
 Martino R, *see* Moreno C  
 Martino S, *see* Davidson NE  
     *see* Hutchins LF  
     *see* Whelan TJ  
 Martone L, *see* Galsky MD  
 Martorana G, *see* Boccardo F  
 Martus P, *see* Rödel C  
 Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, Chan S, Grimes D, Antón A, Lluch A, Kennedy J, O'Byrne K, Conte PF, Green M, Ward C, Mayne K, Extra J-M. Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study Group, 4265  
 Masciari S, Garber JE. Quality or Quantity in the Management of Hereditary Ovarian Cancer Risk: Is It Really a Trade-Off? (editorial), 6817  
 Masera G, *see* Pession A  
 Masiello D, *see* Koon HB  
 Mass R, *see* Herbst RS  
     *see* Kabbinarav FF  
 Mass RD, *see* Kabbinarav FF  
 Massa M, Rosti V, Ramajoli I, Campanelli R, Pecci A, Viarengo G, Meli V, Marchetti M, Hoffman R, Barosi G. Circulating CD34<sup>+</sup>, CD133<sup>+</sup>, and Vascular Endothelial Growth Factor Receptor 2-Positive Endothelial Progenitor Cells in Myelofibrosis with Myeloid Metaplasia, 5688  
 Massard C, *see* Andre F  
 Mâsse B, *see* Dorval M  
     *see* Drolet M  
 Massidda B, *see* Boccardo F  
 Massimini G, *see* Lønning PE  
 Massimino M, *see* Ferrari A  
 Masso O, *see* Giaccone G  
 Masson E, *see* Thomas AL  
 Massuger LF, *see* Madalinska JB  
 Massuti B, *see* Ramirez JL  
 Mastrangelo MJ, *see* Berd D  
 Masutti B, *see* Sastre J  
 Matakidou A, *see* Popat S  
 Matera J, *see* Cristofanilli M  
 Mathew P, Fidler IJ, Bucana C. In Reply (correspondence), 133  
 Mathews CS, *see* Kirsch DG  
 Mathieu-Daudé H, *see* Ray-Coquard I  
 Mathieu M-C, *see* Guibout C  
     *see* Rouzier R  
 Mathieu MC, *see* Andre F  
 Mathijssen RHJ, *see* de Jong FA  
 Mathoulin-Pélissier S, *see* MacGrogan G  
 Matin K, *see* Lalani M  
 Matkovic JJ, *see* Raval A  
 Matloff E, *see* Rebbbeck TR  
 Matoba R, *see* Iwao-Koizumi K  
 Matsubara H, *see* Mizutani Y  
 Matsubara T, *see* Morita T  
 Matsuno Y, *see* Takano T  
 Matsuo K, *see* Hotta K  
 Matsuo K, Hotta K, Ueoka H. They Also Serve Who Only Stand and Wait: Do Individual Clinical Researchers, Too? Hoping for Individual Patient Data As Public Domain (correspondence), 1334  
 Matsuyama RK. Genuine Encounters: Responses to Death, 1583  
 Matsuzaki H, Kobayashi H, Yagyu T, Wakahara K, Kondo T, Kurita N, Sekino H, Inagaki K, Suzuki M, Kanayama N, Terao T. Plasma Bikunin As a Favorable Prognostic Factor in Ovarian Cancer, 1463  
 Mattar B, *see* Burtness B  
 Matthay KK, *see* London WB  
     *see* Schmidt ML  
 Mattioli M, *see* Agnelli L  
     *see* Vacca A  
 Mattko A, *see* Carli M  
 Mattson I, *see* Astrow AB  
 Mattsson JE, *see* Colleoni M  
 Mauch C, *see* Kaufmann R  
 Mauch P, *see* Adams MJ  
 Maudelonde T, *see* Rouanet P  
 Maunsell E, *see* Dorval M  
     *see* Drolet M  
 Maurel J, *see* Martín J  
     *see* Sastre J  
 Maurer MJ, *see* Galanis E  
     *see* Ghobrial IM  
 Mauriac L, *see* MacGrogan G  
     *see* Marty M  
 Mavroukakis SA, *see* Attia P  
     *see* Dudley ME  
 Maxwell J, *see* Quinn JA  
 May M, *see* Behringer K  
 Mayano J, *see* Bruera E  
 Maydar M, *see* Ulusakarya A  
 Mayer RJ, *see* Berger AC  
     *see* Farag SS

## AUTHOR INDEX

- see* Haller DG  
*see* Marcucci G  
*see* Poplin EA
- Mayer S, Cypess AM, Kocher ON, Berman SM, Huberman MS, Hartzband PI, Halmos B. Uncommon Presentations of Some Common Malignancies: Sequential Paraneoplastic Endocrine Syndromes in Small-Cell Lung Cancer, 1312
- Mayerson J, *see* Morrison C
- Mayne K, *see* Marty M
- Mayo N, *see* Gagnon B
- Mazabel E, *see* Bissett D
- Mazewski C, *see* Geyer JR
- Mazumdar M, *see* Akhurst T  
*see* Guillem JG  
*see* Huang H-Y
- Mazzaro C, Spina M, Tirelli U. Regression of Low-Grade Non-Hodgkin's Lymphoma After Treatment With Pegylated Interferon Plus Ribavirin in Hepatitis C Virus Infection (correspondence), 4470
- Mazzarol G, *see* Colleoni M
- Mazzi B, *see* Ferreri AJM
- Mazzolini G, Alfaro C, Sangro B, Feijó E, Ruiz J, Benito A, Tirapu I, Arina A, Sola J, Herraiz M, Lucena F, Olagüe C, Subtil J, Quiroga J, Herrero I, Sádaba B, Bendani M, Qian C, Prieto J, Melero I. Intratumoral Injection of Dendritic Cells Engineered to Secrete Interleukin-12 by Recombinant Adenovirus in Patients With Metastatic Gastrointestinal Carcinomas, 999
- Mbaoma R, *see* Gaba A
- McArthur GA, Demetri GD, van Oosterom A, Heinrich MC, Debiec-Rychter D, Corless CL, Nikolova Z, Dimitrijevic S, Fletcher JA. Molecular and Clinical Analysis of Locally Advanced Dermatofibrosarcoma Protuberans Treated With Imatinib: Imatinib Target Exploration Consortium Study B2225, 866
- McBride R, *see* Hershman D
- McCabe M, *see* Basch E
- McCaffery K, *see* McKoy JM
- McCaffrey KR, *see* Wolf MS
- McCarthy P, *see* Czuczman MS  
*see* Pavletic SZ
- McCarty M, *see* Hainsworth JD
- McCaskill-Stevens W, McKinney MM, Whitman CG, Minasian LM. Increasing Minority Participation in Cancer Clinical Trials: The Minority-Based Community Clinical Oncology Program Experience, 5247
- McCaughan BC, *see* Fulham MJ
- McClement S, *see* Chochinov JM
- McCleod M, *see* Kabbavar FF
- McClure B, *see* Rischin D
- McColl S, *see* Vanderwerker LC
- McCoy J, *see* Hirsch FR  
*see* Williamson SK
- McCredie MRE, *see* Phillips K-A
- McCulloch T, *see* Robbins KT
- McCully C, *see* Blaney SM
- McDermott DF, *see* Floyd SR
- McDermott DF, Atkins MB, Regan MM. In Reply (correspondence), 6798
- McDermott DF, Regan MM, Clark JIH, Flaherty LE, Weiss GR, Logan TF, Kirkwood JM, Gordon MS, Sosman JA, Ernstoff MS, Tretter CPG, Urba WJ, Smith JW, Margolin KA, Mier JW, Gollob JA, Dutcher JP, Atkins MB. Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma, 133
- McDermott DF, Regan MM. In Reply (correspondence), 6268
- McDonald RA, *see* Gross TG
- McDonnell TJ, *see* Bueso-Ramos C
- McGhee RB Jr, *see* Hricak H
- McGinn CJ, *see* Worden FP
- McGinn S, *see* Lutgendorf SK
- McGlynn KA, Devesa SS, Graubard BI, Castle PE. Increasing Incidence of Testicular Germ Cell Tumors Among Black Men in the United States, 5757
- McGratten M, *see* Miles SA
- McGreevey L, *see* Corless CL
- McGregor CG, *see* Ghobrial IM
- McGuire SE, *see* Gonzalez-Angulo A
- McGuire WP. CA-125 and Early Ovarian Cancer: Does This Help the Clinician or Further Muddy the Water? (editorial), 5862
- McGuire WP III. Perioperative Morbidity and the Rush to Chemotherapy (editorial), 665
- McIntosh L, *see* Dark GG
- McKenna A, *see* Canil CM
- McKenzie P, *see* Joshua AM
- McKinney MM, *see* McCaskill-Stevens W
- McKoy JM, *see* Wolf MS
- McKoy JM, Lyons EA, Obadina E, Carson K, Pickard AS, Schellhammer P, McLeod D, Boyd CE, McWilliams N, Sartor O, Schumock GT, McCaffery K, Bennett CL. Caveat Medicus: Consequences of Federal Investigations of Marketing Activities of Pharmaceutical Supplies of Prostate Cancer Drugs, 8894
- McLachlan SA, *see* Yates P
- McLaughlin P, *see* Goy A  
*see* Khouri IF  
*see* Romaguera JE
- McLaughlin WP, *see* Miller DC
- McLean JM, *see* Fulham MJ
- McLean TW, Fisher CJ, Snively BM, Chauvenet AR. Central Venous Lines in Children With Lesser Risk Acute Lymphoblastic Leukemia: Optimal Type and Timing of Placement, 3024
- McLelland R, *see* Koomen M
- McLendon RE, *see* Quinn JA  
*see* Reardon DA
- McLennan J, *see* Powell CB
- McLeod D, *see* McKoy JM  
*see* Sharma R  
*see* Zhou P
- McLeod DG, *see* Stewart AJ
- McLeod HL, *see* Walgren RA
- McMeekin DS, *see* Chan JK  
*see* Long HJ III
- McNeal JE, *see* Patel DA
- McNeel T, *see* Bellizzi KM
- McNeil DE, *see* Bowers DC
- McNicol E, Carr DB. In Reply (correspondence), 2443
- McNiff KK, *see* Neuss MN
- McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting Recommendations for Tumor Marker Prognostic Studies, 9067
- McShane TM, *see* Liu G
- McSweeney P, *see* Sorrow ML
- McTiernan A, *see* Irwin ML
- McWatters K-L, *see* Chang J
- McWilliams N, *see* McKoy JM
- Mead GM, *see* Jones WG
- Mead L, *see* Southey MC
- Meadows AT, *see* Perkins JL
- Meazza C, *see* Ferrari A
- Mecucci C, *see* Aversa F
- Medeiros LJ, *see* Romaguera JE
- Medina P, *see* Goodin S
- Medio F, *see* Ferreira MR

AUTHOR INDEX

- Meeske KA, Siegel SE, Globe DR, Mack WJ, Bernstein L. Prevalence and Correlates of Fatigue in Long-Term Survivors of Childhood Leukemia, 5501
- Meguid MM, *see* Laviano A
- Mehta M, *see* Belani CP  
*see* Cloughesy TF  
*see* Manon R
- Mehta MP, *see* Langer CJ
- Meijer-van Gelder ME, *see* Jansen MPH
- Meinardi MT, *see* Nuver J
- Meinders AE, *see* van Rooden CJ
- Meisenberg B, *see* Badros AZ
- Meiser B, *see* Thewes B
- Mekhail TM, Abou-Jawde RM, BouMerhi G, Malhi S, Wood L, Elson P, Bukowski R. Validation and Extension of the Memorial Sloan-Kettering Prognostic Factors Model for Survival in Patients With Previously Untreated Metastatic Renal Cell Carcinoma, 832
- Melakopoulos I, *see* Bamias A
- Melemed AS, Mockbee C, Orlando M. Comprehensive Review of Chemotherapy in Patients With Metastatic Breast Cancer (correspondence), 8139
- Melero I, *see* Mazzolini G
- Meli V, *see* Massa M
- Melian E, *see* Nagda SN
- Melillo G, *see* Ryan QC
- Mellado B, *see* Aparicio J
- Mellano D, *see* Nathan SS
- Meller J, *see* Liersch T
- Melloul M, *see* Stojadinovic A
- Melnick AM, Adelson K, Licht JD. The Theoretical Basis of Transcriptional Therapy of Cancer: Can It Be Put Into Practice? 3957
- Melucci MT, Ascierto PA
- Memoll V, *see* Dragnev KH
- Ménard S, Pupa SM, Campiglio M, Taglibue E, Balsari A, Fagnoni F, Costa A. Apoptosis Induction by Trastuzumab: Possible Role of the Core Biopsy Intervention (correspondence), 7238
- Menda Y, *see* Juweid ME
- Mendelson DS, *see* Agus DB
- Mendiola C, *see* Colleoni M  
*see* Colomer R
- Mendrzyk F, Radlwimmer B, Joos S, Kokocinski F, Benner A, Stange DE, Neben K, Fiegler H, Carter NP, Reifemberger G, Korshunov A, Lichter P. Genomic and Protein Expression Profiling Identifies CDKG As Novel Independent Prognostic Marker in Medulloblastoma, 8853
- Menetrier-Caux C, *see* Negrier S
- Mennel R, *see* Jones SE  
*see* Muss HB
- Menon U, Skates SJ, Lewis S, Rosenthal AN, Rufford B, Sibley K, MacDonald N, Dawnay A, Jeyarajah A, Bast RC Jr, Oram D, Jacobs IJ. Prospective Study Using the Risk of Ovarian Cancer Algorithm to Screen for Ovarian Cancer, 7919
- Mentha G, *see* Poston GJ
- Mentzer S, *see* Mamon HJ
- Mercadante S, Ferrera P, Villari P, Casuccio A. Rapid Switching Between Transdermal Fentanyl and Methadone in Cancer Patients, 5229
- Mercadante S. Looking for the Role of NSAIDs in Cancer Pain (correspondence), 2442
- Merchant T, *see* Fouladi M
- Merchant TE, *see* Krasin MJ  
*see* Mulhern RK  
*see* Tekautz TM
- Mercier J-P, *see* Bairati I
- Mercier R, *see* Bissett D
- Mercuri M, *see* Ferrari S
- Mergenthaler H-G, *see* Köhne C-H
- Merkle E, *see* von Minckwitz G
- Merli F, *see* Gobbi PG
- Merlini G, *see* Baldini L
- Meropol NJ, *see* Cohen SJ
- Meropol NJ. Epidermal Growth Factor Receptor Inhibitors in Colorectal Cancer: It's Time to Get Back on Target (editorial), 1791
- Mertens A, *see* Emmons KM
- Mertens AC, *see* Castellino SM  
*see* Park ER  
*see* Perkins JL
- Mertens D, *see* Kienle DL
- Merx H, *see* Arndt V
- Mesiti M, *see* Boccardo F
- Metges J-P, *see* Conroy T
- Metzger ML, *see* Krasin MJ
- Metzner B, *see* Lenz G
- Meucci MA, *see* Walgren RA
- Meuth M, *see* Catto JWF
- Mey U, *see* Tasci S
- Meyer F, *see* Bairati I
- Meyer H-J, *see* Stahl M
- Meyer J, *see* Weber RW
- Meyer MB, *see* LoRusso PM
- Meyer RG, *see* van Baren N
- Meyer RM, Gospodarowicz MK, Connors JM, Pearcey RG, Bezjak A, Wells WA, Burns BF, Winter JN, Horning SJ, Dar AR, Djurfeldt MS, Ding K, Shepherd LE. Randomized Comparison of ABVD Chemotherapy With a Strategy That Includes Radiation Therapy in Patients With Limited-Stage Hodgkin's Lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group, 4634
- Meyer RM, Gospodarowicz MK, Connors JM, Pearcey RG, Shepherd LE. In Reply (correspondence), 8915
- Meyer U, *see* Seidemann K
- Meyerhardt JA, Fuchs CS. In Reply (correspondence), 650
- Meyerhardt JA, Heseltine D, Campos H, Holmes MD, Willet WC, Winer EP, Enginger PC, Bunnell CA, Kulke MH, Fuchs CS. Assessment of a Dietary Questionnaire in Cancer Patients Receiving Cytotoxic Chemotherapy, 8453
- Meyerowitz BE, *see* Stanton AL
- Meyers ML, *see* Jones SE
- Meyers P, *see* Huang H-Y
- Meyers PA, *see* Marina N
- Meyers PA, Krailo M, Grier H, Bernstein M. In Reply (correspondence), 6438
- Meyers PA, Schwartz CL, Krailo M, Kleinerman ES, Betcher D, Bernstein ML, Conrad E, Ferguson W, Gebhardt M, Goorin AM, Harris MB, Healey J, Huvas A, Link M, Montebello J, Nadel H, Nieder M, Sato J, Siegal G, Weiner M, Wells R, Wold L, Womer R, Grier H. Osteosarcoma: A Randomized, Prospective Trial of the Addition of Ifosfamide and/or Muramyl Tripeptide to Cisplatin, Doxorubicin, and High-Dose Methotrexate, 2004
- Meyerson M, Carbone D. Genomic and Proteomic Profiling of Lung Cancers: Lung Cancer Classification in the Age of Targeted Therapy, 3219
- Meyskens FL Jr, Hietanen P, Tannock IF. Talking to a Patient, 4463
- Mezetti A, *see* Marchetti A
- Mezzetti A, *see* Marchetti A
- Mian S, Ugurel S, Parkinson E, Schlenzka I, Dryden I, Lancashire L, Ball G, Creaser C, Rees R, Schadendorf D. Serum Proteomic Fingerprinting Discriminates Between Clinical Stages and Predicts Disease Progression in Melanoma Patients, 5088
- Miceli MH, *see* Mahfouz T  
*see* Talamo G

## AUTHOR INDEX

- Miceli R, *see* Fiore M  
*see* Gronchi A
- Michael M, *see* Lim L
- Michael M, Doherty MM. Tumoral Drug Metabolism: Overview and Its Implications for Cancer Therapy, 205
- Michaelis LC, *see* Stadler WM
- Michaelson JS, *see* Livestro DP
- Micheel S, *see* Thuss-Patience PC
- Michel P, *see* Conroy T
- Micheli L, *see* Correale P
- Michiels S, Koscielny S
- Michon J, *see* Cecchetto G  
*see* Valteau-Couanet D
- Mickisch GHJ, *see* Aass N
- Mielcarek M, *see* Baron F
- Mieler W, *see* Chévez-Barrios P
- Mier JW, *see* McDermott DF
- Migaldi M, *see* Rossi G
- Migliorino MR, *see* Maione P
- Mignogna M, *see* Maranzano E
- Mihm MC Jr, *see* Livestro DP
- Mikami K, *see* Mizutani Y
- Mikhael J, *see* Jaksic W
- Miki T, *see* Mizutani Y
- Mikkelsen WM, *see* Mamounas EP
- Milà M, *see* Puig S
- Milan C, *see* Barbare J-C
- Miles SA, McGratten M. Persistent Panhypogammaglobulinemia After CHOP-Rituximab for HIV-Related Lymphoma (correspondence), 247
- Milford R, *see* Mori T
- Milicić B, *see* Jeremić B
- Milicic B, *see* Jeremic B
- Milislavljević S, *see* Jeremić B
- Milislavljevic S, *see* Jeremic B
- Milito CB, *see* Spector N
- Millan JM-S, *see* Montalban C
- Millar K, *see* Purushotham AD
- Miller A, *see* Dressler LG
- Miller AA, *see* Lilenbaum RC  
*see* Niell HB
- Miller B, *see* Mamounas EP
- Miller C, *see* Feldman EJ
- Miller DC, *see* Geyer JR
- Miller DC, Sanda MG, Dunn RL, Montie JE, Pimentel H, Sandler HM, McLaughlin WP, Wei JT. Long-Term Outcomes Among Localized Prostate Cancer Survivors: Health-Related Quality-of-Life Changes After Radical Prostatectomy, External Radiation, and Brachytherapy, 2772
- Miller DS, *see* Long HJ III
- Miller KD, *see* Schneider BP
- Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, Dickler M, Overmoyer BA, Reimann JD, Sing AP, Langmuir V, Rugo HS. Randomized Phase III Trial of Capecitabine Compared with Bevacizumab Plus Capecitabine in Patients with Previously Treated Metastatic Breast Cancer, 792
- Miller MC, *see* Cristofanilli M
- Miller TE, *see* Koon HB
- Miller TP, *see* Czuczman MS  
*see* Fisher RI
- Miller TP, Grogan TM. In Reply (correspondence), 9030
- Miller VA, *see* Eberhard DA  
*see* Herbst RS  
*see* Pao W  
*see* Shah NT
- Miller VA, Hirsch FR, Johnson DH. Systemic Therapy of Advanced Bronchioloalveolar Cell Carcinoma: Challenges and Opportunities, 3288
- Millham R, *see* Ribas A
- Milligan D, *see* Staszynski J  
*see* Tauro S
- Millikan RE, *see* Leibovici D
- Mills B, *see* Romet-Lemonne J-L
- Mills G, *see* Spitz MR
- Mills GM, *see* Williamson SK
- Millward M, *see* Giaccone G
- Millward MJ, *see* Chan ATC
- Milne RL, *see* Honrado E  
*see* Phillips K-A
- Milowsky MI, *see* Bander NH
- Milroy R, *see* Brown J
- Min H-Q, *see* Chua DTT
- Minami H, *see* Kohno N
- Minami H. A Point, a Line, or an Area? Which Is the Most Important in the Pharmacological Analysis of Cancer Chemotherapy? (editorial), 405
- Minasian LM, *see* Buchanan DR  
*see* McCaskill-Stevens W
- Mineau G, *see* Florell SR
- Mineur L, *see* Bosset J-F
- Ming ME, *see* Gimotty PA
- Mininberg E, *see* Herbst RS
- Minischetti M, *see* Montemurro F
- Minna JD, *see* Carbone DP
- Mino-Kenudson M, *see* Willett CG
- Minsky B, *see* Petrelli NJ
- Minsky BD, *see* Desch CE  
*see* Guillem JG  
*see* Rengan R  
*see* Suntharalingam M
- Mintzer DM, Chmielewski L. On the Deluge of Unsubscribed Medical Oncology Information (correspondence), 4806
- Mirimanoff R-O, *see* Azria D
- Mirkovic N, *see* Farray D
- Mirolo B, *see* Yates P
- Misailidou D, *see* Athanassiou H
- Mischer P, *see* Richtig E
- Misino A, *see* Colucci G
- Misra SC, *see* Ulusakarya A
- Mitby PA, *see* Bowers DC  
*see* Perkins JL
- Mitchell BS, *see* Kurtzberg J  
*see* Muss HB
- Mitchell DG, *see* Hricak H
- Mitchell DY, *see* LoRusso PM
- Mitchell JB, *see* Camphausen K
- Mitra N, *see* Basch E
- Mitrou PS, *see* Rummel MJ
- Mitry E, *see* Lutz MP
- Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hhida T, Mori S, Hatooka S, Shinoda M, Takahashi T, Yatabe Y. Mutations of the Epidermal Growth Factor Receptor Gene Predict Prolonged Survival After Gefitinib Treatment in Patients With Non-Small-Cell Lung Cancer With Postoperative Recurrence, 2513
- Miura S, *see* Noguchi S
- Mixalopoulou P, *see* Georgoulis V
- Miyamoto H, *see* Yokote T
- Miyoshi Y, *see* Iwao-Koizumi K
- Mizutani Y, Nakanishi H, Yamamoto K, Li YN, Matsubara H, Mikami K, Okihara K, Kawachi A, Bonavida B, Miki T. Downregulation of Smac/

- DIABLO Expression in Renal Cell Carcinoma and Its Prognostic Significance, 448
- MMiller K, *see* Lehmann J
- Mo F, *see* Mok TSK
- Mocco J, *see* Komotar RJ
- Moch H, *see* Lardinois D
- Mockbee C, *see* Melemed AS
- Modak S, *see* Kushner BH
- Mody DR, *see* Austin RM
- Moeslein G, *see* Bian Y
- Mohammed N, *see* Morrison C
- Mohindra M, *see* Raja V
- Mohr A, *see* Czuczman MS
- Mohsin S, *see* Chang JC
- Mohsin SK, *see* Gutierrez MC
- Mohsin SK, Weiss HL, Gutierrez MC, Chamness GC, Schiff R, DiGiovanna MP, Wang C-X, Hilsenbeck SG, Osborne CK, Allred DC, Elledge R, Chang JC. Neoadjuvant Trastuzumab Induces Apoptosis in Primary Breast Cancers, 2460
- Moingeon P, *see* van Baren N
- Moinpour CM, *see* Donaldson GW
- Moiseyenko VM, *see* Ajani JA
- Moisio A-L, *see* Ollikainen M  
*see* Renkonen ET
- Mok TSK, Yeo W, Yu S, Lai P, Chan HLY, Chan ATC, Lau JWY, Wong H, Leung N, Hui EP, Sung J, Koh J, Mo F, Zee B, Johnson PJ. An Intensive Surveillance Program Detected a High Incidence of Hepatocellular Carcinoma Among Hepatitis B Virus Carriers With Abnormal Alpha-Fetoprotein Levels or Abdominal Ultrasonography Results, 8041
- Moldavy J, *see* Schwab R
- Molina A, *see* Bhatia R  
*see* Pavletic SZ
- Molina A, Zain J, Arber DA, Angelopolou M, O'Donnell M, Murata-Collins J, Forman SJ, Nademanee A. Durable Clinical, Cytogenetic, and Molecular Remissions After Allogeneic Hematopoietic Cell Transplantation for Refractory Sezary Syndrome and Mycosis Fungoides, 6163
- Molina J-M, *see* Boulanger E
- Molina L, *see* Jourdan E
- Molines A, *see* Ortega JJ
- Moller P, *see* Eisen A
- Møller P, *see* Stormorken AT
- Molokhia P, *see* Taghian AG
- Monclair T, *see* Cecchetto G
- Mondor M, *see* Dorval M
- Mone SM, *see* Lipshultz SE
- Monetti F, *see* Tiseo M
- Monfardini S, *see* Ardizzoni A
- Monga M, *see* Ryan QC
- Monk BJ, *see* Lanciano R  
*see* Wenzel L
- Monk BJ, Huang HQ, Cella D, Long HJ III. Quality of Life Outcomes From a Randomized Phase III Trial of Cisplatin With or Without Topotecan in Advanced Carcinoma of the Cervix: A Gynecologic Oncology Group Study, 4617
- Montagna C, *see* Ghadimi BM
- Montagu C, Grau JJ, Grimalt R, Codony J, Ferrando J, Albanell J. Abnormal Hair Growth in a Patient With Head and Neck Cancer Treated With the Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab (correspondence), 5273
- Montalban C, Martin-Aresti J, Patier JL, Millan JM-S, Cosio MG. Unusual Cases in Multiple Myeloma and a Dramatic Response in Metastatic Lung Cancer. Intracranial Plasmacytoma With Cranial Nerve Neuropathy in Multiple Myeloma, 233
- Montebello J, *see* Meyers PA
- Montefiore F, *see* Boccardo F.
- Montefusco V, *see* Vacca A
- Monteiro-Grillo I, *see* Ravasco P
- Montell L, *see* Lara PN Jr
- Montella L, *see* Caraglia M
- Montemurro F, Faggiuolo R, Redana S, Donadio M, Minischette M, Durando A, Vietti-Ramus G, Buosi R, Aglietta M. Continuation of Trastuzumab Beyond Disease Progression (correspondence), 2866
- Montie JE, *see* Miller DC
- Montone KT, *see* Gimotty PA
- Montoto S, *see* López-Guillermo A
- Montserrat E, *see* López-Guillermo A  
*see* Moreno C  
*see* Pavletic SZ
- Montserrat E. Treatment of Chronic Lymphocytic Leukemia: Achieving Minimal Residual Disease—Negative Status As a Goal (editorial), 2884
- Mool W, *see* Luiten RM
- Moon J, *see* Urba SG
- Mooney M, *see* Harlan LC
- Moore C, *see* Mack JW
- Moore D II, *see* DiGiovanna MP
- Moore DH, *see* Lanciano R
- Moore HG, *see* Guillem JG
- Moore J, *see* Feldman EJ
- Moore JO, *see* Czuczman MS  
*see* Farag SS  
*see* Marcucci G
- Moore L, *see* Chan S
- Moore MJ, *see* Canil CM  
*see* Knox JJ  
*see* von der Maase H
- Morabito F, *see* Agnelli L
- Morain C, *see* Lara PN Jr
- Morais JC, *see* Spector N
- Morakkabati-Spitz N, *see* Kuhl CK
- Morales S, *see* Baseiga J
- Moran CA, *see* Sasaki R
- Moran M, *see* Marcucci G
- Moran T, *see* Ramirez JL
- Morandi P, *see* Altundag K  
*see* Gonzalez-Angulo A  
*see* Gonzalez-Angulo AM
- Morandi U, *see* Rossi G
- Morant R, *see* Chan S
- Morat L, *see* Dômont J
- Moreau D, *see* Thiéry G
- Morel P, *see* Baldini L
- Moreno C, Montserrat E. In Reply (correspondence), 8127
- Moreno C, Villamor N, Colomer D, Esteve J, Martino R, Nomdedéu J, Bosch F, López-Guillermo A, Campo E, Sierra J, Montserrat E. Allogeneic Stem-Cell Transplantation May Overcome the Adverse Prognosis of Unmutated *VH* Gene in Patients With Chronic Lymphocytic Leukemia, 3433
- Moreton P. In Reply (correspondence), 7241, 8123
- Moreton P, Kennedy B, Lucas G, Leach M, Rassam SMB, Haynes A, Tighe J, Oscier D, Fegan C, Rawstron A, Hillmen P. Eradication of Minimal Residual Disease in B-Cell Chronic Lymphocytic Leukemia After Alemtuzumab Therapy Is Associated With Prolonged Survival, 2971
- Morgan B, *see* Thomas AL
- Morgan G, *see* Augustson BM  
*see* Greipp PR
- Morgan-Meadows SL, *see* Rothenberg ML
- Morgan PB, Chundru S, Hatch SS, Hawkins HK, Adegboyega PA, Eltorkey

## AUTHOR INDEX

- MA. Uncommon Malignancies. Low-Grade Myofibroblastic Sarcoma of the Breast, 6249
- Morgner A, *see* Wündisch T
- Mori M, *see* Garzotto M
- Mori S, *see* Mitsudomi T
- Mori T, O'Day SJ, Umetani N, Martinez SR, Kitago M, Koyanagi K, Kuo C, Takeshima T-L, Milford R, Wang H-J, Vu VD, Nguyen SL, Hoon DSB. Predictive Utility of Circulating Methylated DNA in Serum of Melanoma Patients Receiving Biochemotherapy, 9351
- Moriarty AT, *see* Austin RM
- Morich J, *see* Corless CL
- Morin CM, *see* Savard J
- Morita T, Akechi T, Ikenaga M, Kizawa Y, Kohara H, Mukaiyama T, Nakaho T, Nakashima N, Shima Y, Matsubara T, Uchitomi Y. Late Referrals to Specialized Palliative Care Service in Japan, 2637
- Mornex F, *see* Fournel P
- Moroni C, *see* Vallisa D
- Moroni M, *see* Comoli P
- Morra E, *see* Baldini L
- Morris CD, *see* Nathan SS
- Morris G, *see* Issa J-PJ
- Morris J, *see* Ajani JA
- Morris T, *see* Collette L
- Morris WJ, *see* Lukka H
- Morrison C, Radmacher M, Mohammed N, Suster D, Auer H, Jones S, Riggenbach J, Kelbick N, Bos G, Mayerson J. MYC Amplification and Polysomy 8 in Chondrosarcoma: Array Comparative Genomic Hybridization, Fluorescent In Situ Hybridization, and Association With Outcome, 9369
- Morrison G, *see* Grem JL
- Morrison PJ, *see* Bian Y
- Morrissey LH, *see* Hainsworth JD
- Morrow M, *see* Katz SJ
- Morschhauser F, *see* Feugier P  
*see* Schnell R
- Morse M, *see* Kemeny N
- Mortimer JE, *see* Muss HB
- Morton DL, *see* Kang JC
- Morton RF, *see* Galanis E  
*see* Witzig TE
- Mosca S, *see* Verso M
- Moschel RC, *see* Quinn JA
- Moschos SJ, Land S, Kirkwood JM. In Reply (correspondence), 2431
- Moskowitz C, *see* O'Connor OA
- Mossbacher U, *see* Richtig E
- Mosseri V, *see* Cecchetto G  
*see* Oyharcabal-Bourden V
- Mott LA, *see* Ahles TA
- Mottaghy FM, *see* Juweid ME
- Motzer RJ, *see* Kondagunta GV  
*see* Ronnen EA  
*see* Stephenson AJ
- Moughan J, *see* Suntharalingam M
- Moul JW, *see* Cooperberg MR  
*see* Stewart AJ  
*see* Zhou P
- Moul JW. In Reply (correspondence), 1322
- Moulopoulos LA, *see* Bamias A
- Mourey L, *see* Chevreau C
- Mouridsen H, *see* Knoop AS
- Mourits MJE, *see* Madalinska JB  
*see* Reesink-Peters N
- Movsas B, *see* Ettinger DS
- Movsas B, Scott C, Langer C, Werner-Wasik M, Nicolaou N, Komaki R, Machtay M, Smith C, Axelrod R, Sarna L, Wasserman T, Byhardt R. Randomized Trial of Amifostine in Locally Advanced Non-Small-Cell Lung Cancer Patients Receiving Chemotherapy and Hyperfractionated Radiation: Radiation Therapy Oncology Group Trial 98-01, 2145
- Movsas B, Scott C, Langer C, Werner-Wasik M, Nicolaou N, Machtay M, Smith C, Axelrod R, Sarna L, Wasserman T, Byhardt R. In Reply (correspondence), 7233
- Movsas B. Will Future Progress in Non-Small-Cell Lung Cancer Be Step by Step... or by Leaps and Bounds? (editorial), 5859
- Moy B, *see* Burstein HJ
- Moynihan T, Kelly DG, Fisch MJ. To Feed or Not to Feed: Is That the Right Question? 6256
- Moynihan TJ, *see* Ryan M
- Mross K, *see* Chan S
- Mrózek K, *see* Farag SS  
*see* Marcucci G
- Mrsic-Krmpotic Z, *see* Zielinski C
- Mucilli F, *see* Marchetti A
- Muckaden MA, *see* Laskar S
- Muderspach L, *see* Ell K
- Mueller A, *see* Ruhstaller T
- Mueser M, *see* Chan ATC
- Muggia F, *see* Muss HB
- Muggia FM, *see* Hamilton AL
- Muir B, *see* Bell DW
- Mukaiyama T, *see* Morita T
- Mulder AA, *see* van Doorn R
- Mulder NH, *see* Nieboer P  
*see* Westra JL
- Mulders P, *see* Aass N
- Mulders PFA, *see* Brouwers AH  
*see* Patard J-J
- Müldner A, *see* Hofheinz R-D
- Mulhern R, *see* Beebe DW  
*see* Fouladi M
- Mulhern RK, Palmer SL, Merchant TE, Wallace D, Kocak M, Brouwers P, Krull K, Chintagumpala M, Stargatt R, Ashley DM, Tyc VL, Kun L, Boyett J, Gajjar A. Neurocognitive Consequences of Risk-Adapted Therapy for Childhood Medulloblastoma, 5511
- Mullamitha S, *see* Jayson GC
- Müller C, *see* Ferrari S
- Müller-Hermelink K, *see* Engert A
- Müller L, *see* Köhne C-H
- Müller R-P, *see* Josting A
- Mulshine JL. New Developments in Lung Cancer Screening, 3198
- Munn LL, *see* Willett CG
- Muñoz A, *see* Fernández-Rodríguez R
- Munsell M, *see* Romet-Lemonne J-L
- Munsell MF, *see* Frumovitz M
- Munson PJ, *see* Petricoin EF III
- Muntañola A, *see* López-Guillermo A
- Murakami H, *see* Yamamoto N
- Muramatsu M, *see* Kanazawa S
- Murat A, *see* Amar L
- Murata-Collins J, *see* Molina A
- Murgo A, *see* Berg SL  
*see* Hotte SJ  
*see* Ryan QC
- Murgo AJ, *see* Hotte SJ
- Murphy B, *see* Gibson MK
- Murphy R, *see* Blaney SM
- Murphy SB, *see* Laver JH
- Murray E, *see* Colleoni M
- Murray N, *see* Butts C

- see Ho C  
 see Singh S  
 Murray R, *see* Smith MR  
 Murry T, *see* Gimotty PA  
 Musa D, *see* Trauth JM  
 Muscas G, *see* Boccardo F  
 Muss D, *see* Leonard JP  
 Muss H, *see* Dressler LG  
 Muss HB, *see* Kimmick GG  
   *see* Warr DG  
   *see* Whelan TJ  
 Muss HB. In Memoriam. Byrl James Kennedy MD, 3297  
 Muss HB, Von Roenn J, Damon LE, Deangelis LM, Flaherty LE, Harari PM, Kelly K, Kosty MP, Loscalzo MJ, Mennel R, Mitchell BS, Mortimer JE, Muggia F, Perez EA, Pisters PWT, Saltz L, Schapira L, Sparano J. ACCO: ASCO Core Curriculum Outline, 2049  
 Mussi C, *see* Fiore M  
 Muthuramalingam SR, *see* Madhusudan S  
 Muzikansky A, *see* Livestro DP  
 Muzzy J, *see* O'Connor OA  
 Myerson ML, *see* Cho D  
 Mykletun A, Dahl AA, Haaland CF, Bremnes R, Dahl O, Klepp O, Wist E, Fosså SD. Side Effects and Cancer-Related Stress Determine Quality of Life in Long-Term Survivors of Testicular Cancer, 3061  
 Myles JP, *see* Purushotham AD
- N**
- Nabal M, *see* Maltoni M  
 Nabhan C, Bitran JD. Chronic Lymphocytic Leukemia: To Transplant or Not to Transplant. . . That Is the Question? (correspondence), 8126  
 Nabhan C. Should We Transplant Indolent Lymphoma? (correspondence), 6263  
 Nabid A, *see* Bairati I  
   *see* Choy H  
 Nadaf S, *see* Carbone DP  
 Nadel H, *see* Meyers PA  
 Nadella P, *see* Eisenbeis CF  
 Nademanee A, *see* Bhatia R  
   *see* Molina A  
 Nadler LM, *see* Brown JR  
 Naehrig J, *see* Amendola MA  
   *see* Avril N  
 Næsted J, *see* Boesen EH  
 Nafa K, *see* Bian Y  
 Naftalis EZ, *see* Patterson AR  
 Nagaria NC, Cogswell J, Choe JK, Kasimis B. Side Effects and Good Effects From New Chemotherapeutic Agents. Gefitinib-Induced Interstitial Fibrosis, 2423  
 Nagase M, *see* Kawashima M  
 Nagawa H, *see* Watanabe T  
 Nagda SN, Lo SS, Melian E, Manera R, Emami B. Unusual Thoracic Problems in Patients With Malignancies. Neuroblastoma Presenting With Intracardiac Tumor Thrombus, 2856  
 Nagel S, *see* Schuette W  
 Nagengast FM, *see* van Kouwen MCA  
 Naglieri E, *see* Verso M  
 Nagourney R. Chemosensitivity and Resistance Assays: A Systematic Review? (correspondence), 3640  
 Nagtegaal ID, van de Velde CJH, Marijnen CAM, van Krieken JHJM, Quirke P. Low Rectal Cancer: A Call for a Change of Approach in Abdominoperineal Resection—The Pathology Review Committee and the Cooperative Clinical Investigators of the Dutch Colorectal Cancer Group, 9257  
 Naidoo K, *see* Townsley C  
 Nair MK, *see* Ibrahim NK  
 Nair S, *see* Alberts SR  
   *see* Jatoi A  
   *see* Ma CX  
 Najam A, *see* Yao JC  
 Nakagawara A, *see* Gotoh T  
 Nakaho T, *see* Morita T  
 Nakamichi I, *see* Sakane-Ishikawa E  
 Nakamura S, *see* Kohno N  
 Nakanishi H, *see* Mizutani Y  
 Nakano J, *see* Huang C-I  
 Nakashima N, *see* Morita T  
 Nakatusuka S-i, *see* Sakane-Ishikawa E  
 Nam SJ, *see* Rhee J-Y  
 Namer M, *see* Bonnetterre J  
 Nanjo H, *see* Okada K  
 Nantel SH, *see* Forrest DL  
 Nanus DM, *see* Bander NH  
 Napp V, *see* Brown J  
 Narod SA, *see* Eisen A  
   *see* Rebbeck TR  
 Narod SA, Offit K. Prevention and Management of Hereditary Breast Cancer, 1656  
 Nasca S, *see* Conroy T  
 Nasi ML, *see* Gruber G  
 Nasti G, Tirelli U. Highly Active Antiretroviral Therapy in AIDS-Associated Kaposi's Sarcoma (KS): Implications for the Design of Therapeutic Trials in Patients With Advanced Symptomatic KS (correspondence), 2433  
 Natale RB, *see* Agus DB  
   *see* Cella D  
 Natarajan L, *see* Rock CL  
 Nathan SS, Healey JH, Mellano D, Hoang B, Lewis I, Morris CD, Athanasian EA, Boland PJ. Survival in Patients Operated on for Pathologic Fracture: Implications for End-of-Life Orthopedic Care, 6072  
 Nathwani BN, *see* Lim S-T  
   *see* Lim ST  
 Nattam S, *see* Kindler HL  
 Nattinger AB. Variation in the Choice of Breast-Conserving Surgery or Mastectomy: Patient or Physician Decision Making? (editorial), 5429  
 Naume B, *see* Braun S  
 Nava ME, *see* Cheewakriangkrai R  
 Navarro M, *see* Sastre J  
 Nayak S, Pradhan JPB, Reddy S, Palmer JL, Zhang T, Bruera E. Cancer Patients' Perception of the Quality of Communication Before and After the Implementation of a Communication Strategy in a Regional Cancer Center in India, 4771  
 Neal-Ferguson D, *see* Trauth JM  
 Neben K, *see* Mendrzyk F  
 Neckers L, *see* Grem JL  
 Needle M, *see* Robert F  
 Needle MN, *see* Thienelt CD  
 Neeman Z, *see* Pingpank JF  
 Neglia JP, *see* Perkins JL  
 Negrier S, *see* Keilholz U  
 Négrier S, *see* van Baren N  
 Negrier S, Perol D, Menetrier-Caux C, Blay J-Y, Escudier B. In Reply (correspondence), 1044  
 Neise M, *see* Rummel MJ  
 Nelson B, *see* Kabbavar FF  
 Nelson DW, *see* Le Q-T  
 Nelson M, *see* Bower M  
   *see* Stebbing J  
 Nematollahi M, *see* Knox JJ

AUTHOR INDEX

- Nencini C, *see* Correale P  
 Neri A, *see* Agnelli L  
   *see* Vacca A  
 Neubauer A, *see* Lenz G  
   *see* Wündisch T  
 Neuberger D, *see* Brown JR  
 Neuberger DS, *see* Anderson JR  
 Neuenschwander S, *see* Cecchetto G  
   *see* Oyharcabal-Bourden V  
 Neugut AI, *see* Hershman D  
 Neugut I, *see* Doyle JJ  
 Neuhausen SL, *see* Eisen A  
   *see* Rebeck TR  
 Neumann TA, *see* Vogel CL  
 Neuss MN, Desch CE, McNiff KK, Eisenberg PD, Gesme DH, Jacobson JO, Jahanzeb M, Padberg JJ, Rainey JM, Guo JJ, Simone JV. A Process for Measuring the Quality of Cancer Care: The Quality Oncology Practice Initiative, 6233  
 Neuwelt E, *see* Shankier TN  
 Neuwelt EA, *see* Abrey LE  
   *see* Knight KRG  
 Nevanlinna H, *see* Honrado E  
 Nevill TJ, *see* Forrest DL  
 Neville BA, *see* Steyerberg EW  
 Newling D, *see* Collette L  
 Newman LA, *see* Kuerer HM  
 Newman LA, Kuerer HM. Advances in Breast Conservation Therapy, 1685  
 Newman VA, *see* Rock CL  
 Newsom-Davis T, *see* Bower M  
 Newton RU, *see* Galvão DA  
 Ng C, *see* Liu G  
 Ng TY, *see* Chan YW  
 Ngan HYS, *see* Chan YW  
 Ngan RKC, *see* Lee AWM  
 Nguyen D, *see* Karlin JD  
 Nguyen DT, *see* Floyd JD  
 Nguyen PL, Chakravarti A, Finkelstein DM, Hochberg FH, Batchelor TT, Loeffler JS. Results of Whole-Brain Radiation As Salvage of Methotrexate Failure for Immunocompetent Patients With Primary CNS Lymphoma, 1507  
 Nguyen SL, *see* Mori T  
 Niccoll-Sire P, *see* Amar L  
 Nichol G, *see* Attia P  
   *see* Sanderson K  
 Nicholson AG, *see* Travis WD  
 Nicholson J, *see* Vandesomepe J  
 Nickening C, *see* Hiddemann WL  
 Nicklin J, *see* Paramasivan S  
 Nico B, *see* Vacca A  
 Nicolaou N, *see* Movsas B  
 Nicolson M, *see* Bissett D  
 Nieboer P, Buijs C, Rodenhuis S, Seynaeve C, Beex LVAM, van der Wall E, Richel DJ, Nooij MA, Voest EE, Hupperets P, Mulder NH, van der Graaf WTA, TenVergert EM, van Tinteren H, de Vries EGE. Fatigue and Relating Factors in High-Risk Breast Cancer Patients Treated With Adjuvant Standard or High-Dose Chemotherapy: A Longitudinal Study, 8296  
 Nieder M, *see* Meyers PA  
 Niell HB, Herndon JE II, Miller AA, Watson DM, Sandler AB, Kelly K, Marks RS, Perry MC, Ansari RH, Otterson G, Ellerton J, Vokes EE, Green MR. Randomized Phase III Intergroup Trial of Etoposide and Cisplatin With or Without Paclitaxel and Granulocyte Colony-Stimulating Factor in Patients With Extensive-Stage Small-Cell Lung Cancer: Cancer and Leukemia Group B Trial 9732, 3752  
 Nielsen JN, *see* Jakobsen A  
 Nielsen KV, *see* Knoop AS  
 Nielsen OS, *see* Le Cesne A  
 Nieminen P, *see* Renkonen ET  
 Niesvizky R, *see* Leonard JP  
 Niethammer D, *see* Koscielniak E  
 Nieto M, *see* Salar A  
 Nihei K, *see* Kawashima M  
 Nijhuis CO, Kamps WA, Daenen SMG, Gietema JA, van der Graaf WTA, Groen HJM, Vellenga E, ten Vergert EM, Vermeulen KM, de Vries-Hospers HG, de Bont ESJM. Feasibility of Withholding Antibiotics in Selected Febrile Neutropenic Cancer Patients, 7437  
 Nijman HW, *see* Reesink-Peters N  
 Nikcevich DA, *see* Ma CX  
 Nikolova Z, *see* McArthur GA  
 Nilsson BN, *see* Prochazka M  
 Nilsson J, *see* Praga C  
 Nishio K, *see* Yamamoto N  
 Nishio T, *see* Kawashima M  
 Nissan A, *see* Stojadinovic A  
 Nistico C, *see* Ferretti G  
 Nistico C, *see* Papaldo P  
 Nitsch T, *see* Schmid P  
 Nivers R, *see* Ajani JA  
 Noberasco C, *see* DePas T  
   *see* Sessa C  
 Noberasco C, De Pas T, Curigliano G, Manzoni S, Dodaro L, Pelosi G, Spaggiari L, De Braud F. Immunohistochemical Detection of HER1/HER2 Can Be Considered a Predictive Marker of Gefitinib Activity in Non-Small-Cell Lung Cancer? (correspondence), 921  
 Noel P, *see* Kreitman RJ  
 Nogova L, *see* Behringer K  
 Nogová L, *see* Josting A  
 Noguchi M, *see* Travis WD  
 Noguchi S, *see* Iwao-Koizumi K  
 Noguchi S, Koyama H, Uchino J, Abe R, Miura S, Sugimachi K, Akazawa K, Abe O. Postoperative Adjuvant Therapy With Tamoxifen, Tegaruf Plus Uraclil, or Both in Women With Node-Negative Breast Cancer: A Pooled Analysis of Six Randomized Controlled Trials, 2172  
 Noguera R, *see* Combaret V  
 Nokihara H, *see* Takano T  
   *see* Yamamoto N  
 Nomdedéu J, *see* Moreno C  
 Nomoto N, *see* Ogose A  
 Nomura S, *see* Kanazawa S  
 Nooij MA, *see* Nieboer P  
 Nooijen WJ, *see* Luiten RM  
 Noordijk EM, *see* Kramer GWPM  
 Nordenskjöld B, *see* Rydén L  
 Nordlinger B, *see* Bilchik AJ  
   *see* Köhne C-H  
   *see* Lutz MP  
   *see* Poston GJ  
 Norén T, *see* Stormorken AT  
 Norkool P, *see* Tomlinson GE  
 Normanno N, De Luca A. In Reply (correspondence), 3866  
 Normanno N, De Luca A, Maiello MR, Gridelli C. Modulation of Epidermal Growth Factor Receptor-Positive Circulating Tumor Cells by Chemotherapy in Non-Small-Cell Lung Cancer Patients (correspondence), 7746  
 Normanno N. Gefitinib and Cisplatin-Based Chemotherapy in Non-Small-Cell Lung Cancer: Simply a Bad Combination? (correspondence), 928  
 Normolle D, *see* Ben-Josef E

- Norris CM Jr, *see* Wirth LJ  
 Norris MD, *see* Laughton SJ  
 Nortier JWR, *see* Jansen SJT  
 Norton L, *see* Dressler LG  
   *see* Peters WP  
   *see* Sartor CI  
 Nosov D, *see* Arpin D  
 Novello S, *see* Maione P  
 Novick S, *see* Marcucci G  
 Novick SC, *see* O'Brien SM  
 Novo A, *see* Ortega JJ  
 Novotny D, *see* Dressler LG  
 Novotny PJ, *see* Witzig TE  
 Novotny WF, *see* Hurwitz HI  
   *see* Kabbinavar FF  
 Nowak M, *see* Borgwardt L  
 Noy A, *see* Schöder H  
 Noy A, Scadden DT, Lee J, Dezube BJ, Aboulafia D, Tulpule A, Walmsley S, Gill P. Angiogenesis Inhibitor IM862 Is Ineffective Against AIDS-Kaposi's Sarcoma in a Phase III Trial, but Demonstrates Sustained, Potent Effect of Highly Active Antiretroviral Therapy: From the AIDS Malignancy Consortium and IM862 Study Team, 990  
 Noy A, Yahalom J, Zaretsky L, Brett I, Zelenetz AD. Gastric Mucosa-Associated Lymphoid Tissue Lymphoma Detected by Clonotypic Polymerase Chain Reaction Despite Continuous Pathologic Remission Induced by Involved-Field Radiotherapy, 3768  
 Noyes RD, *see* Florell SR  
 Nupponen NN, *see* Sihto H  
 Nuver J, Smit AJ, van der Meer J, van den Berg MP, van der Graaf WTA, Meinardi MT, Sleijfer DT, Hoekstra HJ, van Gessel AI, van Roon AM, Gietema JA. Acute Chemotherapy-Induced Cardiovascular Changes in Patients With Testicular Cancer, 9130  
 Nuver J, Smit AJ, Wolffenbuttel BHR, Sluiter WJ, Hoekstra HJ, Sleijfer DT, Gietema JA. The Metabolic Syndrome and Disturbances in Hormone Levels in Long-Term Survivors of Disseminated Testicular Cancer, 3718  
 Nygren P, *see* Sandström M  
 Nyhus C, *see* Subdø J  
 Nyman DW, Campbell KJ, Hersh E, Long K, Richardson K, Trieu V, Desai N, Hawkins MJ, Von Hoff DD. Phase I and Pharmacokinetics Trial of ABI-007, a Novel Nanoparticle Formulation of Paclitaxel in Patients With Advanced Nonhematologic Malignancies, 7785
- O**
- O SK, *see* Lee AWM  
 Oakes LL, *see* Hinds PS  
 Obadina E, *see* McKoy JM  
 Obasaju C, *see* Ma CX  
 Obedian E, *see* Ahn PH  
 Oberlin O, *see* Guibout C  
   *see* Orbach D  
   *see* Stevens MCG  
 Obermair A, *see* Paramasivan S  
 Obralic N, *see* Rades D  
 O'Brien P, *see* Shankier TN  
 O'Brien S, *see* Cortes J  
   *see* Keating MJ  
   *see* Wierda W  
 O'Brien SM, Cunningham CC, Golenkov AK, Turkina AG, Novick SC. Phase I and II Multicenter Study of Oblimersen Sodium, a Bcl-2 Antisense Oligonucleotide, in Patients With Advanced Chronic Lymphocytic Leukemia, 7697  
 O'Byrne K, *see* Marty M  
 O'Byrne KJ, *see* Bissett D  
   *see* Le Q-T  
   *see* Welsh TJ  
 O'Callaghan CJ, *see* Sargent DJ  
 Ocana A, *see* Gonzalez-Angulo A  
 Ochs JS, *see* Bell DW  
   *see* Cella D  
 O'Connell M, *see* Sargent DJ  
 O'Connell MJ, *see* Mahoney MR  
 O'Connell MJ. Combined-Modality Neoadjuvant Therapy for Rectal Cancer (editorial), 5450  
 O'Connell MJ, Wolmark N, Beart R, Petrelli N. Update on Design of the National Surgical Adjuvant Breast and Bowel Project Trial R-04 (correspondence), 933  
 O'Connell P, *see* Chang JC  
 O'Connor DM, *see* Lanciano R  
 O'Connor J, *see* Feldman EJ  
 O'Connor LC, *see* Ayanian JZ  
 O'Connor OA, *see* Kelly WK  
 O'Connor OA. Targeting Histones and Proteasomes: New Strategies for the Treatment of Lymphoma, 6429  
 O'Connor OA, Wright J, Moskowitz C, Muzzy J, MacGregor-Cortelli B, Stubblefield M, Straus D, Portlock C, Hamlin P, Choi E, Dumetrescu O, Esseltine D, Trehu E, Adams J, Schenkein D, Zelenetz AD. Phase II Clinical Experience With the Novel Proteasome Inhibitor Bortezomib in Patients with Indolent Non-Hodkin's Lymphoma and Mantle Cell Lymphoma, 676  
 O'Day S, *see* Weber RW  
 O'Day SJ, *see* Koyanagi K  
   *see* Mori T  
 Odenike O, *see* van Besien K  
 Odogwu L, *see* Marshall JL  
 O'Donnell A, *see* Banerji U  
 O'Donnell M, *see* Bhatia R  
   *see* Molina A  
 Oeffinger KC, *see* Bowers DC  
   *see* Castellino SM  
 Offit K, *see* Eisen A  
   *see* Garber JE  
   *see* Narod SA  
 Øfjord ES, *see* Lønning PE  
 Ogden A, *see* Bolaños-Meade J  
 Ogino T, *see* Kawashima M  
 Ogose A, Kawashima H, Hotta T, Endo N, Umezu H, Nomoto N. Conditions Suggesting Lymphoma. Primary Synovial Lymphoma With Osteoclast-Like Giant Cells Presenting As a Tenosynovial Giant-Cell Tumor, 3847  
 Oh D-Y, *see* Han S-W  
 Oh SW, Yoon YS, Shin S-A. Effects of Excess Weight on Cancer Incidences Depending on Cancer Sites and Histologic Findings Among Men: Korea National Health Insurance Corporation Study, 4742  
 Oh WK, *see* Galsky MD  
 Ohara A, *see* Igarashi S  
 Ohashi Y, *see* Kohno N  
 Ohe Y, *see* Takano T  
   *see* Yamamoto N  
 Ohira M, *see* Gotoh T  
 Öhrling K, Edler D, Hallström M, Ragnhammar P, Blomgren H. Detection of Thymidylate Synthase Expression in Lymph Node Metastases of Colorectal Cancer Can Improve the Prognostic Information, 5628  
 Ohta M, *see* Hamada C  
 Oka S, *see* Yokote T  
 Okada K, Sasaki M, Nanjo H, Ito M, Takahashi S, Itoi E. Benign Lesions in Cancer Patients. Unusual Association of Osteosarcoma and Sarcoidosis, 641

## AUTHOR INDEX

- Okihara K, *see* Mizutani Y
- Okimoto RA, *see* Bell DW
- Okimoto Y, *see* Igarashi S
- Okoroji G-J, *see* Khouri IF
- Oksenhendler E, *see* Boulanger E
- Oktay K, Buyuk E, Libertella N, Akar M, Rosenwaks Z. Fertility Preservation in Breast Cancer Patients: A Prospective Controlled Comparison of Ovarian Stimulation With Tamoxifen and Letrozole for Embryo Cryopreservation, 4347
- Oktay K. Further Evidence on the Safety and Success of Ovarian Stimulation With Letrozole and Tamoxifen in Breast Cancer Patients Undergoing In Vitro Fertilization to Cryopreserve Their Embryos for Fertility Preservation (correspondence), 3858
- Okuno S, Maples WJ, Mahoney MR, Fitch T, Stewart J, Fracasso PM, Kraut M, Ettinger DS, Dawkins F, Erlichman C. Evaluation of Epothilone B Analog in Advanced Soft Tissue Sarcoma: A Phase II Study of the Phase II Consortium, 3069
- Olagüe C, *see* Mazzolini G
- Oldervoll L, *see* Hjermstad MJ
- O'Leary M, *see* Schmidt ML
- Oleson JR, *see* Jones EL
- Olgac S, *see* Kelly WK
- Olipitz W, *see* Sill H
- Oliver T, *see* Shamash J  
*see* von der Maase H
- Olivieri A, *see* Corradini P
- Olivotto IA, *see* Panades M
- Olivotto IA, Bernstein V, Truong PT, Kelly JS. In Reply (correspondence), 932
- Olivotto IA, Truong PT, Bernstein V, Kelly JK. In Reply (correspondence), 3869
- Olivotto TA, *see* Panades M
- Ollikainen M, Abdel-Rahman WM, Moisio A-L, Lindroos A, Kariola R, Järvelä I, Pöyhönen M, Butzow R, Peltomäki P. Molecular Analysis of Familial Endometrial Carcinoma: A Manifestation of Hereditary Non-polyposis Colorectal Cancer or a Separate Syndrome? 4609
- Olmi P, *see* Fiore M  
*see* Gronchi A
- Olmos D, *see* Aparicio J
- Olopade OI, *see* Lynch HT  
*see* Rebbeck TR
- Olsen KE, *see* Knoop AS
- Olsen S, *see* Jones SE
- O'Mahoney D, Kummar S, Gutierrez ME. Non-Small-Cell Lung Cancer Vaccine Therapy: A Concise Review, 9022
- O'Mara A. Who's Taking Care of the Caregiver? (editorial), 6820
- O'Mara AM, *see* Buchanan DR
- O'Meara A, *see* Vandesompele J
- Onat H, *see* Basaran G
- O'Neil B, *see* Burris HA III  
*see* Spector NL
- O'Neill A, *see* Manon R
- O'Neill AM, *see* Davidson NE
- O'Neill BP, *see* Abrey LE  
*see* Shankier TN  
*see* Tu P-h
- Onelöv E, *see* Kreicbergs U
- Onida F, *see* Praga C
- Onilude OE, *see* Ellison DW
- Onn A, *see* Herbst RS
- Onozawa M, Hashino S, Sogabe S, Haneda M, Horimoto H, Izumiyama K, Kondo T, Aldana LP, Hamada K, Asaka M. Side Effects and Good Effects From New Chemotherapeutic Agents. Thalidomide-Induced Interstitial Pneumonitis, 2425
- Ooi GC, *see* Chim CS
- Oosterkamp HM, *see* Hannemann J
- Oosterwijk E, *see* Brouwers AH
- Oosting J, *see* Sieben NLG
- Oram D, *see* Menon U
- Oram DH, *see* Rockall AG
- Orbach D, Rey A, Oberlin O, de Toledo JS, Terrier-Lacombe MJ, van Unnik A, Quintana E, Stevens MCG. Soft Tissue Sarcoma or Malignant Mesenchymal Tumors in the First Year of Life: Experience of the International Society of Pediatric Oncology (SIOP) Malignant Mesenchymal Tumor Committee, 4363
- O'Reilly E, *see* Schwartz GK
- O'Reilly E, *see* Kortmansky J
- O'Reilly S, *see* Hussein MAH  
*see* Sehn LH
- Oreskovich K, *see* Schwab R
- Orlando M, *see* Melemed AS
- Orntoft TF, *see* Eschrich S
- O'Rourke MA, *see* Haller DG
- Ortega JJ, Madero L, Martín G, Verdeguer A, Garcia P, Parody R, Fuster J, Molines A, Novo A, Debén G, Rodríguez A, Conde E, de la Serna J, Allegue MJ, Capote JF, González JD, Bolufer P, González M, Sanz MA. Treatment with All-*Trans* Retinoic Acid and Anthracycline Monotherapy for Children With Acute Promyelocytic Leukemia: A Multicenter Study by the PETHEMA Group, 7632
- Ortiz-Cruz E, *see* Mankin HJ
- Osanto S, *see* van Baren N
- Osborne CK, *see* Arpino G  
*see* Chang JC  
*see* Cui X  
*see* Davidson NE  
*see* Fuqua SAW  
*see* Gutierrez MC  
*see* Hutchins LF  
*see* Mohsin SK  
*see* Pierce LJ
- Osborne CK, Schiff R. Estrogen-Receptor Biology: Continuing Progress and Therapeutic Implications, 1616
- Osborne M, *see* Stearns V
- Oscier D, *see* Moreton P
- O'Shaughnessy J, *see* Gradishar WJ
- Osone S, *see* Gotoh T
- Osorio A, *see* Honrado E
- Ossenkoppele GJ, *see* Breems DA  
*see* van Imhoff GW
- Ostapenko V, *see* Chan S
- Ostertag C, *see* Lutterbach J
- Ostland MA, *see* Eberhard DA
- O'Sullivan B, *see* Lee AWM
- O'Sullivan GC, *see* Hussein MAH
- O'Sullivan MJ, *see* Hussein MAH
- Ott G, *see* Fernández V  
*see* Schmid C
- Ottaiano A, Ascierto PA
- Ottaway JA, *see* Parulekar WR
- Otte J-B, *see* Aronson DC
- Otten H-M, *see* Klerk CPW
- Otten W, *see* Jansen SJT
- Otterson G, *see* Niell HB
- Otu H, *see* Spentzos D
- Ou S-HI, *see* Zell JA
- Oudard S, *see* Scotté F
- Oudard S, Banu E, Beuzeboc P, Voog E, Dourthe LM, Hardy-Bessard AC, Linassier C, Scotté F, Banu A, Coscas Y, Guinet F, Poupon M-F, Andrieu

- J-M. Multicenter Randomized Phase II Study of Two Schedules of Docetaxel, Estramustine, and Prednisone Versus Mitoxantrone Plus Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer, 3343
- Oudet P, *see* Entz-Werlé N
- Overgaard J, *see* Knoop AS
- Overmoyer B, *see* Burris HA III  
*see* Jones SE  
*see* Spector NL
- Overmoyer BA, *see* Miller KD
- Owen JB, *see* Suntharalingam M
- Owen W, *see* Whitlock JA
- Owens R, *see* Thatcher N
- Oyen WJG, *see* Brouwers AH  
*see* Hendrickx BW  
*see* van Kouwen MCA
- Oyharcabal-Bourden V, Kalifa C, Gentet JC, Frappaz D, Edan C, Chastagner P, Sariban E, Pagnier A, Babin A, Pichon F, Neuenschwander S, Vinchon M, Bours D, Mosseri V, LeGales C, Ruchoux M, Carrie C, Doz F. Standard-Risk Medulloblastoma Treated by Adjuvant Chemotherapy Followed by Reduced-Dose Craniospinal Radiation Therapy: A French Society of Pediatric Oncology Study, 4726
- Oza A, *see* Campos S
- Oza AM, *see* Rubin EH
- Oza D, *see* Knox JJ
- Özdemir C, *see* Voit C
- Ozkan M, Eser B, Er O, Dogu GG, Altinbas M. Inhibition of Angiogenesis: Thalidomide or Low-Molecular-Weight Heparin? (correspondence), 2113
- Ozsahin M, *see* Azria D
- Ozyilkan O, *see* Yildirim Y
- P**
- Pacault V, *see* Malka D
- Paccagnella A, *see* Ardizzoni A
- Pacey S, *see* Banerji U
- Pachinger W, *see* Richtig E
- Packer R, *see* Blaney SM  
*see* Geyer JR
- Packer RJ, *see* Bowers DC  
*see* Warren KE
- Packman S, *see* Sanchez R
- Pacquement H, *see* Entz-Werlé N
- Padberg JJ, *see* Neuss MN
- Padera R, *see* Travis WD
- Pagani O, *see* Colleoni M
- Pagaon L, *see* Pulsoni A
- Page DL, Simpson JF. What is Atypical Lobular Hyperplasia and What Does It Mean for the Patient? (editorial), 5432
- Page R, *see* Ibrahim NK
- Pagel JM, *see* Wallen H
- Pagliari LC, *see* Tu S-M
- Pagnier A, *see* Oyharcabal-Bourden V
- Pahlman L, *see* Folkesson J
- Pählman L, *see* Birgisson H  
*see* Brigisson H
- Paik S, *see* van't Veer LJ
- Paillot B, *see* Conroy T
- Palacios J, *see* Honrado E
- Paladini G, *see* Boccardo F
- Palapattu GS, *see* Lotan Y
- Pallarés C, *see* Hitt R
- Palmer A, *see* Bhatia R
- Palmer JL, *see* Bruera E  
*see* Nayak S
- Palmer M, *see* Butts C  
*see* Whelan TJ
- Palmer SL, *see* Mulhern RK
- Palmieri C, *see* Stebbing J
- Palomares MR, Paz B, Weitzel JN. Genetic Cancer Risk Assessment in the Newly Diagnosed Breast Cancer Patient Is Useful and Possible in Practice (correspondence), 3165
- Pan C, *see* Ben-Josef E
- Pan D, *see* Chung KY
- Panades M, Olivotto IA, Speers CH, Shenkier T, Olivotto TA, Weir L, Allan SJ, Truong PT. Evolving Treatment Strategies for Inflammatory Breast Cancer: A Population-Based Survival Analysis, 1941
- Panageas K, *see* Jimenez RE
- Panageas KS, *see* Rietschel P
- Pane F, *see* Soverini S
- Pang C-P, *see* Chan W-M
- Pang ESY, *see* Lee AWM
- Panicali D, *see* Marshall JL
- Panis X, *see* Guibout C
- Pantanowitz L, *see* Floyd SR  
*see* Huang W-Y  
*see* Koon HB
- Pantuck AJ, *see* Patard J-J
- Pantvaitya GH, D'cruz AK, Prabhash K. Palliation in Incurable Head and Neck Cancers: Chemotherapy? (correspondence), 8128
- Pao W, *see* Shah NT
- Pao W, Miller VA. Epidermal Growth Factor Receptor Mutations, Small-Molecule Kinase Inhibitors, and Non-Small-Cell Lung Cancer: Current Knowledge and Future Directions, 2556
- Paoletti F, *see* Verso M
- Paoletti G, *see* Colucci G
- Paolini J, *see* Lønning PE
- Pap A, *see* Schwab R
- Papadimitriou C, *see* Bamias A  
*see* Dimopoulos MA
- Papadopoulos T, *see* Rödel C
- Papaldo P, *see* Ferretti G
- Papaldo P, Lopez M, Marolla P, Cortesi E, Antimi M, Terzoli E, Vici P, Barone C, Ferretti G, Di Cosimo S, Carlini P, Nisticò C, Conti F, Di Lauro L, Botti C, Di Filippo F, Fabi A, Giannarelli D, Calabresi F. Impact of Five Prophylactic Filgrastim Schedules on Hematologic Toxicity in Early Breast Cancer Patients Treated With Epirubicin and Cyclophosphamide, 6908
- Papanikolaou A, *see* Arnold A
- Papay J, *see* Schwab R
- Pappert WS, *see* Scheier MF
- Pappo AS, Devidas M, Jenkins J, Rao B, Marcus R, Thomas P, Gebhardt M, Pratt C, Grier HE. Phase II Trial of Neoadjuvant Vincristine, Ifosfamide, and Doxorubicin With Granulocyte Colony-Stimulating Factor Support in Children and Adolescents With Advanced-Stage Nonrhabdomyosarcomatous Soft Tissue Sarcomas: A Pediatric Oncology Group Study, 4031
- Paquette S, *see* Cloughesy TF
- Paramasivam S, Tripcony L, Crandon A, Quinn M, Hammond I, Marsden D, Proietto A, Davy M, Carter J, Nicklin J, Perrin L, Obermair A. Prognostic Importance of Preoperative CA-125 in International Federation of Gynecology and Obstetrics Stage I Epithelial Ovarian Cancer: An Australian Multicenter Study, 5938
- Paraskevaidis M, *see* Athanassiou H
- Parc R, *see* Taïieb J
- Pardee R, *see* Herrinton LJ

## AUTHOR INDEX

- Parekh S, Hebert T, Ratch H, Sparano J. Spontaneous Regression of HIV-Associated Burkitt's Lymphoma of the Cecum, 8116
- Parham G, *see* Lanciano R
- Pari F, *see* Ardizzoni A
- Pariente A, *see* Barbare J-C
- Parise P, *see* Verso M
- Park E, *see* Emmons KM
- Park ER, Li FP, Liu Y, Emmons KM, Ablin A, Robison LL, Mertens AC. Health Insurance Coverage in Survivors of Childhood Cancer: The Childhood Cancer Survivor Study, 9187
- Park JO, *see* Rhee J-Y
- Park JR, *see* Gross TG
- Park JW, *see* Liu G  
*see* Rugo HS
- Park K, *see* Choi JY  
*see* Rhee J-Y
- Park S, *see* Marshall JL
- Park YS, *see* Rhee J-Y
- Parker A, *see* Tauro S
- Parker C. Watchful Waiting, Temporarily Deferred Therapy, or Active Surveillance? (correspondence), 1322
- Parker CA, *see* Ribas A
- Parker GJM, *see* Jayson GC
- Parker JA, *see* Costa DB
- Parker LM, *see* Burstein HJ
- Parkes R, *see* Wunder JS
- Parkinson E, *see* Mian S
- Parlhar R, *see* Eisenbeis CF
- Parmar A, *see* Fennell DA
- Parmar BKB, *see* Swart AMC
- Parmar M, *see* Langley RE
- Parmar MKB, *see* Brown J
- Parnes HL, Thompson IM, Ford LG. Prevention of Hormone-Related Cancers: Prostate Cancer, 368
- Parody R, *see* Ortega JJ
- Parry A, *see* de Botton S
- Parsons SK, *see* Tao ML
- Partridge AH, *see* Burstein HJ
- Partridge AH, Winer EP. Fertility After Breast Cancer: Questions Abound (editorial), 4259
- Parulekar W, *see* Singh S
- Parulekar WR, Day AG, Ottaway JA, Shepherd LE, Trudeau ME, Bramwell V, Levine M, Pritchard KI. Incidence and Prognostic Impact of Amenorrhea During Adjuvant Therapy in High-Risk Premenopausal Breast Cancer: Analysis of a National Cancer Institute of Canada Clinical Trials Group Study—NCIC CTG MA.5, 6002
- Parwaresch R, *see* Claviez A  
*see* Koch P  
*see* Lenz G
- Pasche B, *see* Bian Y
- Pasche B, Kaklamani V, Rademaker A, Hou N, Ahsan H, Chen Y. In Reply (correspondence), 7744
- Pascutto C, *see* Malcovati L
- Pashos CL, *see* Smith MR
- Passamonti F, *see* Malcovati L
- Pastan I, *see* Kreitman RJ
- Pastor P, *see* Hitt R
- Pastorino U, *see* Spinola M
- Pastrana FG, *see* Espinosa E
- Patard J-J, Leray E, Rioux-Leclercq N, Cindolo L, Ficarra V, Zisman A, De La Taille A, Tostain J, Artibani W, Abbou CC, Lobel B, Guillé F, Chopin DK, Mulders PFA, Wood CG, Swanson DA, Figlin RA, Belldegrun AS, Pantuck AJ. Prognostic Value of Histologic Subtypes in Renal Cell Carcinoma: A Multicenter Experience, 2763
- Patchell RA, *see* Kwok Y
- Patel A, *see* Rietschel P
- Patel DA, Presti JC Jr, McNeal JE, Gill H, Brooks JD, King CR. Preoperative PSA Velocity Is an Independent Prognostic Factor for Relapse After Radical Prostatectomy, 6157
- Patel JD. Lung Cancer in Women, 3212
- Patel KM, *see* Ibrahim NK
- Patel P, *see* Keilholz U
- Patel T, *see* Kabbinavar FF
- Pater J, *see* Brundage M
- Pater J, Goss P, Ingle J, Shelley W, Shepherd L. The Ethics of Early Stopping Rules (correspondence), 2862
- Pater JL, *see* Whelan TJ
- Paterniti DA, *see* Lara PN Jr
- Patier JL, *see* Montalban C
- Patil A, *see* Arshad M
- Patnaik A, *see* Beeram M
- Patriarca F, *see* Corradini P
- Patrono C, *see* Marchioli R
- Patt DA, Goodwin JS, Kuo Y-F, Freeman JL, Zhang DD, Buchholz TA, Hortobagyi GN, Giordano SH. Cardiac Morbidity of Adjuvant Radiotherapy for Breast Cancer, 7475
- Patt Y, *see* Poston GJ
- Patten CA, *see* Vickers KS
- Patterson AR, Robinson LD, Naftalis EZ, Haley BB, Tomlinson GE. Custodianship of Genetic Information: Clinical Challenges and Professional Responsibility, 2100
- Patterson F, *see* Lerman C
- Paty P, *see* Kemeny N  
*see* Rengan R
- Paty PB, *see* Guillem JG  
*see* Traina TA
- Patz EF Jr, Swensen SJ, Herndon JE. In Reply (correspondence), 2107
- Patz EF Jr, Swensen SJ, Herndon JE II. In Reply (correspondence), 2440
- Paul J, *see* Bruzzi P  
*see* Crawford SC
- Paul N, *see* Levine MN
- Paule B, *see* Bralet M-P
- Paulus R, *see* Bradley JD
- Pavic D, *see* Koomen M
- Pavletic SZ, Khouri IF, Haagenson M, King RJ, Bierman PJ, Bishop MR, Carston M, Giral S, Molina A, Copelan EA, Ringdén O, Roy V, Ballen K, Adkins DR, McCarthy P, Weisdorf D, Montserrat E, Anasetti C. Unrelated Donor Marrow Transplantation for B-Cell Chronic Lymphocytic Leukemia After Using Myeloablative Conditioning: Results From the Center for International Blood and Marrow Transplant Research, 5788
- Pavlick AC, *see* Hamilton AL
- Pavlov D, *see* Ribas A
- Pavone V, *see* Gobbi PG
- Pawlega J, *see* Zielinski C
- Pawlicki M, *see* Leyland-Jones B
- Pawlik TM, *see* Dômont J
- Pawlik TM, Ross MI, Thompson JF, Eggermont AMM, Gershenwald JE. Low Risk of In-Transit Metastasis in Patients With Cutaneous Melanoma Undergoing Sentinel Lymph Node Biopsy, 4588
- Paye F, *see* Taïieb J
- Paysse E, *see* Chévez-Barrios P
- Paz-Ares L, *see* Aparicio J  
*see* Hitt R  
*see* Leighl NB
- Paz B, *see* Palomares MR
- Pazdur R, *see* Anderson KC
- Peake MD, *see* Brown J
- Pearcey RG, *see* Meyer RM

- Pearl M, *see* Ezzo J
- Pearson A, *see* De Preter K
- Pearson AD, *see* Ellison DW
- Peccatori F, *see* Pruneri G
- Pecci A, *see* Massa M
- Pedrazzoli P, *see* Comoli P
- Pedrinis E, *see* Martrinelli G
- Peeters KCMJ, van de Velde CJH, Leer JWH, Martijn H, Junggeburst JMC, Kranenbarg EK, Steup WH, Wiggers T, Rutten HJ, Marijnen CAM. Late Side Effects of Short-Course Preoperative Radiotherapy Combined With Total Mesorectal Excision for Rectal Cancer: Increased Bowel Dysfunction in Irradiated Patients—A Dutch Colorectal Cancer Group Study, 6199
- Pegg AE, *see* Quinn JA
- Peggs K, *see* Tauro S
- Pegram MD, Pietras R, Bajamonde A, Klein P, Fyfe G. Targeted Therapy: Wave of the Future, 1776
- Pehamberger H, *see* Richtig E
- Pei D, *see* Pui C-H
- Pelegrin A, *see* Azria D
- Pelletier MM, *see* Dudley ME
- Pelley R, *see* Berber E
- Pelosi G, *see* De Pas T  
*see* DePas T  
*see* Noberasco C
- Pelozo B, *see* Townsley C
- Peltomäki P, *see* Ollikainen M  
*see* Renkonen ET
- Pendergrass TW, *see* Barker LM
- Pendlebury S, *see* Thewes B
- Pendlebury SC, *see* Hagerty RG
- Pendleton CD, *see* Carbone DP
- Peng B, Capdeville R. In Reply (correspondence), 3857
- Peng P-J, *see* Zhang L
- Peniket A, *see* Tauro S
- Penniment M, *see* Rischin D
- Penning C, *see* Bissett D
- Penson DF. Variations in Prostate Cancer Patterns of Care: Is It the Quality of Care or the Quality of the Data? (editorial), 7783
- Peoples GE, Gurney JM, Hueman MT, Woll MM, Ryan GB, Storrer CE, Fisher C, Shriver CD, Ioannides CG, Ponniah S. Clinical Trial Results of a Her2/*neu* (E75) Vaccine to Prevent Recurrence in High-Risk Breast Cancer Patients, 7536
- Pepper C, *see* Starczynski J
- Peralba JM, *see* Galanis E
- Perel Y, *see* Valteau-Couanet D
- Perez E, *see* Jatoi A
- Perez EA, *see* Goetz MP  
*see* Muss HB
- Perez N, *see* Taäieb J
- Pérez-Rosada A, *see* Agrelo R
- Perez-Soler R, *see* Lu C
- Pérez-Soler R, Saltz L. Cutaneous Adverse Effects With HER1/EGFR-Targeted Agents: Is There a Silver Lining?, 5235
- Perilongo G, *see* Aronson DC
- Perissinotto E, *see* Grignani G
- Perkins C, *see* Winer EP
- Perkins CL, *see* Lyman GH
- Perkins JL, Liu Y, Mitby PA, Neglia JP, Hammond S, Stovall M, Meadows AT, Hutchinson R, Dreyer ZE, Robison LL, Mertens AC. Nonmelanoma Skin Cancer in Survivors of Childhood and Adolescent Cancer: A Report From the Childhood Cancer Survivor Study, 3733
- Perlman E, *see* Grundy PE  
*see* Tomlinson GE
- Perlman EJ, *see* Dome JS
- Perol D, *see* Arpin D  
*see* Negrier S
- Perol M, *see* Arpin D
- Pérol M, *see* Fournel P
- Perotte P, *see* Lotan Y
- Perotti A, *see* Sessa C
- Perotti C, *see* Comoli P
- Perotti J, *see* Winer EP
- Perren T, *see* Evans TRJ
- Perrin L, *see* Paramasivan S
- Perrone F, *see* Gridelli C  
*see* Maione P  
*see* Pignata S
- Perrotti D, *see* Marcucci G
- Perrou B, *see* Kabbinavar FF
- Perry A, *see* Tu P-h
- Perry J, *see* Loblaw DA
- Perry MC, *see* Floyd JD  
*see* Lilenbaum RC  
*see* Niell HB
- Persons DL, *see* Dressler LG
- Pertuiset E, *see* Femand J-P
- Peruzzotti G, *see* Colleoni M
- Peschel C, *see* Leighl NB
- Peshkin BN, *see* Schwartz MD
- Peshkin BN, Isaacs C, Willey S, Schwartz MD. In Reply (correspondence), 3166
- Pession A, Valsecchi MG, Masera G, Kamps WA, Magyarosy E, Rizzari C, van Wering ER, Lo Nigro L, van der Does A, Locatelli F, Basso G, Aricó M. Long-Term Results of a Randomized Trial on Extended Use of High Dose L-Asparaginase for Standard Risk Childhood Acute Lymphoblastic Leukemia, 7161
- Petak I, *see* Schwab R
- Peterlongo P, *see* Bian Y
- Peters L, *see* Garzotto M  
*see* Rischin D
- Peters N, *see* Armstrong K
- Peters RPH, *see* de Jong FA
- Peters WP, *see* Petros WP
- Peters WP, Rosner GL, Vredenburgh JJ, Shpall EJ, Crump M, Richardson PG, Schuster MW, Marks LB, Cirrincione C, Norton L, Henderson IC, Schilsky RL, Hurd DD. Prospective, Randomized Comparison of High-Dose Chemotherapy With Stem-Cell Support Versus Intermediate-Dose Chemotherapy After Surgery and Adjuvant Chemotherapy in Women With High-Risk Primary Breast Cancer: A Report of CALGB 9082, SWOG 9114, and NCIC MA-13, 2191
- Peterson B, *see* Rohatiner AZS
- Peterson BL, *see* Kimmick GG  
*see* Sartor CI
- Peterson SK, *see* Gritz ER
- Petit L, *see* Willett CG
- Petrelli N, *see* O'Connell MJ
- Petrelli NJ, *see* Desch CE  
*see* Khatri VP
- Petrelli NJ, Abbruzzese J, Mansfield P, Minsky B. Hepatic Resection: The Last Surgical Frontier for Colorectal Cancer, 4475
- Petricoin EF III, Bichsel VE, Calvert VS, Espina V, Winters M, Young L, Belluco C, Trock BJ, Lippman M, Fishman DA, Sgroi DC, Munson PJ, Esserman LJ, Liotta LA. Mapping Molecular Networks Using Proteomics: A Vision for Patient-Tailored Combination Therapy, 3614
- Petros WP, Hopkins PJ, Spruill S, Broadwater G, Vredenburgh JJ, Colvin OM, Peters WP, Jones RB, Hall J, Marks JR. Associations Between Drug

- Metabolism Genotype, Chemotherapy Pharmacokinetics, and Overall Survival in Patients With Breast Cancer, 6117
- Petrylak DP, *see* Hussain M
- Pettenati MJ, *see* Farag SS  
*see* Marcucci G
- Petty PM, *see* Frost MH
- Petty WJ, *see* Dragnev KH
- Pewrruccio K, *see* Aversa F
- Peyromaure M, *see* Scotté F
- Pezzella G, *see* Colucci G
- Pfeffer R, *see* Weitzen R
- Pfister DG, *see* Desch CE
- Pfistner B, *see* Engert A  
*see* Klimm B
- Phan GQ, *see* Attia P
- Phelps M, *see* Bolaños-Meade J
- Philip PA, Mahoney MR, Allmer C, Thomas J, Pitot HC, Kim G, Donehower RC, Fitch T, Picus J, Erlichman C. Phase II Study of Erlotinib (OSI-774) in Patients With Advanced Hepatocellular Cancer, 6657
- Philip T, *see* Ray-Coquard I
- Phillips A, *see* Aronson DC
- Phillips K-A, Milne RL, Buys S, Friedlander ML, Ward JH, McCredie MRE, Giles GG, Hopper JL. Agreement Between Self-Reported Breast Cancer Treatment and Medical Records in a Population-Based Breast Cancer Family Registry, 4679
- Phillips KA, *see* Thewes B
- Phillips P, *see* Blaney SM
- Phippard L, *see* Wright J
- Piantadosi S, *see* Hansel DE
- Piantedosi F, *see* Maione P
- Piard F, *see* Lièvre A
- Piazza E, *see* Maione P
- Piccart-Gebhart MJ, *see* Levine MN
- Piccart-Gebhart MJ. Moving Away From the “One Shoe Fits All” Strategy: The Key to Future Progress in Chemotherapy (editorial), 1611
- Piccart M, *see* Praga C
- Piccart MJ, *see* Colozza M
- Picci P, *see* Ferrari S
- Pichert G, *see* Ghilmini M  
*see* Stirling D
- Pichon F, *see* Oyharcabal-Bourden V
- Pickard AS, *see* McKoy JM  
*see* Wolf MS
- Pico F, *see* Faivre S
- Picot V, *see* MacGrogan G
- Picus J, *see* Philip PA
- Pienkowski T, *see* Leyland-Jones B
- Piens J, *see* LoRusso PM
- Pienta KJ, *see* Loberg RD
- Pierce JP, *see* Rock CL
- Pierce L, *see* Haffty BG
- Pierce LJ, *see* Hayman JA
- Pierce LJ, Hutchins LF, Green SR, Lew DL, Gralow JR, Livingston RB, Osborne CK, Albain KS. Sequencing of Tamoxifen and Radiotherapy After Breast-Conserving Surgery in Early-Stage Breast Cancer, 24
- Pierce LJ. The Use of Radiotherapy After Mastectomy: A Review of the Literature, 1706
- Pierce S, *see* Bueso-Ramos C
- Pierga J-Y, Reis-Filho JS. Ewing’s Sarcoma of the Rectum: Can We Afford Not to Use Molecular Pathology? (correspondence), 7761
- Pierotti MA, *see* Frattini M
- Pietras K, Hanahan D. A Multitargeted, Metronomic, and Maximum-Tolerated Dose “Chemo-Switch” Regimen is Antiangiogenic, Producing Objective Responses and Survival Benefit in a Mouse Model of Cancer, 939
- Pietras R, *see* Pegram MD
- Pignata S, Perrone F, Di Maio M, Gallo C, De Placido S. In Reply (correspondence), 2436
- Pignatiello C, *see* Spinola M
- Pigneux A, *see* Jourdan E
- Pignon J-P, *see* Burdett S  
*see* Dômont J
- Pilarski P, *see* Richtig E
- Pilepich MV, *see* Bradley JD  
*see* Lawton CA
- Pili R, *see* Link RE
- Pimentel H, *see* Miller DC
- Pingpank JF, Libutti SK, Chang R, Wood BJ, Neeman Z, Kam AW, Figg WD, Zhai S, Beresneva T, Seidel GD, Alexander HR. Phase I Study of Hepatic Arterial Melphalan Infusion and Hepatic Venous Hemofiltration Using Percutaneously Placed Catheters in Patients With Unresectable Hepatic Malignancies, 3465
- Pink D, *see* Thuss-Patience PC
- Pink D, Schoeler D, Lindner T, Thuss-Patience PC, Kretzschmar A, Knipp H, Vanhoefer U, Reichardt P. Severe Hypoglycemia Caused By Paraneoplastic Production of IGF-II in Patients With Advanced Gastrointestinal Stromal Tumors: A Report of Two Cases (correspondence), 6809
- Pinter F, *see* Schwab R
- Pintilie M, *see* D’Addario G
- Pinto BM, *see* Demark-Wahnefried W
- Pinto BM, Frierson GM, Rabin C, Trunzo JJ, Marcus BH. Home-Based Physical Activity Intervention for Breast Cancer Patients, 3577
- Piovella F, *see* Klerk CPW
- Piperdi B, *see* Lu C
- Piperno-Neumann S, *see* van Baren N
- Piris MA, *see* Agrelo R
- Pirker R, *see* Filipits M
- Pisano ED, *see* Koomen M
- Pisters KMW, Le Chevalier T. Adjuvant Chemotherapy in Completely Resected Non–Small-Cell Lung Cancer, 3270
- Pisters PW, *see* Ajani JA
- Pisters PWT, *see* Muss HB  
*see* Yao JC
- Pithavala YK, *see* Liu G  
*see* Rugo HS
- Pitot HC, *see* Philip PA
- Pizzagalli F, *see* Graziano F
- Pizzo BM, *see* Shah NT
- Plantaz D, *see* Valteau-Couanet D  
*see* Vandesompele J
- Plante M, *see* Campos S
- Plaschkes J, *see* Aronson DC
- Plass C, *see* Raval A
- Platz EA, *see* Freedland SJ
- Plouin P-F, *see* Amar L
- Plukker JTM, *see* Westra JL
- Plunkett W, *see* Keating MJ
- Pócza K, *see* Timár J
- Podoloff D, *see* Horning SJ
- Podoloff DA, *see* Hamaoka T  
*see* Lyman GH  
*see* Sasaki R  
*see* Tu S-M
- Poerio A, *see* Soverini S
- Pogliani E, *see* Baldini L
- Pohar S. Positron Emission Tomography Paradigm Fuzzier Than Reported (correspondence), 4803

AUTHOR INDEX

- Pohl G, *see* Filipits M  
Pohlman B, *see* Sup SJ  
Pollack A, *see* Hayes SB  
Pollack IF, *see* Blaney SM  
Pollak M, *see* Canil CM  
Polli A, *see* Lønning PE  
Pollicino CA, *see* Fullham MJ  
Polyzos A, *see* Georgoulas V  
Pond GR, *see* Hotte SJ  
*see* Knox JJ  
*see* Townsley C  
*see* Zia MI  
Ponet J, *see* Astrow AB  
Ponniah S, *see* Peoples GE  
Ponticelli P, *see* Maranzano E  
Ponzoni M, *see* Ferreri AJM  
*see* Martrinelli G  
*see* Shankier TN  
Poole C, *see* Dark GG  
Poortmans P, *see* Abrey LE  
*see* Rades D  
*see* Shankier TN  
Popat S, Hubner R, Houlston RS. Systematic Review of Microsatellite Instability and Colorectal Cancer Prognosis, 609  
Popat S, Matakidou A, Houlston RS. In Reply (correspondence), 2108  
Poplack D, *see* Blaney SM  
Poplack DG, *see* Blaney SM  
Poplin EA, Benedetti JK, Estes NC, Haller DG, Mayer RJ, Goldberg RM, Weiss R, Rivkin SE, Macdonald JS. Phase III Southwest Oncology Group 9415/Intergroup 0153 Randomized Trial of Fluorouracil, Leucovorin, and Levamisole Versus Fluorouracil Continuous Infusion and Levamisole for Adjuvant Treatment of Stage III and High-Risk Stage II Colon Cancer, 1819  
Popplewell L, *see* Bhatia R  
Porcher R, *see* Delanian S  
Poremba C, *see* Williamson D  
Porpiglia M, *see* Boccardo D  
Port M, Schmelz HU, Stockinger M, Sparwasser C, Albers P, Pottek T, Abend M. Gene Expression Profiling in Seminoma and Noseminoma, 58  
Portengen H, *see* Jansen MPM  
Porteous ME, *see* Stirling D  
Porter-Gill P, *see* Samlowski WE  
Portlock C, *see* O'Connor OA  
Portlock CS, *see* Hollister D Jr  
Poruchynsky MS, *see* Low JA  
Posch M, *see* Richtig E  
Posner MR, *see* Wirth LJ  
Possinger K, *see* Schmid P  
Post S, *see* Hofheinz R-D  
Postmus PE, *see* Hoekstra CJ  
Poston G, *see* Bilchik AJ  
Poston GJ, Adam R, Alberts S, Curley S, Figueras J, Haller D, Kunstlinger F, Mentha G, Nordlinger B, Patt Y, Primrose J, Roh M, Rougier P, Ruers T, Schmoll HJ, Valls C, Vauthey NJ-N, Cornelis M, Kahan JP. OncoSurge: A Strategy for Improving Resectability With Curative Intent in Metastatic Colorectal Cancer, 7125  
Poston GJ. Radiofrequency Ablation of Colorectal Liver Metastases: Where Are We Really Going? (editorial), 1342  
Potenzoni D, *see* Boccardo D  
Potkul RK, *see* Campos S  
Pottek T, *see* Port M  
Potter JD, *see* Epplein M  
Pötter R, *see* Schellong G  
Poujol S, *see* Rouanet P  
Poulsen M, *see* Rischin D  
Poupon M-F, *see* Oudard S  
Poveda A, *see* Martín J  
Powell BL, *see* Farag SS  
*see* Marcucci G  
Powell CB, Kenley E, Chen L-m, Crawford B, McLennan J, Zaloudek C, Komaromy M, Beattie M, Ziegler J. Risk-Reducing Salpingo-Oophorectomy in BRAC Mutation Carriers: Role of Serial Sectioning in the Detection of Occult Malignancy, 127  
Powell EF, *see* Wolf MS  
Powell SN, *see* Taghian AG  
Powers CN, *see* Austin RM  
Powles R, *see* Greipp PR  
Powles T, *see* Bower M  
*see* Liu WM  
*see* Shamash J  
Powles TJ, *see* Winer EP  
Pöyhönen M, *see* Ollikainen M  
Poza MA, *see* Pozo-Rodríguez F  
Pozo-Rodríguez F, Martín de Nicolás JL, Sánchez-Nistal MA, Maldonado A, García de Barajas S, Calero-García R, Pozo MA, Martín-Escribano P, Martín-García I, García-Lujan R, Lopez-Encuentra A, Arenas de Pablo A. Accuracy of Helical Computed Tomography and [<sup>18</sup>F] Fluorodeoxyglucose Positron Emission Tomography for Identifying Lymph Node Mediastinal Metastases in Potentially Resectable Non-Small-Cell Lung Cancer, 8348  
Prabhash K, *see* Pantvaidya GH  
Pradhan JPB, *see* Nayak S  
Prados M, *see* Blaney SM  
*see* Cloughesy TF  
Praet M, *see* De Paep P  
*see* Lutz MP  
Praga C, Bergh J, Bliss J, Bonnetterre J, Cesana B, Coombes RC, Fargeot P, Folin A, Fumoleau P, Giuliani R, Kerbrat P, Hery M, Nilsson J, Onida F, Piccart M, Shepherd L, Therasse P, Wils J, Rogers D. Risk of Acute Myeloid Leukemia and Myelodysplastic Syndrome in Trials of Adjuvant Epirubicin for Early Breast Cancer: Correlation With Doses of Epirubicin and Cyclophosphamide, 4179  
Prager D, *see* Cella D  
*see* Herbst RS  
Prager G, *see* Raderer M  
Prandoni P, *see* Klerk CPW  
Pras E, *see* Reesink-Peters N  
Prat J, *see* Sieben NLG  
Prats M, *see* Salar A  
Pratt C, *see* Pappo AS  
Pratt G, *see* Starczynski J  
Prentice A, *see* Glasmacher A  
Press MF, *see* Agus DB  
Press OA, *see* Vallböhmer D  
Press OW, *see* Fisher RI  
*see* Wallen H  
Prestayko AW, Ascierto PA  
Presti JC Jr, *see* Freedland SJ  
*see* Patel DA  
Price A, *see* Bissett D  
*see* Butts C  
Price K, *see* Colleoni M  
Price KN, *see* Gruber G  
Prichard H, *see* Lukka H  
Prieto J, *see* Mazzolini G  
Prieto JM, Atala J, Blanch J, Carreras E, Rovira M, Cirera E, Espinal A,

## AUTHOR INDEX

- Gasto C. Role of Depression As a Predictor of Mortality Among Cancer Patients After Stem-Cell Transplantation, 6063
- Prieto VG, *see* Clayman GL
- Prigerson HG, *see* Vanderwerker LC
- Primrose J, *see* Poston JG
- Prindiville SA, *see* Calzone KA
- Prins M, *see* Lee AYY
- Prins MH, *see* Klerk CPW
- Pritchard-Jones K, *see* de Kraker J  
*see* Williamson D
- Pritchard K, *see* Whelan TJ
- Pritchard KI, *see* Jones SE  
*see* Levine MN  
*see* Parulekar WR  
*see* Winer EP
- Pritchard KI. Aromatase Inhibitors in Adjuvant Therapy of Breast Cancer: Before, Instead of, or Beyond Tamoxifen, 4850
- Pro B, *see* Goy A  
*see* Khouri IF  
*see* Romaguera JE
- Probst A, *see* Koch P
- Prochazka M, Hall P, Gagliardi G, Granath F, Nilsson BN, Shields PG, Tennis M, Czene K. Ionizing Radiation and Tobacco Use Increases the Risk of a Subsequent Lung Carcinoma in Women With Breast Cancer: Case-Only Design, 7467
- Procopio G, *see* Bajetta E
- Proebstle T, *see* Voit C
- Proebstle TM, *see* Keilholz U
- Proietto A, *see* Paramasivan S
- Pronk T, *see* ten Tije AJ
- Proper J, *see* Koon HB
- Prosnitz LR, *see* Jones EL
- Prosnitz RG, Marks LB. Radiation-Induced Heart Disease: Vigilance Is Still Required (editorial), 7391
- Prosper F, *see* Roman-Gomez J
- Provenzale JM, *see* Quinn JA  
*see* Reardon DA
- Prtichard KI, *see* Goodwin PJ
- Pruneri G, *see* Colleoni M  
*see* Laszlo D  
*see* Martrinelli G
- Pruneri G, Cinieri S, Peccatori F, Viale G. Unusual Cases in Multiple Myeloma and a Dramatic Response in Metastatic Lung Cancer. Plasma Cell Myeloma Coexisting With Metastatic Breast Carcioma in the Bone Marrow, 232
- Puccetti D, *see* Geyer JR
- Puccio-Pick M, *see* Thomas AL
- Puchalski TA, *see* Garcia-Carbonero R
- Puglisi F, de Azambuja E, de Castro G Jr, Demonty G. Shrinking the Tumor, Shrinking the Patient Sample Size: The Early Disclosure Dilemma (correspondence), 6803
- Pui C-H, Pei D, Sandlund JT, Campana D, Ribeiro RC, Razzouk BI, Rubnitz JE, Howard SC, Hijjiya N, Jeha S, Cheng C, Downing JR, Evans WE, Relling MV, Hudson M. Risk of Adverse Events After Completion of Therapy for Childhood Acute Lymphoblastic Leukemia, 7936
- Puig S, Malveyh J, Badenas C, Ruiz A, Jimenez D, Cuellar F, Azon A, González U, Castel T, Campoy A, Herrero J, Marti R, Brunet-Vidal J, Milà M. Role of the *CDKN2A* Locus in Patients With Multiple Primary Melanomas, 3043
- Puisieux A, *see* Combaret V
- Pulczynski EJ, *see* Abrey LE
- Puleo E, *see* Emmons KM
- Pulsipher M, *see* Sorrow ML
- Pulsoni A, Pagano L. Treatment of Secondary Acute Myeloid Leukemia (correspondence), 926
- Punglia RS, Burstein HJ. In Reply (correspondence), 8546
- Punglia RS, Kuntz KM, Winer EP, Weeks JC, Burstein HJ. Optimizing Adjuvant Endocrine Therapy in Postmenopausal Women With Early-Stage Breast Cancer: A Decision Analysis, 5178
- Punt CJA, *see* de Vries IJM  
*see* Keilholz U
- Puntervold R, *see* Subdø J
- Puntoni M, *see* Boccardo F
- Pupa SM, *see* Ménard S
- Purnell G, *see* Mahfouz T
- Pursche S, *see* Bornhäuser M
- Purushotham AD, Upponi S, Klevesath MB, Bobrow L, Millar K, Myles JP, Duffy SW. Morbidity After Sentinel Lymph Node Biopsy in Primary Breast Cancer: Results From a Randomized Controlled Trial, 4312
- Pusateri A, *see* Gordan LN
- Pusztai L, *see* Buzdar AU  
*see* Gianni L  
*see* Green MC  
*see* Rouzier R
- Putnam JB, *see* Sasaki R
- Putter H, *see* Hartgrink HH  
*see* Marijnen CAM
- Putzu C, *see* DePas T

## Q

- Qi X, *see* Jaksic W
- Qian C, *see* Mazzolini G
- Qian W, *see* Langley RE  
*see* Rudd RM  
*see* Thatcher N
- Quackenbush J, *see* Eschrich S
- Quenet F, *see* Ducreux M
- Quezado MM, *see* Attia P  
*see* Weil RJ
- Quigley M, *see* Evans TRJ
- Quigley MT, *see* Garcia-Carbonero R
- Quinn JA, *see* Reardon DA
- Quinn JA, Desjardins A, Weingart J, Brem H, Dolan ME, Delaney SM, Vredenburgh J, Rich J, Friedman AH, Reardon DA, Sampson JH, Pegg AE, Moschel RC, Birch R, McLendon RE, Provenzale JM, Gururangan S, Dancy JE, Maxwell J, Tourt-Uhlig S, Herndon JE II, Bigner DD, Friedman HS. Phase I Trial of Temozolomide Plus  $O^6$ -Benzylguanine for Patients With Recurrent or Progressive Malignant Glioma, 7178
- Quinn-Laquer B, *see* Lynch HT
- Quinn M, *see* Paramasivan S
- Quintana E, *see* Orbach D
- Quintavalla R, *see* Verso M
- Quirke P, *see* Nagtegaal ID
- Quiroga J, *see* Mazzolini G
- Quon A, Gambhir SS. FDG-PET and Beyond: Molecular Breast Cancer Imaging, 1664
- Qureshi A, *see* Arshad M

## R

- Raab G, *see* von Minckwitz G
- Raab R, *see* Rödel C
- Rabbani F, *see* Dotan ZA
- Rabe KF, *see* Annema JT
- Rabin C, *see* Pinto BM
- Rabinowitz I, *see* Bibb J

- Radcliffe J, *see* Geyer JR
- Rademaker A, *see* Pasche B
- Rademaker AW, *see* Ferreira MR
- Rademaker J, *see* Voit C
- Raderer M, Wöhler S, Bartsch R, Prager G, Drach J, Hejna M, Gaiger A, Turetschek K, Jaeger U, Streubel B, Zielinski CC. Phase II Study of Oxaliplatin for Treatment of Patients With Mucosa-Associated Lymphoid Tissue Lymphoma, 8442
- Rades D, Stalpers LJA, Veninga T, Schulte R, Hoskin PJ, Obralic N, Bajrovic A, Rudat V, Schwarz R, Hulshof MC, Poortmans P, Schild SE. Evaluation of Five Radiation Schedules and Prognostic Factors for Metastatic Spinal Cord Compression, 3366
- Radford J, *see* Le Cesne A
- Radford JA, *see* Johnson PWM  
*see* Kaminski MS
- Radich JP, *see* Sorror ML
- Radlwimmer B, *see* Mendrzyk F
- Radmacher M, *see* Morrison C
- Radmacher MD, *see* Marcucci G
- Radošević-Jelic L, *see* Bosset J-F
- Rae JM, *see* Goetz MP
- Raemaekers JMM, Aleman BMP, Henry-Amar M. Radiotherapy in Advanced-Stage Hodgkin's Lymphoma (correspondence), 245
- Raez LE, Lopes G, Lilenbaum R. Clinical Responses to Gefitinib After Failure of Treatment With Cetuximab in Advanced Non-Small-Cell Lung Cancer, 4244
- Raftopoulos H, *see* Warr DG
- Raghavachar A, *see* Schuette W
- Raghavan D. Hidden by HIPAA: The Costs of Cure (editorial), 3663
- Ragnhammar P, *see* Öhrling K
- Rai SN, *see* Krasin MJ
- Raimondi M, *see* Ardizzoni A
- Raines S, *see* Gimotty PA
- Rainey JM, *see* Neuss MN
- Raizer JJ, *see* Aghajanian C
- Raja V, Balakrishnan R, Bollinger W, Crabtree D, Downey E, Mohindra M. Double Diagnosis in Cancer Patients and Cutaneous Reaction Related to Gemcitabine: Mixed Carcinoid-Adenocarcinoma of the Appendix, 7223
- Rajendran JG, *see* Hawkins DS
- Rajkumar SV, *see* Kumar S
- Rajkumar SV, Richardson PG, Hideshima T, Anderson KC. Proteasome Inhibition As a Novel Therapeutic Target in Human Cancer, 630
- Ramajoli I, *see* Massa M
- Ramanathan RK, *see* Rothenberg ML
- Ramaswamy G, *see* Arshad M
- Rambaldi A, *see* Corradini P
- Ramies D, *see* Herbst RS
- Ramies DA, *see* Eberhard DA  
*see* Herbst RS
- Ramirez G, *see* Ezzo J
- Ramirez JL, Rosell R, Taron M, Sanchez-Ronco M, Alberola V, de las Peñas R, Sanchez JM, Moran T, Camps C, Massuti B, Sanchez JJ, Salazar F, Catot S. 14-3-3 $\sigma$  Methylation in Pretreatment Serum Circulating DNA of Cisplatin-Plus-Gemcitabine-Treated Advanced Non-Small-Cell Lung Cancer Patients Predicts Survival: The Spanish Lung Cancer Group, 9105
- Ramnath N, *see* Cheewakriangkrai R
- Ramón JM, *see* Salar A
- Ramos R, *see* Martín J
- Ramsey SD, *see* Epplein M
- Rankin EM, *see* Luiten RM  
*see* Rudd RM
- Rankin L, *see* Charles W
- Ransom ER, *see* Komotar RJ
- Rao B, *see* Pappo AS
- Rao PV, *see* Bagatell R
- Rao SC, *see* Ibrahim NK
- Rao SR, *see* Jatoui I
- Raoul J-L, *see* Barbare J-C
- Rapiti E, *see* Bouchardy C
- Rapoport AP, *see* Badros AZ
- Rapp C, *see* Boulanger E
- Rappersberger K, *see* Richtig E
- Rashid A, *see* Dömöt J
- Rasmussen BB, *see* Knoop AS
- Raspi E, *see* Arroyo GF
- Rassam SMB, *see* Moreton P
- Rassenti L, *see* Raval A
- Rastogi P, *see* Tan-Chiu E
- Ratain MJ, *see* Stadler WM
- Ratech H, *see* Parekh S
- Ratterree B, *see* Badros AZ
- Raubitschek A, *see* Schnell R
- Raut CP, Hunt KK, Kuerer HM. In Reply (correspondence), 3648
- Ravagnani F, *see* Spinola M
- Raval A, Lucas DM, Matkovic JJ, Bennett KL, Liyanarachchi S, Young DC, Rassenti L, Kipps TJ, Grever MR, Byrd JC, Plass C. *TWIST2* Demonstrates Differential Methylation in Immunoglobulin Variable Heavy Chain Mutated and Unmutated Chronic Lymphocytic Leukemia, 3877
- Ravasco P, Monteiro-Grillo I, Vidal PM, Camilo ME. Dietary Counseling Improves Patient Outcomes: A Prospective, Randomized, Controlled Trial in Colorectal Cancer Patients Undergoing Radiotherapy, 1431
- Ravaud P, *see* Ferman J-P
- Ravdin PM, *see* Hutchins LF  
*see* Jones SE
- Rawstron A, *see* Moreton P
- Ray-Coquard I, *see* Le Cesne A  
*see* Van Glabbeke M
- Ray-Coquard I, Philip T, de Laroche G, Froger X, Suchaud J-P, Voloch A, Mathieu-Daudé H, Lurkin A, Farsi F, Bertrand P, Chauvin F. Persistence of Medical Change at Implementation of Clinical Guidelines on Medical Practice: A Controlled Study in a Cancer Network, 4414
- Raymond E, *see* Faivre S
- Raynaud F, *see* Banerji U
- Rayson D. Witness, 2429
- Razzouk BI, *see* Pui C-H
- Re D, Küppers R, Diehl V. Molecular Pathogenesis of Hodgkin's Lymphoma, 6379
- Read EJ, *see* Carbone DP
- Reaman G, *see* Berg SL  
*see* Whitlock JA
- Reaman GH, *see* Daw NC
- Reardon DA, *see* Quinn JA
- Reardon DA, Egorin MJ, Quinn JA, Rich JN Sr, Gururangan I, Vredenburgh JJ, DEsjeardins A, Sathornsumetee S, Provenzale JM, Herndon JE II, Dowell JM, Badruddoja MA, McLendon RE, Lagattuta TF, Kiczielinski KP, Dresermann G, Sampson JH, Friedman AH, Salvado AJ, Friedman HS. Phase II Study of Imatinib Mesylate Plus Hydroxyurea in Adults With Recurrent Glioblastoma Multiforme, 9359
- Rebeck T, *see* Eisen A
- Rebeck TR, *see* DeMichele A
- Rebeck TR, Friebe T, Wagner T, Lynch HT, Garber JE, Daly MB, Isaacs C, Olopade OI, Neuhasen SL, van't Veer L, Eeles R, Evans DG, Tomlinson G, Matloff E, Narod SA, Eisen A, Domchek S, Armstrong K, Weber BL. Effect of Short-Term Hormone Replacement Therapy on Breast Cancer Risk Reduction After Bilateral Prophylactic Oophorectomy in *BRCA1* and *BRCA2* Mutation Carriers: The PROSE Study Group, 7804

- Reblando J, *see* Mamon HJ  
 Rech J, *see* Elter T  
 Recher C, *see* Jourdan E  
 Recht A, *see* Bellon JR  
 Recht LD, *see* Chamberlain MC  
 Redana S, *see* Montemurro F  
 Reddy S, *see* Nayak S  
   *see* Yao JC  
 Redondo A, *see* Espinosa E  
 Reece D, *see* Jaksic W  
 Reece WHH, *see* Abratt RP  
 Rees R, *see* Mian S  
 Reesink-Peters N, van der Velden J, ten Hoor KA, Boezen HM, de Vries EGE, Schilthuis MS, Mourits MJE, Nijman HW, Alders JG, Hollema H, Pras E, Duk JM, van der Zee AGJ. Preoperative Serum Squamous Cell Carcinoma Antigen Levels in Clinical Decision Making for Patients With Early-Stage Cervical Cancer, 1455  
 Reeves C, *see* Fouladi M  
 Regan MM, *see* McDermott DF  
 Regine WF, *see* Kwok Y  
 Rehman I, *see* Catto JWF  
 Reich SD, *see* Liu G  
   *see* Rugo HS  
 Reichardt P, *see* Köhne C-H  
   *see* Lutz MP  
   *see* Pink D  
   *see* Thuss-Patience PC  
 Reid J, *see* Goetz MP  
   *see* LoRusso PM  
 Reid JM, *see* Whitlock JA  
 Reifemberger G, *see* Mendrzyk F  
 Reiffers J, *see* Jourdan E  
 Reigner B, *see* Camidge R  
 Reiher F, *see* Lehmann J  
 Reilly A, *see* Kazak AE  
 Reimann JD, *see* Miller KD  
 Reinartz G, *see* Koch P  
 Reineke T, *see* Behringer K  
   *see* Klimm B  
 Reis-Filho JS, *see* Pierra J-Y  
 Reiser M, *see* Elter T  
 Reißig A, *see* Schuette W  
 Reisner Y, *see* Aversa F  
 Reiter A, *see* Seidemann K  
 Reith A, *see* Subdø J  
 Reker S, *see* Andersen MH  
 Relling MV, *see* Pui C-H  
 Reman O, *see* de Botton S  
 Remenár ě, *see* Tímár J  
 Remington P, *see* Wilding G  
 Renaudin K, *see* Thuret R  
 Rengan R, Paty P, Wong WD, Guillem J, Weiser M, Temple L, Saltz L, Minsky BD. Distal cT2N0 Rectal Cancer: Is There an Alternative to Abdominoperineal Resection? 4905  
 Renkonen ET, Nieminen P, Abdel-Rahman WM, Moisio A-L, Järvelä I, Arte S, Järvinen HJ, Peltomäki P. Adenomatous Polyposis Families That Screen APC Mutation-Negative by Conventional Methods are Genetically Heterogeneous, 5651  
 Rennert G, *see* Eisen A  
 Répássy G, *see* Tímár J  
 Repetto L, *see* Maione P  
 Repp M, *see* Thuss-Patience PC  
 Reske SN, *see* Juweid ME  
 Resti AG, *see* Ferreri AJM  
 Restifo NP, *see* Attia P  
   *see* Dudley ME  
 Restuccia N, *see* Boccardo F  
 Retsas S. In Reply (correspondence), 4469  
 Retter A, *see* Figg WD  
 Retz M, *see* Lehmann J  
 Reuben JM, *see* Cristofanilli M  
   *see* Ribas A  
 Reuter VE. Lymphovascular Invasion As an Independent Predictor of Recurrence and Survival in Node-Negative Bladder Cancer Remains to Be Proven (editorial), 6450  
 Reuther A, *see* Stephenson AJ  
 Rey A, *see* Orbach D  
   *see* Stevens MCG  
 Reyes F, *see* Feugier P  
 Reymond E, *see* Hardy J  
 Reynolds C, *see* Goetz MP  
 Reynolds CP, *see* London WB  
 Reznik RH, *see* Rockall AG  
 Rhee J-Y, Park JO, Kwon GY, Nam SJ, Yoo BC, Park YS, Im Y-h, Kang WK, Park K. Positive Positron Emission Tomography Scan in Sarcoidosis and Two Challenging Cases of Metastatic Cancer: Hepatocellular Carcinoma With Metastasis to the Breast, 8908  
 Rhee JC, *see* Lalani M  
 Rhodes KE, *see* Vallböhmer D  
 Ribas A, Camacho LH, Lopez-Berestein G, Pavlov D, Bulanagui CA, Millham R, Comin-Anduix B, Reuben JM, Seja E, Parker CA, Sharma A, Glaspy JA, Gomez-Navarro J. Antitumor Activity in Melanoma and Anti-Self Responses in a Phase I Trial With the Anti-Cytotoxic T Lymphocyte-Associated Antigen 4 Monoclonal Antibody CP-675,206, 8968  
 Ribatti D, *see* Vacca A  
 Ribeiro RC, *see* Pui C-H  
 Ricci S, *see* von der Maase H  
 Rich J, *see* Quinn JA  
 Rich JN Sr, *see* Reardon DA  
 Rich S, *see* van Besien K  
 Richard S, *see* Amar L  
 Richards D, *see* Jones SE  
 Richardson D, *see* Le Q-T  
 Richardson D, *see* Welsh TJ  
 Richardson K, *see* Nyman DW  
 Richardson MA, *see* Ezzo J  
 Richardson P, *see* Hideshima T  
 Richardson PG, *see* Floyd SR  
   *see* Peters WP  
   *see* Rajkumar SV  
 Richardson S, *see* Kelly WK  
 Richel DJ, *see* Klerk CPW  
   *see* Nieboer P  
 Richly H, *see* Strumberg D  
 Richman PJ, *see* Bentzen SM  
 Richon VM, *see* Kelly WK  
 Richtig E, Soyer HP, Posch M, Mossbacher U, Bauer P, Teban L, Svolba G, Wolf IH, Fritsch P, Zelger B, Volc-Platzer B, Gebhart W, Mischer P, Steiner A, Pachinger W, Hintner H, Gschnalt F, Rappersberger K, Pilsarski P, Pehamberger H. Prospective, Randomized, Multicenter, Double-Blind Placebo-Controlled Trial Comparing Adjuvant Interferon Alfa and Isotretinoin With Interferon Alfa Alone in Stage IIA and IIB Melanoma: European Cooperative Adjuvant Melanoma Treatment Study Group, 8655  
 Rickles FR, *see* Lee AYY  
 Rico MA, *see* Bruera E  
 Ricotta R, *see* Bajetta E  
 Ried T, *see* Ghadimi BM

AUTHOR INDEX

- Riedel E, *see* D'Adamo DR  
 Riedel ER, *see* Akhurst T  
 Riemenschneider MJ, *see* Bell DW  
 Riepenhausen M, *see* Schellong G  
 Rietjens JAC, *see* Voogt E  
 Rietschel P, Panageas KS, Hanlon C, Patel A, Abramson DG, Chapman PB. Variates of Survival in Metastatic Uveal Melanoma, 8076  
 Rigal-Huguet F, *see* Jourdan E  
 Rigas JR, *see* Dragnev KH  
 Riggenbach J, *see* Morrison C  
 Rimm DL, *see* Austin RM  
 Rimmer S, *see* Stirling D  
 Rinaldini M, *see* Boccardo F  
 Ring AE, Smith IE, Jones A, Shannon C, Galani E, Ellis PA. Chemotherapy for Breast Cancer During Pregnancy: An 18-Year Experience From Five London Teaching Hospitals, 4192  
 Ringdén O, *see* Pavletic SZ  
 Ringdén O. In Reply (correspondence), 649  
 Rini B, *see* Stadler WM  
 Rini BI, *see* Webster WS  
 Rini BI, Small EJ. Biology and Clinical Development of Vascular Endothelial Growth Factor-Targeted Therapy in Renal Cell Carcinoma, 1028  
 Rioux-Leclercq N, *see* Patard J-J  
 Ris MD, *see* Beebe DW  
 Risberg B, *see* Subdø J  
 Rischin D, Peters L, Fisher R, Macann A, Denham J, Poulsen M, Jackson M, Kenny L, Penniment M, Corry J, Lamb D, McClure B. Tirapazamine, Cisplatin, and Radiation Versus Fluorouracil, Cisplatin, and Radiation in Patients With Locally Advanced Head and Neck Cancer: A Randomized Phase II Trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02), 79  
 Ristow KM, *see* Ghobrial IM  
   *see* Martin WG  
 Ritchey ML, *see* Grundy PE  
 Ritchie J, *see* Lutgendorf SK  
 Ritchie JM, *see* Juweid ME  
 Ritstier K, *see* Jansen MPH  
 Ritter G, *see* van Baren N  
 Ritvo P, *see* Brundage M  
 Rivas C, *see* Honrado E  
 Rivera E, *see* Green MC  
 Rivkin SE, *see* Hutchins LF  
   *see* Poplin EA  
 Rixe O, *see* Conroy T  
 Rizo A, *see* Hitt R  
 Rizzari C, *see* Pession A  
 Rizzo A, *see* Cecchetto G  
   *see* Manzitti C  
 Rizzo JD, *see* Andrykowski MA  
 Ro JY, *see* Lu C  
 Roa W, *see* Choy H  
 Roa W, Urtasun R, Bauman G, Cairncross JG, Forsyth P. In Reply (correspondence), 1588  
 Roach M III, *see* Speight JL  
 Robbiati SF, *see* Maione P  
 Robbins KT, Kumar P, Harris J, McCulloch T, Cmelak A, Sofferman R, Levine P, Weisman R, Wilson W, Weymuller E, Fu K. Supradose Intra-Arterial Cisplatin and Concurrent Radiation Therapy for the Treatment of Stage IV Head and Neck Squamous Cell Carcinoma Is Feasible and Efficacious in a Multi-Institutional Setting: Results of Radiation Therapy Oncology Group Trial 9615, 1447  
 Robbins N, *see* Fouladi M  
 Robbins RJ, Villanueva J, Tempst P. Distilling Cancer Biomarkers From the Serum Peptidome: High Technology Reading of Tea Leaves or an Insight to Clinical Systems Biology? 4835  
 Robert F, *see* Divers SG  
 Robert F, Blumenschein G, Herbst RS, Fossella FV, Tseng J, Saleh MN, Needle M. Phase I/IIa Study of Cetuximab With Gemcitabine Plus Carboplatin in Patients With Chemotherapy-Naïve Advanced Non-Small Lung Cancer, 9089  
 Robert NJ, *see* Whelan TJ  
 Roberts C, *see* Jayson GC  
 Roberts JR, *see* Auethavekiat P  
 Roberts JT, *see* Jones WG  
   *see* von der Maase H  
 Roberts K, *see* Hershman D  
 Robidoux A, *see* Dorval M  
   *see* Mamounas EP  
 Robinet G, *see* Fournel P  
 Robins HI, *see* Cloughesy TF  
 Robinson E, *see* Boyle FM  
 Robinson LD, *see* Patterson AR  
 Robinson MR, *see* Attia P  
   *see* Dudley ME  
 Robinson P, *see* Browman GP  
 Robinson WA, *see* Koyanagi K  
 Robison LL, *see* Bowers DC  
   *see* Castellino SM  
   *see* Park ER  
   *see* Perkins JL  
 Roboz GJ, *see* Feldman EJ  
 Roca E, *see* Chacón M  
 Roché H, *see* Bonnetterre J  
 Rock CL. Dietary Counseling Is Beneficial for the Patient With Cancer (editorial), 1348  
 Rock CL, Flatt SW, Natarajan L, Thomson CA, Bardwell WA, Newman VA, Hollenbach KA, Jones L, Caan BJ, Pierce JP. Plasma Carotenoids and Recurrence-Free Survival in Women With a History of Breast Cancer, 6631  
 Rock MJ, *see* Wunder JS  
 Rock MK, *see* Czuczman MS  
 Rockall AG, Sohaib SA, Harisinghani MG, Babar SA, Singh N, Jeyarajah AR, Oram DH, Jacobs IJ, Shepherd JH, Reznick RH. Diagnostic Performance of Nanoparticle-Enhanced Magnetic Resonance Imaging in the Diagnosis of Lymph Node Metastases in Patients With Endometrial and Cervical Cancer, 2813  
 Rodary C, *see* Valteau-Couanet D  
 Rodeck U, *see* Dicker AP  
 Rödel C, Martus P, Papadopoulos T, Füzesi L, Klimpfinger M, Fietkau R, Liersch T, Hohenberger W, Raab R, Sauer R, Wittekind C. Prognostic Significance of Tumor Regression After Preoperative Chemoradiotherapy for Rectal Cancer, 8688  
 Rodenhuis S, *see* Hannemann J  
   *see* Le Cesne A  
   *see* Nieboer P  
 Rodgers A, *see* Warr DG  
 Rodríguez A, *see* Ortega JJ  
 Rodríguez AM, *see* Goy A  
 Rodríguez J, *see* Gianni L  
 Rodríguez M, *see* Agrelo R  
 Rodríguez MA, *see* Romaguera JE  
 Rodríguez R, *see* Bhatia R  
 Roehl KA, *see* D'Amico AV  
 Roehrborn CG, *see* Lotan Y  
 Roemeng MJM, *see* Sieben NLG  
 Rogers CG, *see* Lotan Y  
 Rogers D, *see* Praga C

## AUTHOR INDEX

- Rogers LJ, *see* Dudley ME  
 Rogers T, *see* ten Tije AJ  
 Roggli V, *see* Travis WD  
 Roh J-L, Kim A-Y, Cho MJ. Xerostomia Following Radiotherapy of the Head and Neck Affects Vocal Function, 3016  
 Roh M, *see* Poston GJ  
 Rohatiner AZS, Gregory WM, Peterson B, Borden E, Solal-Celigny P, Hagenbeek A, Fisher RI, Unterhalt M, Arranz R, Chisesi T, Lister TA, Aviles A. Meta-Analysis to Evaluate the Role of Interferon in Follicular Lymphoma  
 2215  
 Rohmer V, *see* Amar L  
 Rohren EM, *see* Juweid ME  
 Roignot P, *see* Lièvre A  
 Rojo F, *see* Baselga J  
     *see* Tabernero J  
 Rolfe L, *see* Jayson GC  
 Rolnick S, *see* Herrinton LJ  
 Romaguera JE, *see* Goy A  
 Romaguera JE, Fayad L, Rodriguez MA, Broglio KR, Hagemester FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Sarris AH, Dang NH, Wang M, Beasley V, Medeiros LJ, Katz RL, Gagneja H, Samuels BI, Smith TL, Cabanillas FF. High Rate of Durable Remissions After Treatment of Newly Diagnosed Aggressive Mantle-Cell Lymphoma With Rituximab Plus Hyper-CVAD Alternating With Rituximab Plus High-Dose Methotrexate and Cytarabine, 7013  
 Roman-Gomez J, Jimenez-Velasco A, Agirre X, Prosper F, Heiniger A, Torres A. Lack of CpG Island Methylator Phenotype Defines a Clinical Subtype of T-Cell Acute Lymphoblastic Leukemia Associated With Good Prognosis, 7043  
 Rome LS, *see* Giaccone G  
 Romeo D, *see* Boccardo F  
 Romet-Lemonne J-L, Mills B, Fridman WH, Munsell M. Prospectively Planned Analysis of Data From a Phase III Study of Liposomal Muramyltripeptide Phosphatidylethanolamine in the Treatment of Osteosarcoma (correspondence), 6437  
 Romito S, *see* Colucci G  
 Romond E, *see* Tan-Chiu E  
 Ronnen EA, Kondagunta GV, Bacik J, Marion S, Bajorin DF, Sheinfeld J, Bosl GJ, Motzer RJ. Incidence of Late-Relapse Germ Cell Tumor and Outcome to Salvage Chemotherapy, 6999  
 Roodman GD. High Bone Turnover Markers Predict Poor Outcome in Patients With Bone Metastasis, 4821  
 Rosai J, *see* Gronchi A  
 Rosales MF, *see* Green MC  
 Roscoe JA, *see* Ezzo J  
 Rose M, *see* Dómont J  
     *see* Weber RW  
 Rose PG, *see* Wenzel L  
 Rosell R, *see* Gridelli C  
     *see* Ramirez JL  
 Rosen LS, *see* Bilchik AJ  
 Rosenbaum E, *see* Hoque MO  
 Rosenberg A, *see* Thienelt CD  
 Rosenberg CL, *see* Larson PS  
 Rosenberg PS, *see* Kramer JL  
 Rosenberg SA, *see* Attia P  
     *see* Dudley ME  
 Rosenblum RK, *see* Bhat SR  
 Rosendaal FR, *see* van Rooden CJ  
 Rosenthal AN, *see* Menon U  
 Rosenwaks Z, *see* Oktay K  
 Rosenwald A, *see* Fernández V  
 Rosetti F, *see* Maione P  
 Rosner B, *see* Kroenke CH  
 Rosner BA, *see* Cho E  
 Rosner G, *see* Bueso-Ramos C  
     *see* Stadler WM  
 Rosner GL, *see* Peters WP  
 Ross JS, *see* Gianni L  
 Ross L, *see* Boesen EH  
 Ross MI, *see* Cormier JN  
     *see* Pawlik TM  
 Rossi A, *see* Baldini L  
 Rossi E, *see* Cappuzzo F  
 Rossi G, Cavazza A, Marchioni A, Longo L, Migaldi M, Sartori G, Bigiani N, Schirosi L, Casali C, Morandi U, Facciolongo N, Maiorans A, Bavieri M, Fabbri LM, Brambilla E. Role of Chemotherapy and the Receptor Tyrosine Kinases KIT, PDGFR $\alpha$ , PDGFR $\beta$ , and Met in Large-Cell Neuroendocrine Carcinoma of the Lung, 8774  
 Rossi J-F, *see* Jourdan E  
 Rossi R, *see* Maranzano E  
 Rossi S, *see* Fiorentini G  
 Rosso R, *see* Ardizzoni A  
     *see* Bruzzi P  
 Rost A, *see* Rummel MJ  
 Rosti G, *see* Soverini S  
 Rosti V, *see* Massa M  
 Roth A, *see* Leyland-Jones B  
 Roth BJ. In Reply (correspondence), 8125  
 Roth BJ. Prostate Cancer Chemotherapy: Emerging From the Shadows (editorial), 3302  
 Roth JA, *see* Sasaki R  
 Roth S, *see* Lehmann J  
 Rothenberg ML, LaFleur B, Levy DE, Washington MK, Morgan-Meadows SL, Ramanathan RK, Berlin JD, Benson AB III, Coffey RJ. Randomized Phase II Trial of the Clinical and Biological Effects of Two Dose Levels of Gefitinib in Patients With Recurrent Colorectal Adenocarcinoma, 9265  
 Rothermel J, *see* Rubin EH  
 Rotmensz N, *see* Colleoni M  
 Rouanet P, Linares-Cruz G, Dravet F, Poujol S, Gourgou S, Simony-Lafontaine J, Grenier J, Kramar A, Girault J, Le Nestour E, Maudelonde T. Neoadjuvant Percutaneous 4-Hydroxytamoxifen Decreases Breast Tumoral Cell Proliferation: A Prospective Controlled Randomized Study Comparing Three Doses of 4-Hydroxytamoxifen Gel to Oral Tamoxifen, 2980  
 Roudas M, *see* Lardinois D  
 Rougier P, *see* Barbare J-C  
     *see* Bilchik AJ  
     *see* Köhne C-H  
     *see* Poston GJ  
 Rouzier R, *see* Gianni L  
     *see* Gonzalez-Angulo A  
     *see* Hennessy BT  
 Rouzier R, Pusztai L, Delalogue S, Gonzalez-Angulo AM, Andre F, Hess KR, Buzdar AU, Garbay J-R, Spielmann M, Mathieu M-C, Symmans WF, Wagner P, Atallah D, Valero V, Berry DA, Hortobagyi GN. Nomograms to Predict Pathologic Complete Response and Metastasis-Free Survival After Preoperative Chemotherapy for Breast Cancer, 8331  
 Rovira M, *see* Prieto JM  
 Rowe JM, *see* Tallman MS  
 Rowinsky EK, *see* Beeram M  
 Rowinsky EK. Targeted Induction of Apoptosis in Cancer Management: The Emerging Role of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor Activating Agents, 9394  
 Rowland JH, *see* Bellizzi KM  
     *see* Demark-Wahnefried W  
     *see* Stanton AL

- Rowland K, *see* Alberts SR  
*see* Jatoi A
- Rowland KM, *see* Ma CX  
*see* Witzig TE
- Roy J, *see* Bairati I
- Roy M-A, *see* Gaudreau J-D
- Roy V, *see* Pavletic SZ
- Royal RE, *see* Attia P  
*see* Dudley ME
- Royce SG, *see* Southey MC
- Royer B, *see* Fermand J-P
- Roz L, *see* Sozzi G
- Rubagotti A, *see* Boccardo F  
*see* Boccardo F.
- Ruben SL, *see* Whitlock JA
- Rubenstein J, *see* Shanker TN
- Rubie H, *see* Valteau-Couanet D
- Rubin EH, Rothermel J, Tesfaye F, Chen T, Hubert M, Ho Y-Y, Hsu C-H, Oza AM. Phase I Dose-Finding Study of Weekly Single-Agent Patupilone in Patients With Advanced Solid Tumors, 9120
- Rubin MA, *see* Hofer MD
- Rubino C, *see* Guibout C
- Rubinstein LV, Korn EL, Freidlin B, Hunsberger S, Ivy SP, Smith MA. Design Issues of Randomized Phase II Trials and a Proposal for Phase II Screening Trials, 7199
- Rubinstein WS. Surgical Management of *BRCA1* and *BRCA2* Carriers: Bitter Choices Slightly Sweetened (editorial), 7772
- Rubio B, *see* Gallardo J
- Rubnitz JE, *see* Pui C-H
- Ruchoux M, *see* Oyharcabal-Bourden V
- Rückle-Lanz H, *see* Köhne C-H
- Rudant J, *see* Delanian S
- Rudas M, *see* Filipits M
- Rudat V, *see* Rades D
- Rudd R, *see* Fennell DA
- Rudd RM, *see* Brown J
- Rudd RM, Gower NH, Spiro SG, Eisen TG, Harper PG, Littler JAH, Hatton M, Johnson PWM, Martin WMC, Rankin EM, James LE, Gregory WM, Qian W, Lee SM. Gemcitabine Plus Carboplatin Versus Mitomycin, Ifosfamide, and Cisplatin in Patients With Stage IIIB or IV Non-Small-Cell Lung Cancer: A Phase III Randomized Study of the London Lung Cancer Group, 142
- Rudd RM, Gower NH, Spiro SG, Lee SM, Eisen TG, Harper PG, Hatton M, Martin WMC, Rankin EM. In Reply (correspondence), 6270
- Rudek MA, Zhao M, He P, Hartke C, Gilbert J, Gore SD, Carducci MA, Baker SD. Pharmacokinetics of 5-Azacididine Administered With Phenylbutyrate in Patients with Refractory Solid Tumors or Hematologic Malignancies, 3906
- Rudenstam C-M, *see* Colleoni M  
*see* Gruber G
- Ruers T, *see* Poston GJ
- Rufford B, *see* Menon U
- Ruggeri L, *see* Aversa F
- Ruggieri P, *see* Ferrari S
- Rugo HS, *see* Liu G  
*see* Miller KD
- Rugo HS, Herbst RS, Liu G, Park JW, Kies MS, Steinfeldt HM, Pithavala YK, Reich SD, Freddo JL, Wilding G. Phase I Trial of the Oral Antiangiogenesis Agent AG-013736 in Patients With Advanced Solid Tumors: Pharmacokinetic and Clinical Results, 5474
- Rühl U, *see* Schellong G
- Ruhstaller T, Mueller A, Koeberle D, Thuerlimann B. Is There Really Enough Evidence to Abandon Surgery After Radiation Chemotherapy in Esophageal Cancer? (correspondence), 8547
- Ruit JB, *see* Bontenbal M
- Ruiter DJ, *see* de Vries IJM
- Ruiz A, *see* Baselga J  
*see* Puig S
- Ruiz J, *see* Mazzolini G
- Rumchev P, *see* Bagatell R
- Rummel MJ, Al-Batran SE, Kim S-Z, Welslau M, Hecker R, Kofahl-Krause D, Josten K-M, Dürk H, Rost A, Neise M, von Grünhagen U, Chow KU, Hansmann M-L, Hoelzer D, Mitrou PS. Bendamustine Plus Rituximab Is Effective and Has a Favorable Toxicity Profile in the Treatment of Mantle Cell and Low-Grade Non-Hodgkin's Lymphoma, 3383
- Ruppert AS, *see* Farag SS  
*see* Marcucci G
- Rusch V, *see* Gaspar LE
- Rusch VW. Mediastinoscopy: An Endangered Species? (editorial), 8283
- Ruso S, *see* Saif MW
- Russell C, *see* Ell K
- Russell N, *see* Tauro S
- Russo C, Wong AF. The Bereaved Parent, 8109
- Russo M, Bazan V, Iacopetta B, Kerr D, Soussi T, Gebbia N. The TP53 Colorectal Cancer International Collaborative Study on the Prognostic and Predictive Significance of *p53* Mutation: Influence of Tumor Site, Type of Mutation, and Adjuvant Treatment, 7518
- Russo PA, *see* Warnke PH
- Rutgers EJ, *see* Hannemann J
- Rutka JT, *see* Mabbott DJ
- Rutke S, *see* Amendola MA  
*see* Avril N
- Rutten HJ, *see* Marijnen CAM  
*see* Peeters KCMJ
- Ruzzo A, *see* Graziano F
- Ryan CJ, Eisenberger M. Chemotherapy for Hormone-Refractory Prostate Cancer: Now It's a Question of "When?", 8242
- Ryan CJ, Smith EJ. Early Versus Delayed Androgen Deprivation for Prostate Cancer: New Fuel for an Old Debate, 8225
- Ryan DP, *see* Garcia-Carbonero R  
*see* Hamilton AL  
*see* Willett CG
- Ryan GB, *see* Peoples GE
- Ryan M, Moynihan TJ, Loprinzi CL. As-Needed Morphine: Yes, but at What Dose and at What Interval? 3849
- Ryan PD, *see* Burstein HJ
- Ryan QC, Headlee D, Acharya M, Sparreboom A, Trepel JB, Ye J, Figg WD, Hwang K, Chung EJ, Murgo A, Melillo G, Elsayed Y, Monga M, Kalnitskiy M, Zwiebel J, Sausville EA. Phase I and Pharmacokinetic Study of MS-275, a Histone Deacetylase Inhibitor, in Patients With Advanced and Refractory Solid Tumors or Lymphoma, 3912
- Ryckman FC, *see* Gross TG
- Rydén L, Jirstrom K, Bendahl P-O, Fernö M, Nordenskjöld B, Stål O, Thorstenson S, Jönsson P-E, Landberg G. Tumor-Specific Expression of Vascular Endothelial Growth Factor Receptor 2 but Not Vascular Endothelial Growth Factor or Human Epidermal Growth Factor Receptor 2 Is Associated With Impaired Response to Adjuvant Tamoxifen in Premenopausal Breast Cancer, 4695
- Ryder D, *see* Johnson PWM

## S

- Saab JP, *see* Aversa F
- Saad F, *see* Coleman RE  
*see* Smith MR
- Sabate K, *see* Mar Fan HG
- Sabatier L, *see* Dômont J
- Sabbatini P, *see* Aghajanian C

## AUTHOR INDEX

- see* Basch E
- Sabloff B, *see* Travis WD
- Sacchi S, *see* Vallisa D
- Sacco R, *see* Marchetti A
- Sachs BA, Shahab N, Kaplan PA, Doll DC, Haider S. Conditions Suggesting Lymphoma. Lymphomatoid Papulosis, 3843
- Sachs DL, *see* Shah NT
- Sádaba B, *see* Mazzolini G
- Sadoul J-L, *see* Amar L
- Sáenz A, *see* Aparicio J
- Sæter G, *see* Ferrari S
- Safgren S, *see* Goetz MP
- Safgren SL, *see* Goetz MP
- Sagalowsky AI, *see* Lotan Y
- Saghafifar F, *see* Mahfouz T
- Saglio G, *see* Soverini S
- Sagstuen H, Aass N, Fosså SD, Dahl O, Klepp O, Wist EA, Wilsgaard T, Bremnes RM. Blood Pressure and Body Mass Index in Long-Term Survivors of Testicular Cancer, 4980
- Sahani DV, *see* Willett CG
- Sahin A, *see* Hennessy BT
- Sahin AA, *see* Buzdar AU  
*see* Green MC
- Saif MW, Eloubeidi MA, Ruso S, Steg A, Thornton J, Fiveash J, Carpenter M, Blanquicett C, Diaslo RB, Johnson MR. Phase I Study of Capecitabine With Concomitant Radiotherapy for Patients With Locally Advanced Pancreatic Cancer: Expression Analysis of Genes Related to Outcome, 8679
- Saijo N, *see* Yamamoto N
- Saito T, *see* Igarashi S
- Sakamoto H, *see* Takano T
- Sakane-Ishikawa E, Nakatsuka S-i, Tomita Y, Fujita S, Nakamichi I, Takakuwa T, Sugiyama H, Fukuhara S, Hino M, Kanamaru A, Soma T, Tsukaguchi M, Igarashi K, Kanakura Y, Aozasa K. Prognostic Significance of BACH2 Expression in Diffuse Large B-Cell Lymphoma: A Study of the Osaka Lymphoma Study Group, 8012
- Sakar B, Basaran G, Basaran M. Ewing's Sarcoma of the Rectum: Are Four Cycles of Chemotherapy Enough? (correspondence), 5849
- Sakiyama T, *see* Takano T
- Sakr WA, *see* Hussain M
- Sala R, *see* Bruera E
- Salar A, Bellosillo B, Serrano S, Besses C. Persistent Residual Disease in t(11;18)(q21;q21) Positive Gastric Mucosa-Associated Lymphoid Tissue Lymphoma Treated With Chemotherapy or Rituximab (correspondence), 7361
- Salar A, Ramón JM, Barranco C, Nieto M, Prats M, Serrano S, Besses C. Double Diagnosis in Cancer Patients and Cutaneous Reaction Related to Gemcitabine: Synchronous Mucosa-Associated Lymphoid Tissue Lymphoma and Gastrointestinal Stromal Tumors of the Stomach, 7221
- Salazaar S, *see* Goetz MP
- Salazar F, *see* Ramirez JL
- Salazar LG, Disis ML. Cancer Vaccines: The Role of Tumor Burden in Tipping the Scale Toward Vaccine Efficacy (editorial), 7397
- Saleh MN, *see* Robert F
- Salem B, *see* Katz SJ
- Saliba RM, *see* Khouri IF
- Sallan SE, *see* Li FP  
*see* Lipshultz SE
- Salles G, *see* Feugier P
- Salsman JM, *see* Andrykowski MA
- Salter J, *see* Dowsett M
- Saltz L, *see* Bilchik AJ  
*see* Guillem JG  
*see* Muss HB  
*see* Pérez-Soler R  
*see* Rengan R
- Saltz L. In Reply (correspondence), 923
- Saltz LB, *see* Chung KY  
*see* Kortmansky J
- Saltz LB, Chung, KY. In Reply (correspondence), 6275
- Salvado AJ, *see* Reardon DA
- Salvatore S, *see* Marchetti A
- Salzberg M, *see* Chan S
- Samaniego F, *see* Goy A  
*see* Romaguera JE
- Samaras N, *see* Georgoulas V
- Sambrook RJ, *see* Thatcher N
- Samet JM, *see* Alberg AJ
- Samlowski WE, *see* Florell SR
- Samlowski WE, Leachman SA, Wade M, Cassidy P, Porter-Gill P, Busby L, Wheeler R, Boucher K, Fitzpatrick F, Jones DA, Karpf AR. Evaluation of a 7-Day Continuous Intravenous Infusion of Decitabine: Inhibition of Promoter-Specific and Global Genomic DNA Methylation, 3897
- Samonigg H, *see* Filipits M
- Samonis G, *see* Georgoulas V
- Sampson JH, *see* Quinn JA  
*see* Reardon DA
- Samson DJ, *see* Schrag D
- Samuels B, *see* Goy A  
*see* Ibrahim NK
- Samuels BI, *see* Romaguera JE
- Samuelsson M, *see* Subdø J
- Samuelsson R, *see* Subdø J
- Samulski TV, *see* Jones EL
- San Miguel J, *see* de Botton S  
*see* Greipp PR
- Sánchez A, *see* Aparicio J
- Sanchez-Aguilera A, *see* Agrelo R
- Sanchez de Toledo J, *see* Stevens MCG
- Sanchez JJ, *see* Ramirez JL
- Sánchez JJ, *see* Espinosa E
- Sanchez JM, *see* Ramirez JL
- Sanchez K, *see* Ell K
- Sánchez L, *see* Honrado E
- Sánchez M, *see* Aparicio J
- Sánchez MA, *see* Hitt R
- Sánchez-Nistal MA, *see* Pozo-Rodríguez F
- Sanchez R, Etzell J, Kim G, Packman S, Fairley C, Goldsby R. Pediatric Malignancies. Peripheral T-Cell Lymphoma in an Adolescent With Unsuspected Gaucher Disease, 4792
- Sanchez-Ronco M, *see* Ramirez JL
- Sancho MA, *see* Garcia-Carbonero R
- Sanda MG, *see* Miller DC
- Sanderink G-J, *see* Soepenberg O
- Sanders JE, *see* Barker LM
- Sanders LL, *see* Jones EL
- Sanderson K, Scotland R, Lee P, Liu D, Groshen S, Snively J, Sian S, Nichol G, Davis T, Keler T, Yellin M, Weber J. Autoimmunity in a Phase I Trial of a Fully Human Anti-Cytotoxic T-Lymphocyte Antigen-4 Monoclonal Antibody with Multiple Melanoma Peptides and Montanide ISA 51 for Patients With Resected Stages III and IV Melanoma, 741
- Sandler A, *see* Herbst RS
- Sandler AB, *see* Niell HB
- Sandler HM, *see* Miller DC  
*see* Taylor JMG
- Sandlund JT, *see* Pui C-H
- Sandmaier BM, *see* Baron F  
*see* Sorror ML

- Sandström M, Lindman H, Nygren P, Lidbrink E, Bergh J, Karlsson MO. Model Describing the Relationship Between Pharmacokinetics and Hematologic Toxicity of the Epirubicin-Docetaxel Regimen in Breast Cancer Patients, 413
- Sanger W, *see* Lynch HT
- Sangro B, *see* Mazzolini G
- Santana VM, Furman WL, Billups CA, Hoffer F, Davidoff AM, Houghton PJ, Stewart CF. Improved Response in High-Risk Neuroblastoma With Protracted Topotecan Administration Using a Pharmacokinetically Guided Dosing Approach, 4039
- Santillan A, Garg R, Zahurak ML, Gardner GJ, Giuntoli RL II, Armstrong DK, Bristow RE. Risk of Epithelial Ovarian Cancer Recurrence in Patients With Rising Serum CA-125 Levels Within the Normal Range, 9338
- Santini D, *see* Graziano F  
*see* Vincenzi B
- Santini G, *see* Gobbi PG
- Santoro A, *see* Leigh NB  
*see* Verso M
- Santucci A, *see* Aversa F
- Sanz-Lacalle J-J, *see* Feliu J
- Sanz M, *see* de Botton S
- Sanz MA, *see* Ortega JJ
- Saranchuk JW, Kattan MW, Elkin E, Touijer AK, Scardino PT, Eastham JA. Achieving Optimal Outcomes After Radical Prostatectomy, 4146
- Sargen DJ, *see* Mahoney MR
- Sargent D, *see* Grothey A
- Sargent DJ, *see* Alberts SR  
*see* Crane CH  
*see* Grothey A
- Sargent DJ, Conley BA, Allegra C, Collette L. Clinical Trial Designs for Predictive Marker Validation in Cancer Treatment Trials, 2020
- Sargent DJ, Wieand HS, Haller DG, Gray R, Benedetti JK, Buyse M, Lablanca R, Seitz JF, O'Callaghan CJ, Francini G, Grothey A, O'Connell M, Catalano PJ, Blanke CD, Kerr D, Green E, Wolmark N, Andre T, Goldberg RM, De Gramont A. Disease-Free Survival Versus Overall Survival As a Primary End Point for Adjuvant Colon Cancer Studies: Individual Patient Data From 20,898 Patients on 18 Randomized Trials, 8664
- Sariban E, *see* Oyharcabal-Bourden V
- Saris G, *see* Athanassiou H
- Sarkar S, *see* Kabbinavar FF
- Sarker D, *see* Liu WM
- Sarlomo-Rikala M, *see* Sihto H
- Sarna L, *see* Movsas B
- Saroyan JM, Schechter WS, Tresgallo ME, Granowetter L. Role of Intraspinal Analgesia in Terminal Pediatric Malignancy, 1318
- Sarris AH, *see* Goy A  
*see* Romaguera JE
- Sartor CI, Peterson BL, Woolf S, FitzGerald TJ, Laurie F, Turrisi AJ, Bogart J, Henderson IC, Norton L. Effect of Addition of Adjuvant Paclitaxel on Radiotherapy Delivery and Locoregional Control of Node-Positive Breast Cancer: Cancer and Leukemia Group B 9344, 30
- Sartor O, *see* McKoy JM
- Sartori E, Gadducci A, *see* Buda A
- Sartori G, *see* Rossi G
- Sasaki M, *see* Okada K
- Sasaki R, *see* Komaki R
- Sasaki R, Komaki R, Macapinlac H, Erasmus J, Allen P, Forster K, Putnam JB, Herbst RS, Moran CA, Podoloff DA, Roth JA, Cox JD. [<sup>18</sup>F]Fluorodeoxyglucose Uptake by Positron Emission Tomography Predicts Outcome of Non-Small-Cell Lung Cancer, 1136
- Sassen S, *see* Avril N
- Sastre J, Marcuello E, Masutti B, Navarro M, Gil S, Antón A, Abad A, Aranda E, Maurel J, Valladares M, Maestu I, Carrato A, Vicent JM, Díaz-Rubio E. Irinotecan in Combination With Fluorouracil in a 48-Hour Continuous Infusion As First-Line Chemotherapy for Elderly Patients With Metastatic Colorectal Cancer: A Spanish Cooperative Group for the Treatment of Digestive Tumors Study, 3545
- Sathornsumetee S, *see* Reardon DA
- Sathya J, *see* Lukka H
- Sathya JR, Davis IR, Julian JA, Guo Q, Daya D, Dayes IS, Lukka HR, Levine M. Randomized Trial Comparing Iridium Implant Plus External-Beam Radiation Therapy With External-Beam Radiation Therapy Alone in Node-Negative Locally Advanced Cancer of the Prostate, 1192
- Sato J, *see* Meyers PA
- Sato T, *see* Berd D
- Satrústegul JJ, *see* Aparicio J
- Sauer R, *see* Rödel C
- Sauerbrei W, *see* McShane LM
- Sauleda S, *see* Baselga J
- Saunders M, *see* Jayson GC
- Saunders MI, *see* Bentzen SM
- Sausville EA, *see* Ryan QC
- Sausville EA, Carducci MA. Making Bad Cells Go Good: The Promise of Epigenetic Therapy, 3875
- Sausville EA. Indifferently Pursued or Unowned Drugs: Who Should Lead Where Companions Do Not Tread? (editorial), 1796
- Sauter ER, *see* Floyd JD
- Sauter G, Simon R, Al-Kuraya K, Terracciano L. In Reply (correspondence), 5271
- Savage DG, *see* Mantha S
- Savaraj N, Ascierto PA
- Savard J, Simard S, Ivers H, Morin CM. Randomized Study on the Efficacy of Cognitive-Behavioral Therapy for Insomnia Secondary to Breast Cancer, Part I: Sleep and Psychological Effects, 6083
- Savard J, Simard S, Ivers H, Morin CM. Randomized Study on the Efficacy of Cognitive-Behavioral Therapy for Insomnia Secondary to Breast Cancer, Part II: Immunologic Effects, 6097
- Saville W, *see* Lilenbaum RC
- Sawhney R, *see* Butts C
- Sawyers CL, *see* Scher HI
- Saykin AJ, *see* Ahles TA
- Scadden DT, *see* Noy A  
*see* Willett CG
- Scala S, Ascierto PA
- Scali S, *see* Boccardo F
- Scardino PT, *see* Dotan ZA  
*see* Saranchuk JW  
*see* Stephenson AJ
- Scartozzi M, *see* Graziano F
- Scartozzi M, Berardi R, Bearzi I, Cascinu S. In Reply (correspondence), 5844
- Scavelli C, *see* Vacca A
- Schaapveld M, *see* Westra JL
- Schadendorf D, *see* Kaufmann R  
*see* Keilholz U  
*see* Mian S
- Schaefer P, *see* Mahoney MR
- Shapira L, *see* Burstein HJ  
*see* Muss HB
- Scharenborg NM, *see* de Vries IJM
- Schattner M, *see* Schrag D
- Schechter WS, *see* Saroyan JM
- Scheel-Walter H-G, *see* Schellong G
- Schefer H, *see* Ghilmini M
- Scheier MF, Helgeson VS, Schulz R, Colvin S, Berga S, Bridges MW, Knapp J, Gerszten K, Pappert WS. Interventions to Enhance Physical and

## AUTHOR INDEX

- Psychological Functioning Among Younger Women Who Are Ending Nonhormonal Adjuvant Treatment for Early-Stage Breast Cancer, 4298
- Scheinberg D, *see* Feldman EJ
- Scheithauer BW, *see* Galanis E  
*see* Tu P-h
- Schellhammer P, *see* McKoy JM
- Schellong G, *see* Claviez A
- Schellong G, Dörffel W, Claviez A, Körholz D, Mann G, Scheel-Walter H-G, Bökkerink JPM, Riepenhausen M, Lüders H, Pötter R, Rühl U. Salvage Therapy of Progressive and Recurrent Hodgkin's Disease: Results From a Multicenter Study of the Pediatric DAL/GPOH-HD Study Group, 6181
- Schenkein D, *see* Goy A  
*see* O'Connor OA
- Scher H, *see* Kelly WK
- Scher HI, *see* Dotan ZA  
*see* Galsky MD  
*see* Stewart AJ  
*see* Zelefsky MH
- Scher HI, Sawyers CL. Biology of Progressive, Castration-Resistant Prostate Cancer: Directed Therapies Targeting the Androgen-Receptor Signaling Axis, 8253
- Scher K, *see* Basch E
- Scherübl H, *see* Grabowski P
- Scheu K, *see* D'Adamo DR
- Scheulen ME, *see* Chan S  
*see* Strumberg D
- Schianca FC, *see* Grignani G
- Schiavo R, *see* Comoli P
- Schicha H, *see* Schnell R
- Schiff D, *see* Cloughesy TF
- Schiff R, *see* Cui X  
*see* Gutierrez MC  
*see* Mohsin SK  
*see* Osborne CK
- Schiffer CA, *see* Farag SS  
*see* Marcucci G
- Schild HH, *see* Kuhl CK
- Schild SE, *see* Jatoi A  
*see* Ma CX  
*see* Rades D
- Schiller J, *see* Belani CP
- Schiller JH, *see* Cella D  
*see* Hoang T
- Schiller M, *see* Lehmann J
- Schilling G, *see* Schuch G
- Schilsky RL, *see* Peters WP
- Schilthuis MS, *see* Reesink-Peters N
- Schimek MG, *see* Sill H
- Schinköthe T, *see* Elter T
- Schipper MJ, *see* Hayman JA
- Schippers EF, *see* van Rooden CJ
- Schippinger W, *see* Schmid P
- Schiroli L, *see* Rossi G
- Schlechter BL, *see* Larson PS
- Schlemmer B, *see* Thiéry G
- Schlemmer M, *see* Van Glabbeke M
- Schlenzka I, *see* Mian S
- Schleucher N, *see* Strumberg D
- Schleuning M, *see* Schmid C
- Schleyer E, *see* Bornhäuser M
- Schlichting E, *see* Lønning PE
- Schlom J, *see* Marshall JL
- Schlumberger M, *see* Amar L  
*see* Dromain C
- Schmalfeldt B, *see* Amendola MA  
*see* Avril N
- Schmeler KM, *see* Soliman PT
- Schmelz HU, *see* Port M
- Schmid C, Diem H, Hermann K, Voltz R, Ott G, Hallek M. Unusual Site of Malignancies: Central Neurogenic Hyperventilation As a Complication of Richter's Syndrome, 2096
- Schmid C, Schleuning M, Ledderose G, Tischer J, Kolb H-J. Sequential Regimen of Chemotherapy, Reduced-Intensity Conditioning of Allogeneic Stem-Cell Transplantation, and Prophylactic Donor Lymphocyte Transfusion in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome, 5675
- Schmid P, Schippinger W, Nitsch T, Huebner G, Heilmann V, Schultze W, Hausmaninger H, Wischnowsky M, Possinger K. Up-Front Tandem High-Dose Chemotherapy Compared With Standard Chemotherapy With Doxorubicin and Paclitaxel in Metastatic Breast Cancer: Results of a Randomized Trial, 432
- Schmid RA, *see* Weber T
- Schmidt E-W, *see* Schuette W
- Schmidt G, *see* Boesen EH
- Schmidt JE, *see* Andrykowski MA
- Schmidt ML, Lal A, Seeger RC, Maris JM, Shimada H, O'Leary M, Gerbing RB, Matthay KK. Favorable Prognosis for Patients 12 to 18 Months of Age With Stage 4 Nonamplified MYCN Neuroblastoma: A Children's Cancer Group Study, 6474
- Schmidt-Wolf IGH, *see* Glasmacher A
- Schmiegelow K, *see* Borgwardt L
- Schmits R, *see* Koch P
- Schmitt BP, *see* Ferreira MR
- Schmitt C, *see* Entz-Werlé N
- Schmitt G, *see* Stahl M
- Schmitt M, *see* Stahl M
- Schmittl A, *see* Keilholz U
- Schmitz, S-FH, *see* Ghilmini M
- Schmitz PI, *see* Bontenbal M
- Schmitz T, *see* Behringer K
- Schmoll HJ, *see* Poston GJ
- Schnater JM, *see* Aronson DC
- Schneider A, *see* Entz-Werlé N  
*see* Glas J
- Schneider BP, Miller KD. Angiogenesis of Breast Cancer, 1782
- Schnell R, *see* Elter T
- Schnell R, Dietlein M, Staak JO, Borchmann P, Schomaecker K, Fischer T, Eschner W, Hansen H, Morschhauser F, Schicha H, Diehl V, Raubitschek A, Engert A. Treatment of Refractory Hodgkin's Lymphoma Patients With an Iodine-131—Labeled murine anti-CD30 Monoclonal Antibody, 4669
- Schnipper LE, *see* Li FP
- Schnirer II, *see* Yao JC
- Schober T, *see* Josting A
- Schöder H, *see* Dotan ZA
- Schöder H, Noy A, Gönen M, Weng L, Green D, Erdi YE, Larson SM, Yeung HWD. Intensity of <sup>18</sup>Fluorodeoxyglucose Uptake in Positron Emission Tomography Distinguishes Between Indolent and Aggressive Non-Hodgkin's Lymphoma, 4643
- Schoder V, *see* Loges S
- Schoeler D, *see* Pink D
- Schoenberg MP, *see* Lotan Y
- Scholl C, *see* Fröhling S
- Scholten M, *see* Kramer GWPM
- Scholten WK. Medicinal Cannabis in Oncology Practice: Still a Bridge Too Far? (correspondence), 7755
- Scholz C, *see* Thuss-Patience PC

- Schomaecker K, *see* Schnell R  
 Schonau A, *see* Knoop AS  
 Schothorst KL, *see* Bontenbal M  
 Schouten HC, *see* van Imhoff GW  
 Schover LR, *see* Frumovitz M  
 Schrading S, *see* Kuhl K  
 Schrag D, *see* Basch E  
   *see* Chung KY  
 Schrag D. Communication and Coordination: The Keys to Quality (editorial), 6452  
 Schrag D, Samson DJ, Seidenfeld J, Aronson N, Garewal H, Burstein HJ, Von Hoff DD, Somerfield MR. In Reply (correspondence), 3646  
 Schrag D, Weiser M, Schattner M, Shia J, Akhurst T. An Increasingly Common Challenge: Management of the Complete Responder With Multi-Focal Metastatic Colorectal Cancer, 1799  
 Schramel FJHM, *see* Hoekstra CJ  
 Schrappe M, *see* Einsiedel HG  
 Schraub S, *see* Bonneterre J  
 Schröder FH, *see* Collette L  
 Schroeder A, *see* Corless CL  
 Schroen AT, Brenin DR, Kelly MD, Knaus WA, Slingluff CL Jr. Impact of Patient Distance to Radiation Therapy on Mastectomy Use in Early-Stage Breast Cancer Patients, 7074  
 Schubert S, *see* Warnke PH  
 Schuch G, *see* Loges S  
 Schuch G, de Wit M, Hóltje J, Laack E, Schilling G, Hossfeld DK, Fiedler W, Scigalla P, Jacobs MS. Difficult Diagnostic Cases. Hemangioblastomas: Diagnosis of von Hippel-Lindau Disease and Antiangiogenic Treatment With SU5416, 3624  
 Schuette W, Nagel S, Blankenburg T, Lautenschlaeger C, Hans K, Schmidt E-W, Dittrich I, Schweisfurth H, von Weikersthal LF, Raghavachar A, Reißig A, Serke M. Phase III Study of Second-Line Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Weekly Compared With 3-Weekly Docetaxel, 8389  
 Schuetze SM, *see* Hawkins DS  
 Schuller DE, *see* Urba SG  
 Schulman C, *see* Smith MR  
 Schulman P, *see* Feldman EJ  
 Schulte R, *see* Rades D  
 Schultz KR, *see* Baker KS  
 Schultze W, *see* Schmid P  
 Schulz-Ertner D, *see* Combs SE  
 Schulz H, *see* Elter T  
 Schulz J, *see* Kabbinar FF  
 Schulz R, *see* Scheier MF  
 Schulz U, *see* Josting A  
 Schumacher M, *see* Kaufman M  
 Schumer ST, *see* Burstein HJ  
   *see* Costa DB  
 Schumock GT, *see* McKoy JM  
   *see* Wolf MS  
 Schuster MW, *see* Leonard JP  
   *see* Peters WP  
 Schütte J, *see* Bauer S  
 Schütte M, *see* von Minckwitz G  
 Schwab F, *see* Vordermark D  
 Schwab M, *see* Bilke S  
 Schwab R, Pinter F, Moldavy J, Papay J, Strausz J, Kopper L, Keri G, Pap A, Petak I, Oreskovich K, Mangel L. Modern Treatment of Lung Cancer. Amplification and Mutation of the Epidermal Growth Factor Receptor in Metastatic Lung Cancer With Remission from Gefitinib, 7736  
 Schwaiger M, *see* Amendola MA  
   *see* Avril N  
 Schwalb JM, *see* Tu P-H  
 Schwartz B, *see* Strumberg D  
 Schwartz CL, *see* Meyers PA  
 Schwartz GK, *see* Chung KY  
   *see* D'Adamo DR  
   *see* Kortmansky J  
 Schwartz GK. Development of Cell Cycle Active Drugs for the Treatment of Gastrointestinal Cancers: A New Approach to Cancer Therapy, 4499  
 Schwartz GK, Shah MA. Targeting the Cell Cycle: A New Approach to Cancer Therapy, 9408  
 Schwartz GK, Weitzman A, O'Reilly E, Brail L, de Alwis DP, Cleverly A, Barile-Thiem B, Vinciguerra V, Budman DR. Phase I and Pharmacokinetic Study of LY293111, an Orally Bioavailable LTB<sub>4</sub> Receptor Antagonist, in Patients With Advanced Solid Tumors, 5365  
 Schwartz JS, *see* Armstrong K  
 Schwartz K, *see* Katz SJ  
 Schwartz L, *see* Chung KY  
   *see* Kelly WK  
   *see* Kemeny N  
 Schwartz LH, *see* Hricak H  
 Schwartz MD, *see* Peshkin BN  
 Schwartz MD. Contralateral Prophylactic Mastectomy: Efficacy, Satisfaction, and Regret (editorial), 7777  
 Schwartz MD, Peshkin BN, Isaacs C. In Reply (correspondence), 1331  
 Schwartzberg LS, *see* Vogel CL  
 Schwarz R, *see* Kempf-Bielack B  
   *see* Rades D  
 Schwarz RE, *see* Smith DD  
 Schwarz RE, Smith DD. Extended Lymph Node Dissection for Gastric Cancer: Who May Benefit? Final Results of the Randomized Dutch Gastric Cancer Group Trial (correspondence), 5404  
 Schwarz RR, *see* Smith DD  
 Schweisfurth H, *see* Schuette W  
 Schwenn M, *see* Laver JH  
 Schwerdtfeger R, *see* Hess G  
 Schwürzer-Voit M, *see* Voit C  
 Scigalla P, *see* Schuch G  
 Scimé R, *see* Corradini P  
 Sciort R, *see* Van Glabbeke M  
   *see* Williamson D  
 Scollo P, *see* Buda A  
 Scopinaro F, De Vincentis G, Varvarigou AD. Use of Radiolabeled Bombesin in Humans (correspondence), 3170  
 Scotland R, *see* Sanderson K  
 Scott AM. Radioimmunotherapy of Prostate Cancer: Does Tumor Size Matter? (editorial), 4567  
 Scott C, *see* Belani CP  
   *see* Choy H  
   *see* Movsas B  
 Scott WJ, *see* Berger AC  
 Scotté F, *see* Oudard S  
 Scotté F, Tourani J-M, Banu E, Peyromaure M, Levy E, Marsan S, Magherini E, Fabre-Guillevin E, Andrieu J-M, Oudard S. Multicenter Study of a Frozen Glove to Prevent Docetaxel-Induced Onycholysis and Cutaneous Toxicity of the Hand, 4424  
 Scotti G, *see* Carli M  
 Scotto J-J, *see* Jourdan E  
 Sculier JP, *see* Berghmans T  
 Scurr M, *see* Banerji U  
 Seaman J, *see* Coleman RE  
 Seay TE, *see* Tan-Chiu E  
 Sebastian G, *see* Kaufmann R  
 Sebban C, *see* Feugier P  
 Sebanovic D, *see* Eberhard DA  
 Sebolt-Leopold J, *see* LoRusso PM

## AUTHOR INDEX

- Sebti SM, *see* Cloughesy TF
- Secondino S, *see* Comoli P
- Secord AA, *see* Cragun JM
- Secrist JP, *see* Kelly WK
- Seddon JM, *see* Kleinerman RA
- Sederholm C, Hillerdal G, Lamberg K, Kölbeck K, Dufmats M, Westberg R, Gawande SR. Phase III Trial of Gemcitabine Plus Carboplatin Versus Single-Agent Gemcitabine in the Treatment of Locally Advanced or Metastatic Non–Small-Cell Lung Cancer: The Swedish Lung Cancer Study Group, 8380
- Sedlacek SM, *see* Mamounas EP
- Seeber S, *see* Stahl M  
*see* Strumberg D
- Seeger K, *see* Wu S
- Seeger RC, *see* London WB  
*see* Schmidt ML
- Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R, MacPherson N, O'Reilly S, Spinelli JJ, Sutherland J, Wilson KS, Gascoyne RD, Connors JM. Introduction of Combined CHOP Plus Rituximab Therapy Dramatically Improved Outcome of Diffuse Large B-Cell Lymphoma in British Columbia, 5027
- Seidel GD, *see* Pingpank JF
- Seidemann K, Zimmermann M, Book M, Myer U, Burkhardt B, Welte K, Reiter A, Stanull A. Tumor Necrosis Factor and Lymphotoxin Alfa Genetic Polymorphisms and Outcome in Pediatric Patients With Non-Hodgkin's Lymphoma: Results From Berlin-Frankfurt-Münster Trial NHL-BFM 95, 8414
- Seiden MV, *see* Campos S  
*see* Garcia-Carbonero R
- Seidenfeld J, *see* Schrag D
- Seidman AD. "Will Weekly Work"? Seems to be so. . . (editorial), 5873
- Seifert B, *see* Carbone DP
- Sein J, *see* Luiten RM
- Seiter K, *see* Arshad M
- Seitz JF, *see* Sargent DJ
- Seja E, *see* Ribas A
- Sekine I, *see* Takano T  
*see* Yamamoto N
- Sekino H, *see* Matsuzaki H
- Selby R, *see* Townsley CA
- Sellers TA, *see* Frost MH
- Selleslach J, *see* Soepenberg O
- Selvaggi FP, *see* Boccardo F.
- Semiglazov V, *see* Chan S  
*see* Leyland-Jones B
- Semik M, *see* Kempf-Bielack B
- Semiond D, *see* Soepenberg O
- Sengelov L, *see* von der Maase H
- Serke M, *see* Schuette W
- Serrano J, *see* Tiseo M
- Serrano S, *see* Salar A
- Seshagiri S, *see* Eberhard DA  
*see* Herbst RS
- Sessa C, De Braud F, Perotti A, Bauer J, Curigliano G, Noberasco C, Zanaboni F, Gianni L, Marsoni S, Jimeno J, D'Incalci M, Dall'ó E, Colombo N. Trabectedin for Women With Ovarian Carcinoma After Treatment With Platinum and Taxanes Fails, 1687
- Sethi V, *see* Wee J
- Setien F, *see* Agrelo R
- Seufert I, *see* Vordermark D
- Severson RK, *see* Chuba PJ
- Seymour JF, *see* Abrey LE
- Seymour L, *see* Canil CM  
*see* Leighl NB
- Seynaeve C, *see* Bontenbal M  
*see* Nieboer P
- Sfikakis PP, *see* Dimopoulos MA
- Sgroi DC, *see* Bell DW  
*see* Petricoin EF III
- Shaffer DW, *see* Hainsworth JD
- Shah M, *see* Chung KY
- Shah MA, *see* Kortmansky J  
*see* Schwartz GK
- Shah MA, Ilson D, Kelsen DP. Thromboembolic Events in Gastric Cancer: High Incidence in Patients Receiving Irinotecan- and Bevacizumab-Based Therapy, 2574
- Shah NT, Kris MG, Pao W, Tyson LB, Pizzo BM, Heinemann M-H, Ben-Porat L, Sachs DL, Heelan RT, Miller VA. Practical Management of Patients With Non–Small-Cell Lung Cancer Treated With Gefitinib, 165
- Shah S, *see* Dragnev KH
- Shahab N, *see* Sachs BA
- Shaheen NJ, *see* Dellon ES
- Shak S, *see* Gianni L
- Sham J, *see* Kwong D
- Sham JST, *see* Chua DTT  
*see* Lee AWM
- Shamash J, *see* Fennell DA
- Shamash J, Powles T, Wilson P, Ansell W, Oliver T. Prognostic Factors in Cytokine-Refractory Renal Cell Carcinoma Treated With Irinotecan, Cisplatin, and Mitomycin Chemotherapy (correspondence), 1323
- Shamberger RC, *see* Grundy PE
- Shamsa F, *see* Chuba PJ
- Shamsaldin A, *see* Guibout C
- Shankar LK, Sullivan DC. Functional Imaging in Lung Cancer, 3203
- Shannon C, *see* Ring AE
- Shannon RP, *see* Tan-Chiu E
- Shapiro CL. Aromatase Inhibitors and Bone Loss: Risks in Perspective, 4847
- Shariat SF, *see* Lotan Y
- Sharma A, *see* Ribas A
- Sharma R, McLeod D, Clarke SJ. Small Blue Cell Tumors of the Rectum Atypical Carcinoid of the Rectum, 914
- Sharma S, *see* Ferraro B
- Shaw BW, *see* Gross TG
- Shaw H, *see* Gradishar WJ
- Sheaff MT, *see* Fennell DA
- Shearer P, *see* Grundy PE
- Sheinfeld J, *see* Kondagunta GV  
*see* Ronnen EA  
*see* Stephenson AJ
- Shek TW, *see* Au WY  
*see* Hon C
- Shelley W, *see* Pater J
- Shellito PC, *see* Willett CG
- Shen J, *see* Ezzo J
- Shen S, *see* Ziari M
- Shen Y, *see* Dowell JE
- Shen Z, *see* Cao Y
- Shenkier T, *see* Abrey LE  
*see* Panades M
- Shenkier TN, Blay J-Y, O'Neill BP, Poortmans P, Thiel E, Jahnke K, Abrey LE, Neuwelt E, Tsang R, Batchelor TT, Harris N, Ferreri AJM, Ponzoni M, O'Brien P, Rubenstein J, Connors JM. Primary CNS Lymphoma of T-Cell Origin: A Descriptive Analysis From the International Primary CNS Lymphoma Collaborative Group, 2233
- Shenton A, *see* Stirling D
- Shepherd F, *see* Gridelli C

## AUTHOR INDEX

- Shepherd FA, *see* Bissett D  
*see* D'Addario G  
*see* Leighl NB  
*see* Singh S
- Shepherd FA. A Targeted Approach to Reducing Lung Cancer Mortality (editorial), 3173
- Shepherd JD, *see* Forrest DL
- Shepherd JH, *see* Rockall AG
- Shepherd L, *see* Pater J  
*see* Praga C
- Shepherd LE, *see* Levine MN  
*see* Meyer RM  
*see* Parulekar WR  
*see* Whelan TJ
- Sher DA, *see* Marcucci G
- Sherrod AE, *see* Vallböhmer D
- Sherry E, *see* Warnke PH
- Sherry RM, *see* Attia P  
*see* Dudley ME
- Shi G, *see* Le Q-T
- Shia J, *see* Chung KY  
*see* Guillem JG  
*see* Klimstra DS  
*see* Schrag D
- Shibata T, *see* Takano T
- Shields PG, *see* Prochazka M
- Shigematsu H, *see* Cappuzzo F
- Shih WJ, *see* Goodin S
- Shim YM, *see* Choi JY
- Shima Y, *see* Morita T
- Shimabukuro-Vornhagen A, Haverkamp H, Engert A, Balleisen L, Majunke P, Heil G, Eich HT, Stein H, Diehl V, Josting A. Lymphocyte-Rich Classical Hodgkin's Lymphoma: Clinical Presentation and Treatment Outcome in 100 Patients Treated Within German Hodgkin's Study Group Trials, 5739
- Shimada H, *see* London WB  
*see* Schmidt ML
- Shiminski-Maher T, *see* Geyer JR
- Shimizu K, *see* Greipp PR
- Shimizu M, *see* Yamamoto N
- Shimonov M, *see* Stojadinovic A
- Shimoyama T, *see* Yamamoto N
- Shin DM, *see* Herbst RS  
*see* Lu C
- Shin HJ, *see* Lu C
- Shin S-A, *see* Oh SW
- Shinoda M, *see* Mitsudomi T
- Shiple J, *see* Williamson D
- Shiraga S, *see* Corless CL
- Shivnan J, *see* Ezzo J
- Shore T, *see* Leonard JP
- Shou J, *see* Gutierrez MC
- Shpall E, *see* Khouri IF
- Shpall EJ, *see* Peters WP
- Shrager S, *see* Mamon HJ
- Shriver CD, *see* Peoples GE  
*see* Stojadinovic A
- Shu T, *see* Ziari M
- Shulman LN, *see* Bellon JR
- Shun C-T, *see* Chen JJW
- Shustik C, *see* Greipp PR
- Sian S, *see* Sanderson K
- Sibley K, *see* Menon U
- Sibony M, *see* Catto JWF
- Sidawy MK, *see* Austin RM
- Sidransky D, *see* Hoque MO
- Sieben NLG, Oosting J, Flanagan AM, Prat J, Roemeng MJM, Kolkman-Uljee SM, van Eijk R, Cornelisse CJ, Fleuren GJ, van Engeland M. Differential Gene Expression in Ovarian Tumors Reveals *Dusp 4* and *Serpina 5* As Key Regulators for Benign Behavior of Serous Borderline Tumors, 7257
- Sieber M, *see* Josting A
- Siegel G, *see* Meyers PA
- Siegel E, *see* Hussain A
- Siegel SE, *see* Meeske KA
- Siegelman ES, *see* Hricak H
- Siegert W, *see* Hess G
- Siena S, *see* Comoli P
- Sierankowski G, *see* MacGrogan G
- Sierra J, *see* Moreno C
- Sieuwerts AM, *see* Jansen MPH
- Siewert JR, *see* von Rahden BHA
- Sigal R, *see* Dromain C
- Sigerdson ER, *see* Berger AC
- Sigstad E, *see* Subdø J
- Sihto H, Sarlomo-Rikala M, Tynninen O, Tanner M, Andersson LC, Franssila K, Nupponen NN, Joensuu H. *KIT* and Platelet-Derived Growth Factor Receptor Alpha Tyrosine Kinase Gene Mutations and *KIT* Amplifications in Human Solid Tumors, 49
- Sikic BI, *see* Kuo T
- Sikov W, *see* Green MC
- Silberfarb PM, *see* Ahles TA
- Silberstein PT, *see* Jones DH  
*see* Witzig TE
- Sill H, Olipitz W, Schimek MG. Therapy-Related Myelodysplastic Syndrome and Acute Myeloid Leukemia After Autologous Bone Marrow Transplantation: *Dosis Facit Venenum?* (correspondence), 8120
- Silvani J-A, *see* Fournel P
- Silver BJ, *see* Bellon JR
- Simard S, *see* Savard J
- Simeone E, Ascierto PA
- Siminoff LA, *see* Trauth JM
- Simmons C, Clemons M. Pattern of Care at the End of Life: Does Age Make a Difference? (correspondence), 2441
- Simmons L, *see* Banerji U
- Simon R, *see* Freidlin B  
*see* Ghadimi BM  
*see* Sauter G
- Simon R. Roadmap for Developing and Validating Therapeutically Relevant Genomic Classifiers, 7332
- Simoncini E, *see* Gruber G
- Simone JV, *see* Neuss MN
- Simonelli C, *see* Spina M
- Simony-Lafontaine J, *see* Rouanet P
- Simpson JF, *see* Nattinger AB
- Simunovic M, Gafni A, Levine M. In Reply (correspondence), 3633
- Sing AP, *see* Miller KD
- Singh DA, *see* Kindler HL
- Singh N, *see* Rockall AG
- Singh S, Parulekar W, Murray N, Feld R, Evans WK, Tu D, Shepherd FA. Influence of Sex on Toxicity and Treatment Outcome in Small-Cell Lung Cancer, 850
- Singletary SE, *see* Buzdar AU  
*see* Hennessy BT
- Siperstein AE, *see* Berber E
- Siragusa A, *see* Boccardo F
- Sismondi P, *see* Boccardo F
- Sitaras NM, *see* Bonovas S

## AUTHOR INDEX

- Siu L, *see* Lee AWM  
 Siu LL, *see* Hotte SJ  
   *see* Knox JJ  
   *see* Townsley C  
   *see* Townsley CA  
   *see* Zia MI
- Sivasubramaniam VH, *see* Lyman GH
- Skalla K, *see* Ahles TA
- Skarin A, *see* Mamon HJ
- Skates SJ, *see* Menon U
- Skene A, *see* Dowsett M  
   *see* Smith IE
- Skerman H, *see* Yates P
- Skipper M, *see* Czuczman MS
- Skobieranda F, *see* Warr DG
- Skolnik JM, *see* Lee DP
- Skovlund E, *see* Thorsen L
- Slack R, *see* Marshall JL  
   *see* Stearns V
- Sledge GW Jr. What Is Taargeted Therapy? (editorial), 1614
- Slejffer DT, *see* Nuver J
- Slezak JM, *see* Frost MH
- Slimane K, *see* Andre F
- Slingluff CL Jr, *see* Schroen AT
- Slingluff CL Jr, Chianese-Bullock K, Yamshchikov G. Interleukin-2 Effects Deserve Further Study: A Need for Better Understanding of Biology and of Optimal Dose Regimens (correspondence), 5267
- Sliwkowski MX, *see* Agus DB
- Sloan A, *see* Chamberlain MC
- Sloan J, *see* Goetz MP
- Sloan JA, *see* Frost MH  
   *see* Witzig TE
- Slomovitz BM, *see* Soliman PT
- Slovak ML, *see* Bhatia R
- Sluiter WJ, *see* Nuver J
- Small E, *see* Stadler WM
- Small EJ, Rini BI, *see* Galsky MD  
   *see* Halabi S  
   *see* Ryan CJ  
   *see* Smith MR  
   *see* Webster WS
- Small EJ, Klein EA. Challenges and Future Directions in the Prevention and Management of Prostate Cancer, 8143
- Smeland S, *see* Ferrari S
- Smit AJ, *see* Nuver J
- Smit EF, *see* Hoekstra CJ  
   *see* van Tinteren H
- Smith A, *see* Augustson BM
- Smith B, *see* Koon HB
- Smith BD, *see* Floyd SR  
   *see* Wilson LD
- Smith BD, Lilly BE, Haffty BG, Wilson LD. Do PET and SNB Reduce the Rate of Elective Neck Dissection? A Hypothesis Still in Need of Validation (correspondence), 2874
- Smith BD, Smith GL, Cooper DL, Wilson LD. The Cutaneous B-Cell Lymphoma Prognostic Index: A Novel Prognostic Index Derived From a Population-Based Registry, 3390
- Smith BD, Smith GL, Haffty BG. Postmastectomy Radiation and Mortality in Women With T1–2 Node-Positive Breast Cancer, 1409
- Smith C, *see* Butts C  
   *see* Choy H  
   *see* Halbert CH  
   *see* Movsas B
- Smith CA, *see* Forrest DL
- Smith D, *see* Baka S
- Smith DA, *see* Burriss HA III  
   *see* Spector NL
- Smith DC, *see* Galsky MD
- Smith DD, *see* Schwarz RE
- Smith DD, Schwarz RR, Schwarz RE. Impact of Total Lymph Node Count on Staging and Survival After Gastrectomy for Gastric Cancer: Data From a Large US-Population Database, 7114
- Smith GL, *see* Smith BD
- Smith HJ, Timmer-Bonte JN
- Smith IE, *see* Dowsett M  
   *see* Ring AE  
   *see* Urruticoechea A
- Smith IE, Dowsett M, Ebbs SR, Dixon JM, Skene A, Blohmer J-U, Ashley SE, Francis S, Boeddinghaus I, Walsh G. Neoadjuvant Treatment of Postmenopausal Breast Cancer With Anastrozole, Tamoxifen, or Both in Combination: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined With Tamoxifen (IMPACT) Multicenter Double-Blind Randomized Trial, 5108
- Smith JA Jr, Herrell SD. Robotic-Assisted Laparoscopic Prostatectomy: Do Minimally Invasive Approaches Offer Significant Advantages? 8170
- Smith JR, *see* Abrey LE
- Smith JW, *see* McDermott DF
- Smith LD, *see* Southey MC
- Smith M, *see* Coleman RE
- Smith MA, *see* Korn EL  
   *see* Rubinstein LV
- Smith MC, *see* Carbone DP
- Smith MR, Kabbinavar F, Saad F, Hussain A, Gittelman MC, Bihartz DL, Wynne C, Murray R, Zinner NR, Schulman C, Linnartz R, Zheng M, Goessl C, Hei Y-J, Small EJ, Cook R, Higano CS. Natural History of Rising Serum Prostate-Specific Antigen in Men With Castrate Non-metastatic Prostate Cancer, 2918
- Smith MR, Lee WC, Brandman J, Wang Q, Botteman M, Pashos CL. Gonadotropin-Releasing Hormone Agonists and Fracture Risk: A Claims-Based Cohort Study of Men With Nonmetastatic Prostate Cancer, 7897
- Smith P, *see* Johnson PWM
- Smith R, *see* Edelman MJ  
   *see* Mamounas EP
- Smith RV, *see* Gaba A
- Smith S, *see* van Besien K
- Smith T, *see* Green MC
- Smith TJ. The American Society of Clinical Oncology Recommended Breast Cancer Surveillance Guidelines Can Be Done in a Routine Office Visit (correspondence), 6807
- Smith TL, *see* Buzdar AU  
   *see* Romaguera JE
- Smith WB, *see* Buchanan DR
- Smorenburg SM, *see* Klerk CPW
- Smuck B, *see* Wright J
- Smythe WR, *see* Lu C
- Sneige N, *see* Cristofanilli M  
   *see* Hennessy BT
- Snively BM, *see* McLean TW
- Snively J, *see* Sanderson K
- Snyder B, *see* Hricak H
- Snyder R, *see* Colleoni M  
   *see* Marty M
- Soballe PW, *see* Calzone KA
- Sober AJ, *see* Livestro DP
- Sobocinski KA, *see* Andrykowski MA
- Sobol H, *see* Eisinger F  
   *see* Lynch HT

- Sobrero A, Bruzzi P. Bevacizumab Plus Fluorouracil: The Value of Being Part of a Developing Story (editorial), 3660
- Soennichsen K, *see* Lengerke C
- Soepenberg O, Dumez H, Verweij J, Semiond D, deJonge MJA, Eskens FALM, ter Steeg J, Selleslach J, Assadourian S, Sanderink G-J, Sparreboom A, van Oosterom AT. Phase I and Pharmacokinetic Study of Oral Irinotecan Given Once Daily for 5 Days Every 3 Weeks in Combination With Capecitabine in Patients With Solid Tumors, 889
- Soetikno R, Kaltenbach T, Yeh R, Gotoda T. Endoscopic Mucosal Resection for Early Cancers of the Upper Gastrointestinal Tract, 4490
- Sofferman R, *see* Robbins KT
- Sogabe S, *see* Onozawa M
- Sohaib SA, *see* Rockall AG
- Sokal M, *see* Jones WG
- Sola J, *see* Mazzolini G
- Solal-Celigny P, *see* Feugier P  
*see* Rohatiner AZS
- Soldatenkova V, *see* Zielinski C
- Soliman PT, Broaddus RR, Schmeler KM, Daniels MS, Gonzalez D, Sломovitz BM, Gershenson DM, Lu KH. Women With Synchronous Primary Cancers of the Endometrium and Ovary: Do They Have Lynch Syndrome? 9344
- Solin L, *see* Haffty BG
- Solin LJ, *see* Harris EER
- Solomon M, *see* Joshua AM
- Solomon MZ, Browning D. Pediatric Palliative Care: Relationships Matter and So Does Pain Control (editorial), 9055
- Soma T, *see* Sakane-Ishikawa E
- Soma V, *see* Hamilton AL
- Somerfield MR, *see* Desch CE  
*see* Lyman GH  
*see* Schrag D  
*see* Winer EP
- Somlo G. In Reply (correspondence), 3860
- Sondak VK, *see* Chugh R  
*see* Worden FP
- Song KW, *see* Forrest DL
- Sonneveld P, *see* Doorduijn JK  
*see* Greipp PR  
*see* van Imhoff GW
- Sonpavde G, *see* Ziari M
- Sood AK, *see* Lutgendorf SK
- Soong S-J, *see* Balch CM
- Soong S-j, *see* Gimotty PA
- Soper JT, *see* Cragun JM
- Soran A, *see* Mamounas EP
- Sorará M, *see* Verso M
- Sørbye H, Glimelius B. In Reply (correspondence), 3862
- Soria J-C, *see* Dômont J
- Sormani MP, *see* Bruzzi P
- Sorosky J, *see* Long HJ III
- Sorosky JJ, *see* Lutgendorf SK
- Sorrór M, *see* Baron F
- Sorrór ML, Maris MB, Sandmaier BM, Storer BE, Stuart MJ, Hegenbart U, Agura E, Chauncey TR, Leis J, Pulsipher M, McSweeney P, Radich JP, Bredeson C, Bruno B, Langston A, Loken MR, Al-Ali H, Blume KG, Storb R, Maloney DG. Hematopoietic Cell Transplantation After Non-myeloablative Conditioning for Advanced Chronic Lymphocytic Leukemia, 3819
- Sosman JA, *see* Hainsworth JD  
*see* McDermott DF
- Sotomatsu M, *see* Igarashi S
- Sotto JJ, *see* de Botton S
- Souhami L, *see* Choy H
- Soulières D, *see* Butts C
- Souliotis VL, *see* Dimopoulos MA
- Souquet P-J, *see* Fournel P
- Soussain C, *see* Abrey LE
- Soussi T, *see* Russo M
- Southey MC, Jenkins MA, Mead L, Whitty J, Trivett M, Tesoriero AA, Smith LD, Jennings K, Grubb G, Royce SG, Walsh MD, Barker MA, Young JP, Jass JR, St John DJB, Macrae FA, Giles GG, Hopper JL. Use of Molecular Tumor Characteristics to Prioritize Mismatch Repair Gene Testing in Early-Onset Colorectal Cancer, 6524
- Sovan A, *see* Mamounas EP
- Soverini S, Martinelli G, Rosti G, Bassi S, Amabile M, Poerio A, Giannini B, Trabacchi E, Castagnetti F, Testoni N, Luatti S, de Vivo A, Cilloni D, Izzo B, Fava M, Abruzzese E, Alberti D, Pane F, Saglio G, Baccarani M. ABL Mutations in Late Chronic Phase Chronic Myeloid Leukemia Patients With Up-Front Cytogenetic Resistance to Imatinib Are Associated With a Greater Likelihood of Progression to Blast Crisis and Shorter Survival: A Study by the GIMEMA Working Party on Chronic Myeloid Leukemia, 4100
- Sowers R, *see* Kortmansky J
- Soyer HP, *see* Richtig E
- Sozzi G, *see* Frattini M
- Sozzi G, Conte D, Roz L. In Reply (correspondence), 3164
- Spaggiari L, *see* De Pas T  
*see* DePas T  
*see* Noberasco C
- Span PN, Sweep CGL, Beex LVAM, Foekens JA. In Reply (correspondence), 3160
- Spanik S, *see* Zielinski C
- Spanos W, *see* Choy H
- Sparano J, *see* Muss HB  
*see* Parekh S
- Sparano J. In Reply (correspondence), 1329
- Sparreboom A, *see* de Jong FA  
*see* Ryan QC  
*see* Soepenberg O
- Sparreboom A, Baker SD, Verweij J. Paclitaxel Repackaged in an Albumin-Stabilized Nanoparticle: Handy or Just a Dandy? (editorial), 7765
- Sparwasser C, *see* Port M
- Spatafora M, *see* Maione P
- Speakman J, *see* Basch E
- Spector N, Milito CB, Biasoli I, Morais JC. p53 Expression As a Prognostic Indicator in Hodgkin's Lymphoma (correspondence), 3158
- Spector NL, *see* Burris HA III
- Spector NL, Xia W, Burris W III, Hurwitz H, Dees EC, Dowlati A, O'Neil B, Overmoyer B, Marcom PK, Blackwell KL, Smith DA, Koch KM, Stead A, Mangum S, Ellis MJ, Liu L, Man AK, Bremer TM, Harris J, Bacus S. Study of the Biologic Effects of Lapatinib, A Reversible Inhibitor of ErbB1 and ErbB2 Tyrosine Kinases, on Tumor Growth and Survival Pathways in Patients With Advanced Malignancies, 2502
- Speers CH, *see* Panades M
- Speight JL, Roach M III. Radiotherapy in the Management of Clinically Localized Prostate Cancer: Evolving Standards, Consensus, Controversies, and New Directions, 8176
- Speights RA, *see* Daw NC
- Speiser D, *see* van Baren N
- Speleman F, *see* De Preter K  
*see* Vandesompele J
- Spencer A, *see* Dawson MA
- Spencer HJ, *see* Alikhan M
- Spencer SA, *see* Divers SG
- Spencer SS, *see* Ang KK
- Spentzos D, Levine DA, Kolia S, Otu H, Boyd J, Libermann TA, Canistra

- SA. Unique Gene Expression Profile Based on Pathologic Response in Epithelial Ovarian Cancer, 7911
- Spicer RD, *see* Stevens MCG
- Spiegler BJ, *see* Mabbott DJ
- Spielmann M, *see* Andre F  
*see* Rouzier R
- Spieth K, *see* Kaufmann R
- Spigel DR, *see* Hainsworth JD
- Spina M, *see* Mazza C
- Spina M, Simonelli C, Talamini R, Tirelli U. Patients with HIV With Burkitt's Lymphoma Have a Worse Outcome Than Those With Diffuse Large-Cell Lymphoma Also in the Highly Active Antiretroviral Therapy Era (correspondence), 8132
- Spinelli JJ, *see* Sehn LH
- Spinola M, Leoni V, Pignatiello C, Conti B, Ravagnani F, Pastorino U, Dragani TA. Functional FGFR4 Gly388Arg Polymorphism Predicts Prognosis in Lung Adenocarcinoma Patients, 7307
- Spiro SG, *see* Brown J  
*see* Rudd RM
- Spitaleri G, *see* Curigliano G
- Spitler LE, *see* Weber RW
- Spits H, *see* Luiten RM
- Spitz MR, *see* Lee H-Y
- Spitz MR, Wu X, Mills G. Integrative Epidemiology: From Risk Assessment to Outcome Prediction, 267
- Spooner D, *see* Stevens MCG
- Spoto R, *see* Geyer JR
- Spreato F, *see* Ferrari A
- Sprengel M, *see* Warnke PH
- Spriggs DR, *see* Aghajanian C
- Springer IN, *see* Warnke PH
- Spruill S, *see* Petros WP
- Spunt SL, *see* Hinds PS
- Spunt SL, Sweeney TA, Hudson MM, Billups CA, Krasin MJ, Hester AL. Late Effects of Pelvic Rhabdomyosarcoma and Its Treatment in Female Survivors, 7143
- Squires DR, *see* Kreitman RJ
- Srinivas S, *see* Badger J
- Srinivasan R, Linehan WM. Targeted for Destruction: The Molecular Basis for Development of Novel Therapeutic Strategies in Renal Cell Cancer (editorial), 410
- St John DJB, *see* Southey MC
- Staa JO, *see* Schnell R
- Staalman CR, *see* Aronson DC
- Stadler WM, *see* Kindler HL
- Stadler WM, Michaelis LC, Ratain MJ. Randomized Phase II Trials and Prostate-Specific Antigen Endpoints in Prostate Cancer: Much Ado About Nothing? (correspondence), 8124
- Stadler WM, Rosner G, Small E, Hollis D, Rini B, Zaentz SD, Mahoney J. Successful Implementation of the Randomized Discontinuation Trial Design: An Application to the Study of the Putative Antiangiogenic Agent Carboxyaminoimidazole in Renal Cell Carcinoma—CALGB 69901, 3726
- Stadtmauer E, *see* DeMichele A
- Stahel R, *see* Ghilmini M
- Stahel RA, *see* Lardinois D
- Stahl K, *see* Kaufman M
- Stahl M, Stuschke M, Lehmann N, Meyer H-J, Walz MK, Seeber S, Klump B, Budach W, Teichmann R, Schmitt M, Schmitt G, Franke C, Wilke H. Chemoradiation With and Without Surgery in Patients With Locally Advanced Squamous Cell Carcinoma of the Esophagus, 2310
- Staib P, *see* Elter T
- Stål O, *see* Rydén L
- Stallings R, *see* Vandesompele J
- Stalpers LJA, *see* Rades D
- Stamatoulas A, *see* de Botton S
- Stamberg J, *see* Farag SS
- Stange DE, *see* Mendrzyk F
- Stanton AL, Ganz PA, Kwan L, Meyerowitz BE, Bower JE, Krupnick JL, Rowland JH, Leedham B, Belin TR. Outcomes From the Moving Beyond Cancer Psychoeducational, Randomized, Controlled Trial with Breast Cancer Patients, 6009
- Stanton AL. How and for Whom? Asking Questions About the Utility of Psychosocial Interventions for Individuals Diagnosed With Cancer, 4818
- Stanulla M, *see* Seidemann K
- Stapleton S, *see* Banerji U
- Starczynski J, Pepper C, Pratt G, Hooper L, Thomas A, Milligan D, Bentley P, Fegan C. Common Polymorphism G(-248)A in the Promoter Region of the *bax* Gene Results in Significantly Shorter Survival in Patients With Chronic Lymphocytic Leukemia Once Treatment Is Initiated, 1514
- Stargatt R, *see* Mulhern RK
- Stasi J, *see* Stephenson AJ
- Stauffer JS, *see* Mamounas EP
- Stea B, *see* Choy H
- Stead A, *see* Burris HA III  
*see* Spector NL
- Stearns V, Slack R, Greep N, Henry-Tilman R, Osborne M, Bunnell C, Ullmer L, Gallagher A, Cullen J, Gehan E, Hayes DF, Isaacs C. Paroxetine Is an Effective Treatment for Hot Flashes: Results From a Prospective Randomized Clinical Trial, 6919
- Stebbing J, *see* Bower M
- Stebbing J, Mandalia S, Palmieri C, Nelson M, Gazzard B, Bower M. Burkitt's Lymphoma and Previous AIDS-Defining Illnesses Are Not Prognostic Factors in AIDS-Related Non-Hodgkin's Lymphoma (correspondence), 8538
- Stebbing J, Walters L, Davies L, Mandalia S, Nelson M, Gazzard B, Bower M. Incidence of Cancer in Individuals Receiving Chronic Zopiclone or Eszopiclone Requires Prospective Study (correspondence), 8134
- Steel CM, *see* Stirling D
- Steele J, *see* Fennell DA
- Steensma DP, Loprinzi CL. Erythropoietin Use in Cancer Patients: A Matter of Life and Death? (editorial), 5865
- Stefani M, *see* Ardizzoni A
- Steg A, *see* Saif MW
- Stegall MD, *see* Ghobrial IM
- Stegmaier C, *see* Arndt V
- Steijaert MMC, *see* van Imhoff GW
- Stein, HJ, *see* von Rahden BHA
- Stein H, *see* Shimabukuro-Vornhagen A
- Stein U, *see* Conroy T
- Steinberg SM, *see* Calzone KA  
*see* Figg WD  
*see* Low JA
- Steineck G, *see* Kricbergs U
- Steiner A, *see* Richtig E
- Steinert HC, *see* Lardinois D
- Steinfeldt HM, *see* Liu G  
*see* Rugo HS
- Steingart R. Mechanisms of Late Cardiovascular Toxicity From Cancer Chemotherapy (editorial), 9051
- Steinhauer H, *see* Lenz G
- Steinle R, *see* Sup SJ
- Stelitano C, *see* Gobbi PG
- Stella P, *see* Jatoui A
- Stem Cell Trialists' Collaborative Group. Allogeneic Peripheral Blood Stem-Cell Compared With Bone Marrow Transplantation in the Man-

- agement of Hematologic Malignancies: An Individual Patient Data Meta-Analysis of Nine Randomized Trials, 5074
- Stenning SP, *see* Johnson PWM  
*see* Jones WG
- Stenning SP, Jones WG, Fossa SD. In Reply (correspondence), 6806
- Stensgard B, *see* Goetz MP
- Stephens C, *see* Kurtzberg J
- Stephens R, *see* Abratt RP  
*see* Macbeth F
- Stephens RJ, *see* Brown J  
*see* Thatcher N
- Stephenson AJ, Bosl GJ, Motzer RJ, Kattan MW, Stasi J, Bajorin DF, Sheinfeld J. Retroperitoneal Lymph Node Dissection for Nonseminomatous Germ Cell Testicular Cancer: Impact of Patient Selection Factors on Outcome, 2781
- Stephenson AJ, Eastham JA. Role of Salvage Radical Prostatectomy for Recurrent Prostate Cancer After Radiation Therapy, 8198
- Stephenson AJ, Scardino PT, Eastham JA, Bianco FJ Jr, Dotan ZA, DiBlasio CJ, Reuther A, Klein EA, Kattan MW. Postoperative Nomogram Predicting the 10-Year Probability of Prostate Cancer Recurrence After Radical Prostatectomy, 7005
- Sterling LJ, *see* Marcucci G
- Stern DF, *see* DiGiovanna MP
- Sternberg CN, *see* Berthold DR
- Sternberg D, *see* Lehmann J
- Sternfeld WC, *see* Alberts SR
- Serry W, *see* Voit C
- Stetler-Stevenson M, *see* Kreitman RJ
- Steup WH, *see* Peeters KCMJ
- Stevens JL, *see* Harlan LC
- Stevens MCG, *see* Orbach D
- Stevens MCG, Rey A, Bouvet N, Ellershaw C, Flamant F, Habrand JL, Marsden HB, Martelli H, Sanchez de Toledo J, Spicer RD, Spooner D, Terrier-Lacombe MJ, van Unnik A, Oberlin O. Treatment of Nonmetastatic Rhabdomyosarcoma in Childhood and Adolescence: Third Study of International Society of Paediatric Oncology—SIOP Malignant Mesenchymal Tumor 89, 2618
- Stevenson MA, *see* Floyd SR
- Steward WP, *see* Thomas AL
- Stewart AJ, Scher HI, Chen M-H, McLeod DG, Carroll PR, Moul JW, D'Amico AV. Prostate-Specific Antigen Nadir and Cancer-Specific Mortality Following Hormonal Therapy for Prostate-Specific Antigen Failure, 6556
- Stewart AK, *see* Jaksic W
- Stewart AK, Fonseca R. Prognostic and Therapeutic Significance of Myeloma Genetics and Gene Expression Profiling, 6339
- Stewart BW, Coates AS. Cancer Prevention: A Global Perspective, 392
- Stewart C, *see* Czuczman MS
- Stewart CF, *see* Daw NC  
*see* Santana VM
- Stewart J, *see* Okuno S
- Stewart L, *see* Burdett S
- Steyerberg EW, *see* Vergouwe Y
- Steyerberg EW, Earle CC, Neville BA, Weeks JC. Racial Differences in Surgical Evaluation, Treatment, and Outcome of Locoregional Esophageal Cancer: A Population-Based Analysis of Elderly Patients, 510
- Stiggelbout AM, *see* Jansen SJT  
*see* Marijnen CAM  
*see* van den Brink M
- Stilgenbauer S, *see* Kienle DL
- Stiller C, *see* Gatta G
- Stinson JA, *see* Eberhard DA
- Stipanov M, *see* Carbone DP
- Stirling D, Evans DGR, Pichert G, Shenton A, Kirk EN, Rimmer S, Steel CM, Lawson S, Busby-Earle RMC, Walker J, Lalloo FI, Eccles DM, Lucassen AM, Porteous ME. Screening for Familial Ovarian Cancer: Failure of Current Protocols to Detect Ovarian Cancer at an Early Stage According to the International Federation of Gynecology and Obstetrics System, 5588
- Stock W, *see* Marcucci G  
*see* van Besien K
- Stockinger M, *see* Port M
- Stöckle M, *see* Lehmann J
- Stockler M. In Reply (correspondence), 1586
- Stojadinovic A, Nissan A, Gallimidi Z, Lenington S, Logan W, Zuley M, Yeshaya A, Shimonov M, Melloul M, Fields S, Allweis T, Ginor R, Gur D, Shriver CD. Electrical Impedance Scanning for the Early Detection of Breast Cancer in Young Women: Preliminary Results of a Multicenter Prospective Clinical Trial, 2703
- Stolpen A, *see* Juweid ME
- Stolte M, *see* Glas J  
*see* Wündisch T
- Stone R, *see* Feldman EJ
- Stone RM, *see* Farag SS
- Stopeck A, *see* Cristofanilli M
- Stopfer JE, *see* Halbert CH
- Stoppa AM, *see* de Botton S
- Storb R, *see* Baron F  
*see* Sorror ML  
*see* Wallen H
- Storer BE, *see* Baron F  
*see* Sorror ML  
*see* Syrjala KL
- Stormorken AT, Bowitz-Lothe IM, Norén T, Kure E, Aase S, Wijnen J, Apold J, Heimdal K, Møller P. Immunohistochemistry Identifies Carriers of Mismatch Repair Gene Defects Causing Hereditary Nonpolyposis Colorectal Cancer, 4705
- Storrer CE, *see* Peoples GE
- Stout R, *see* Baka S
- Stovall M, *see* Bowers DC  
*see* Kleinerman RA  
*see* Perkins JL
- Stovring H, *see* Aabom B
- Strasberg S, *see* Bilchik AJ
- Strasser-Weippl K, Goss PE. Advances in Adjuvant Hormonal Therapy for Postmenopausal Women, 1751
- Stratem Pt, *see* Andersen MH
- Straus D, *see* O'Connor OA
- Straus S, *see* Townsley C
- Strausz J, *see* Schwab R
- Streicher H, *see* Badros AZ
- Streitberger K, *see* Ezzo J
- Streubel B, *see* Raderer M
- Strijk SP, *see* de Vries IJM
- Strom EA, *see* Green MC
- Strom SS, *see* Clayman GL
- Strømme SB, *see* Thorsen L
- Strompf L, *see* Amar L
- Stroobants SG, *see* Hoekstra CJ
- Stroud S, *see* Mahfouz T
- Strouse JJ, Fears TR, Tucker MA, Wayne AS. Pediatric Melanoma: Risk Factor and Survival Analysis of the Surveillance, Epidemiology and End Results Database, 4735
- Struwing JP, *see* Kramer JL
- Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M, Faghiih M, Brendel E, Voliotis D, Haase CG, Schwartz B, Awada A, Voigtmann R, Scheulen ME, Seeber S. Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth

## AUTHOR INDEX

- Factor Receptor Inhibitor BAY 43–9006 in Patients With Advanced Refractory Solid Tumors, 965
- Stuart MJ, *see* Sorrow ML
- Stubblefield M, *see* O'Connor OA
- Studer UE, *see* Fleischmann A
- Stueben G, *see* Budach V
- Stul M, *see* De Paepe P
- Stuschke M, *see* Budach V
- Stuschke M, *see* Stahl M
- Stützer H, *see* Elter T
- Su YB, Krown SE, Livingston PO, Wolchok JD, Chapman PB. In Reply (correspondence), 4236
- Suárez A, *see* Espinosa E
- Suba Z, *see* Timár J
- Subbaramaiah K, *see* Dannenberg AJ
- Subtil J, *see* Mazzolini G
- Suchaud J-P, *see* Ray-Coquard I
- Suciu S, *see* Keilholz U
- Sudan DL, *see* Gross TG
- Sudbø J, *see* Lippman SM
- Sudbø J, Samuelsson R, Risberg B, Heistein S, Nyhus C, Samuelsson M, Puntervold R, Sigstad E, Davidson B, Reith A, Berner A. Risk Markers of Oral Cancer in Clinically Normal Mucosa As an Aid in Smoking Cessation Counseling, 1927
- Sugarbaker DJ, *see* Mamon HJ
- Sugimachi K, *see* Noguchi S
- Sugimoto T, *see* Gotoh T
- Sugino M, *see* Yokote T
- Sugita K, *see* Igarashi S
- Sugita K-i, *see* Igarashi S
- Sugiyama H, *see* Sakane-Ishikawa E
- Sullivan DC, *see* Shankar LK
- Sullivan DJ, *see* Grote T
- Sullivan T, *see* Taghian AG
- Suman VJ, *see* Goetz MP
- Sun CC, *see* Frumovitz M
- Sun D, *see* Chen S
- Sun P, *see* Eisen A
- Sun W, Lipsitz S, Catalano P, Mailliard JA, Haller DG. Phase II/III Study of Doxorubicin With Fluorouracil Compared With Streptozocin With Fluorouracil or Dacarbazine in the Treatment of Advanced Carcinoid Tumors: Eastern Cooperative Oncology Group Study E1281, 4897
- Sundaram P, *see* Eisenbeis CF
- Sundaram S, *see* Jones SE
- Sung J, *see* Mok TSK
- Suntharalingam M, Moughan J, Cola LR, Krasna MJ, Kachnic L, Haller DG, Willet CG, John MJ, Minsky BD, Owen JB. Outcome Results of the 1996–1999 Patterns of Care Survey of the National Practice for Patients Receiving Radiation Therapy for Carcinoma of the Esophagus, 2325
- Sup SJ, Alemañy CA, Pohlman B, Elson P, Malhi S, Thakkar S, Steinle R, Hsi ED. Expression of bcl-2 in Classical Hodgkin's Lymphoma: An Independent Predictor of Poor Outcome, 3773
- Supko JG, *see* Garcia-Carbonero R
- Suster D, *see* Morrison C
- Sutherland HJ, *see* Forrest DL
- Sutherland J, *see* Sehn LH
- Suzuki M, *see* Matsuzaki H
- Svolba G, *see* Richtig E
- Swain SM, *see* Low JA
- see* Tan-Chiu E
- see* Wedam SB
- Swanson DA, *see* Patard J-J
- Swart AMC, Parmar BKB. Observations on the Interpretation of Clinical Trials in Early Ovarian Cancer (correspondence), 927
- Swarte NB, *see* van der Lee ML
- Sweeney CJ, *see* Li J
- Sweeney TA, *see* Spunt SL
- Sweetenham J, *see* Czuczman MS
- Swenerton K, *see* Dark GG
- Swensen SJ, *see* Patz EF Jr
- Swenson WT, Wooldridge JE, Lynch CF, Foreman-Hoffman VL, Chrischilles E, Link BK. Improved Survival of Follicular Lymphoma Patients in the United States, 5019
- Swisher SG, *see* Lu C
- Sydes MR, *see* Johnson PWM
- Sylvester R, *see* Fennell DA
- Sylvester RJ, *see* Aass N
- Symmans WF, *see* Gianni L
- see* Green MC
- see* Rouzier R
- Synan I, *see* Cragun JM
- Synodinou M, *see* Athanassiou H
- Syrigos K, *see* Georgoulas V
- Syrjakoski K, *see* Honrado E
- Syrjala KL, Langer SL, Abrams JR, Storer BE, Martin PJ. Late Effects of Hematopoietic Cell Transplantation Among 10-Year Adult Survivors Compared With Case-Matched Controls, 6596
- Szabo E, *see* Grem JL
- Szabó G, *see* Timár J
- Szanto J, *see* Zielinski C
- Sze WM, *see* Lee AWM
- Sznol M, *see* Eisenbeis CF

## T

- Taber DA, *see* Kindler HL
- Taberero J, Rojo F, Marimón I, Voi M, Albanell J, Guix M, Vázquez, Carulla J, Cooper M, Andreu J, Van Vreckem A, Bellmunt J, Manne V, Manning JA, Garrido C, Felip E, Maria del Campo J, García M, Valverde S, Baselga J. Phase I Pharmacokinetic and Pharmacodynamic Study of Weekly 1-Hour and 24-Hour Infusion BMS-214662, a Farnesyltransferase Inhibitor, in Patients With Advanced Solid Tumors, 2521
- Taberero J, *see* Baselga J
- Tabilio A, *see* Aversa F
- Tabone M-D, *see* Entz-Werlé N
- Taghian AG, Abi-Raad R, Assaad SI, Casty A, Ancukiewicz M, Yeh E, Molokhia P, Attia K, Sullivan T, Kuter I, Boucher Y, Powell SN. Paclitaxel Decreases the Interstitial Fluid Pressure and Improves Oxygenation in Breast Cancers in Patients Treated With Neoadjuvant Chemotherapy: Clinical Implications, 1951
- Taglibue E, *see* Ménard S
- Tahan SR, *see* Koon HB
- Tai BC, *see* Wee J
- Taäieb J, *see* Louvet C
- Taäieb J, Artru P, Paye F, Louvet C, Perez N, André T, Gayet B, Hebbar M, Goebel FM, Tournigand C, Parc R, de Gramont A. Intensive Systemic Chemotherapy Combined With Surgery for Metastatic Colorectal Cancer: Results of a Phase II Study, 502
- Takahashi S, *see* Okada K
- Takahashi T, *see* Mitsudomi T
- Takakuwa T, *see* Sakane-Ishikawa E
- Takano T, Ohe Y, Sakamoto H, Tsuta K, Matsuno Y, Tateishi U, Yamamoto S, Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Shibata T, Sakiyama T, Yoshida T, Tamura T. Epidermal Growth Factor Receptor Gene Mutations and Increased Copy Numbers Predict Gefitinib Sensitivity in Patients With Recurrent Non-Small-Cell Lung Cancer, 6829
- Takashima S, *see* Kohno N

AUTHOR INDEX

- Takebe N, *see* Badros AZ  
 Takeshima T-L, *see* Mori T  
 Takeuchi H, *see* Kim J  
     *see* Koyanagi K  
 Takimoto CH, *see* Grem JL  
 Talamini R, *see* Spina M  
 Talamo G, Angtuaco E, Walker RC, Dong L, Miceli MH, Zangari M, Tricot G, Barlogie B, Anaissie E. Avascular Necrosis of Femoral and/or Humeral Heads in Multiple Myeloma: Results of a Prospective Study of Patients Treated With Dexamethasone-Based Regimens and High-Dose Chemotherapy, 5217  
 Talcott JA. Rebalancing Ratios and Improving Impressions: Later Thoughts From the Prostate Cancer Prevention Trial Investigators (editorial), 7388  
 Tallman MS, *see* Douer D  
 Tallman MS, Rowe JM. In Reply (correspondence), 1327  
 Talor E, *see* Timár J  
 Talpaz M, *see* Issa J-PJ  
 Tamura T, *see* Takano T  
     *see* Yamamoto N  
 Tan-Chiu E, *see* Vogel CL  
 Tan-Chiu E, Yothers G, Romond E, Geyer CE Jr, Ewer M, Keefe D, Shannon RP, Swain SM, Fehrenbacher L, Vogel VG, Seay TE, Rastogi P, Mamounas EP, Wolmark N, Bryant J. Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor2–Overexpressing Breast Cancer: NSABP B-31, 7811  
 Tan EH, *see* Wee J  
 Tan HSK, *see* Wee J  
 Tan T, *see* Wee J  
 Tan Y-H, *see* Wang Y-C  
 Tanabe KK, *see* Livestro DP  
 Tanaka F, *see* Hamada C  
 Tanaka J, *see* Watanabe T  
 Tanaka T, *see* Watanabe T  
 Tang L, *see* Klimstra DS  
     *see* Traina TA  
 Tangen CM, *see* Hussain M  
     *see* Klein EA  
     *see* Thompson IM  
 Tanner M, *see* Sihto H  
 Tannock IF, *see* Berthold DR  
     *see* Mar Fan HG  
     *see* Meyskens FL Jr  
 Tao M, *see* Choo SP  
 Tao ML, *see* Geyer JR  
 Tao ML, Parsons SK. Quality-of-Life Assessment in Pediatric Brain Tumor Patients and Survivors: Lessons Learned and Challenges to Face (editorial), 5424  
 Tao Q, *see* Chen S  
 Tarantolo S, *see* Lynch HT  
 Tarbell N, *see* Laver JH  
 Tarbell NJ, *see* Adams MJ  
     *see* Jagsi R  
 Tarella C, *see* Corradini P  
 Taron M, *see* Ramirez JL  
 Tarone RE, *see* Kleinerman RA  
 Tartaglia J, *see* van Baren N  
 Tasci S, Kovacs A, Leutner C, Zivanovic O, Lüderitz B, Büttner R, Mey U. Patients With Malignancy Requiring Urgent Therapy. Central Airway Obstruction As First Presentation of Ovarian Cancer, 6791  
 Tateishi U, *see* Takano T  
 Tatro D, *see* Ben-Josef E  
 Tatro DS, *see* Cao Y  
 Tattersall MHN, *see* Hagerty RG  
 Taube SE, *see* McShane LM  
 Taube T, *see* Wu S  
 Tauro S, Craddock C, Peggs K, Begum G, Mahendra P, Cook G, Marsh J, Milligan D, Goldstone A, Hunter A, Khwaja A, Chopra R, Littlewood T, Peniket A, Parker A, Jackson G, Hale G, Cook M, Russell N, Mackinnon S. Allogeneic Stem-Cell Transplantation Using a Reduced-Intensity Conditioning Regimen Has the Capacity to Produce Durable Remissions and Long-Term Disease-Free Survival in Patients With High-Risk Acute Myeloid Leukemia and Myelodysplasia, 9387  
 Taverna C, *see* Dubs A  
 Taylor A, *see* Thewes B  
 Taylor C, *see* Agus DB  
 Taylor CR, *see* Chen S  
 Taylor JMG, *see* Worden FP  
 Taylor JMG, Yu M, Sandler HM. Individualized Predictions of Disease Following Radiation Therapy for Prostate Cancer, 816  
 Taylor PR, Greenwald P. Nutritional Interventions in Cancer Prevention, 333  
 Taylor RE, *see* Ellison DW  
 Teban L, *see* Richtig E  
 Tefferi A. Pathogenesis of Myelofibrosis With Myeloid Metaplasia, 8520  
 Teh BS, *see* Ziari M  
 Teicher BA, *see* Gasparini G  
 Teichmann R, *see* Stahl M  
 Tekautz TM, Fuller CE, Blaney S, Fouladi M, Broniscer A, Merchant TE, Krasin M, Dalton J, Hale G, Kun LE, Wallace D, Gilbertson RJ, Gajjar A. Atypical Teratoid/Rhabdoid Tumors (ATRT): Improved Survival in Children 3 Years of Age and Older With Radiation Therapy and High-Dose Alkylator-Based Chemotherapy, 1491  
 Temam S, *see* Faivre S  
 Temple L, *see* Rengan R  
 Temple LKF, *see* Guillem JG  
 Temple RJ. Enrichment Designs: Efficiency in Development of Cancer Treatments, 4838  
 Tempst P, *see* Robbins RJ  
 Ten Haken RK, *see* Ben-Josef E  
 ten Hoor KA, *see* Reesink-Peters N  
 ten Tije AJ, Verweij J, Carducci MA, Graveland W, Rogers T, Pronk T, Verbruggen MP, Dawkins F, Baker SD. Prospective Evaluation of the Pharmacokinetics and Toxicity Profile of Docetaxel in the Elderly, 1070  
 ten Vergert EM, *see* Nijhuis CO  
 Tenen DG, *see* Cho D  
 Tennis M, *see* Prochazka M  
 Tensen CP, *see* van Doorn R  
 TenVergert EM, *see* Nieboer P  
 Tepper JE, Goldberg RM. An Embarrassment of Riches: Neoadjuvant Therapy of Rectal Cancer (editorial), 1339  
 ter Elst A, *see* Westra JL  
 ter Steeg J, *see* Soepenberg O  
 Terao T, *see* Matsuzaki H  
 Terenzi A, *see* Aversa F  
 Terenziani M, *see* Ferrari A  
     *see* Gatta G  
 Termeer A, Timmer–Bonte JN  
 Ternet C, *see* Jones DH  
 Terpos E, *see* Bamias A  
 Terracciano L, *see* Sauter G  
 Terrier-Lacombe MJ, *see* Orbach D  
     *see* Stevens MCG  
 Terrier P, *see* Entz-Werlé N  
 Terris MK, *see* Freedland SJ  
 Terstappen LWMM, *see* Cristofanilli M

## AUTHOR INDEX

- Terzoli E, *see* Ferretti G  
*see* Papaldo P
- Tesfaye F, *see* Rubin EH
- Tesoriero AA, *see* Southey MC
- Testa AC, *see* Timmerman D
- Testa E, *see* Graziano F
- Testoni N, *see* Soverini S
- Têtu B, *see* Bairati I
- Teunissen JJ, *see* Kwekkeboom DJ
- Tewes M, *see* Strumberg D
- Thakkar S, *see* Sup SJ
- Thall A, *see* Czuczman MS
- Thalmann GN, *see* Fleischmann A
- Tham Y-L, *see* Chang JC
- Thatcher N, *see* Baka S
- Thatcher N, Qian W, Clark PI, Hopwood P, Sambrook RJ, Owens R, Stephens RJ, Girling DJ. Ifosfamide, Carboplatin, and Etoposide With Midcycle Vincristine Versus Standard Chemotherapy in Patients With Small-Cell Lung Cancer and Good Performance Status: Clinical and Quality-of-Life Results of the British Medical Research Council Multi-center Randomized LU21 Trial, 8371
- Thayer SP, Ferrone CR
- Theodore C, *see* Thuret R
- Theoret H, *see* Mamounas EP
- Therasse P, *see* Praga C
- Theriault RL, *see* Buzdar AU  
*see* Cristofanilli M  
*see* Giordano SH  
*see* Green MC
- Thewes B, Meiser B, Taylor A, Phillips KA, Pendlebury S, Capp A, Dalley D, Goldstein D, Baber R, Friedlander ML. Fertility- and Menopause-Related Information Needs of Younger Women With a Diagnosis of Early Breast Cancer, 5155
- Thiberville L, *see* Giaccone G
- Thiede C, *see* Wündisch T
- Thiel E, *see* Abrey LE  
*see* Shankier TN
- Thienelt CD, Bunn PA Jr, Hanna N, Rosenberg A, Needle MN, Long ME, Gustafson DL, Kelly K. Multicenter Phase I/II Study of Cetuximab With Paclitaxel and Carboplatin in Untreated Patients With Stage IV Non-Small-Cell Lung Cancer, 8786
- Thiery G, Azoulay É, Darmon M, Ciroidi M, De Miranda S, Lévy V, Fieux F, Moreau D, Le Gall JR, Schlemmer B. Outcome of Cancer Patients Considered for Intensive Care Unit Admission: A Hospital-Wide Prospective Study, 4406
- Thilmann C, *see* Combs SE
- Thirlwell C, *see* Bower M
- Thirman M, *see* van Besien K
- Thomas A, *see* Starczynski J
- Thomas AL, Morgan B, Horsfield MA, Higginson A, Kay A, Lee L, Masson E, Puccio-Pick M, Laurent D, Steward WP. Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PTK787/ZK 222584 Administered Twice Daily in Patients With Advanced Cancer, 4162
- Thomas D, *see* Cortes J  
*see* Keating MJ  
*see* Wierda W
- Thomas ES, *see* Buzdar AU
- Thomas F, *see* Chevreau C
- Thomas J, *see* Keilholz U  
*see* Philip PA
- Thomas JM. Time to Re-Evaluate Sentinel Node Biopsy in Melanoma Post-Multicenter Selective Lymphadenectomy Trial (correspondence), 9443
- Thomas L, *see* Tummala M
- Thomas MB, Abbruzzese JL. Opportunities for Targeted Therapies in Hepatocellular Carcinoma, 8093
- Thomas MB, Zhu AX. Hepatocellular Carcinoma: The Need for Progress, 2892
- Thomas P, *see* Fournel P  
*see* Pappo AS
- Thomas PRM, *see* Grundy PE  
*see* Tomlinson GE
- Thomas R, *see* Grem JL
- Thomas S, *see* Ma CX
- Thomas X, *see* de Botton S
- Thompson IM, *see* Klein EA  
*see* Parnes HL
- Thompson JF, *see* Pawlik TM
- Thomsen BL, *see* Boesen EH
- Thomsen C, *see* Borgwardt L
- Thomson CA, *see* Rock CL
- Thomson IM, Tangen CM, Klein EA, Lippman SM. Phase III Prostate Cancer Prevention Trials: Are the Costs Justified? 8161
- Thönnessen D, Wenz F. Radiotherapeutic Prophylaxis of Gynecomastia (correspondence), 5845
- Thor A, *see* Dressler LG
- Thor AD, *see* DiGiovanna MP
- Thorner P, *see* Bagatell R  
*see* London WB
- Thornton J, *see* Saif MW
- Thorpe H, *see* Brown J
- Thorsen H, *see* Broderickson J
- Thorsen L, Skovlund E, Strømme SB, Hornslien K, Dahl AA, Fosså SD. Effectiveness of Physical Activity on Cardiorespiratory Fitness and Health-Related Quality of Life in Young and Middle-Aged Cancer Patients Shortly After Chemotherapy, 2378
- Thorstenson S, *see* Rydén L
- Tuerlimann B, *see* Ruhstaller T
- Thumboo J, *see* Cheung Y-B
- Thunnisen F, *see* Travis WD
- Thuret R, Renaudin K, Leclere J, Battisti S, Bouchot O, Theodore C. Uncommon Malignancies. Paratesticular Desmoplastic Small Round-Cell Tumor, 6253
- Thürlimann B, *see* Colleoni M  
*see* Gruber G
- Thüroff J, *see* Lehmann J
- Thuss-Patience PC, *see* Pink D
- Thuss-Patience PC, Kretschmar A, Repp M, Kingreen D, Henneser D, Micheel S, Pink D, Scholz C, Dörken B, Reichardt P. Docetaxel and Continuous-Infusion Fluorouracil Versus Epirubicin, Cisplatin, and Fluorouracil for Advanced Gastric Adenocarcinoma: A Randomized Phase II Study, 494
- Tibaldi C, *see* Ardizzoni A
- Tidmarsh G, *see* Leonard JP
- Tiemann M, *see* Claviez A  
*see* Koch P
- Tienghi A, *see* Ferrari S
- Tighe J, *see* Moreton P
- Tilgen W, *see* Kaufmann R
- Tilly H, *see* Feugier P
- Timár J, Ladányi A, Forster-Horváth C, Lukits J, Döme B, Remenár É, Gödény M, Kásler M, Bencsik B, Répásky G, Szabó G, Velich N, Suba Z, Élő J, Balatoni Z, Pócsa K, Zemplén B, Chretien P, Talor E. Neoadjuvant Immunotherapy of Oral Squamous Cell Carcinoma Modulates Intratumoral CD4/CD8 Ratio and Tumor Microenvironment: A Multicenter Phase II Clinical Trial, 3421
- Timmer-Bonte JN, de Boo TM, Smith HJ, Biesma B, Wilschut FA, Cher-

## AUTHOR INDEX

- agwandi SA, Termeer A, Hensing CA, Akkermans J, Adang EM, Bootsma GP, Tjan-Heijnen VC. Prevention of Chemotherapy-Induced Febrile Neutropenia by Prophylactic Antibiotics Plus or Minus Granulocyte Colony-Stimulating Factor in Small-Cell Lung Cancer: A Dutch Randomized Phase III Study, 7974
- Timmerman D, Testa AC, Bourne T, Ferrazzi E, Ameye L, Konstantinovic ML, Van Calster B, Collins WP, Vergote I, Van Huffel S, Valentin L. Logistic Regression Model to Distinguish Between the Benign and Malignant Adnexal Mass Before Surgery: A Multicenter Study by the International Ovarian Tumor Analysis Group, 8794
- Timmerman M, *see* Weber RW
- Tirapu I, *see* Mazzolini G
- Tirelli U, *see* Mazzaro C  
*see* Nasti G  
*see* Spina M
- Tischer J, *see* Schmid C
- Tiseo M, Boni L, Ardizzoni A. Platinum-Based Versus Non-Platinum-Based Chemotherapy in Advanced Non-Small-Cell Lung Cancer: Does Cisplatin Versus Carboplatin Make a Difference? (correspondence), 6276
- Tiseo M, Monetti F, Ferrarini M, Serrano J, Chiaramondia M, Ardizzoni A. Dramatic Responses to Therapy in Rare Tumors: Complete Remission to Corticosteroids in an Oxyteride-Refractory Thymoma, 1578
- Titus-Ernstoff L, *see* Ahles TA
- Tixi L, *see* Ardizzoni A
- Tjan-Heijnen VC, Timmer-Bonte JN
- Tjulandin S, *see* Gradishar WJ  
*see* Leyland-Jones B
- Tjulandin SA, *see* Ajani JA  
*see* Vogel CL
- To KF, *see* Chan ATC  
*see* Chan W-M
- Tockman MS. Improbable Estimate of Lung Cancer Mortality From Screening Trials (correspondence), 2106
- Todd M, *see* Goodin S
- Toft D, *see* Goetz MP
- Tognoni G, *see* Marchioli R
- Tomà P, *see* Cecchetto G
- Tomá P, *see* Manzitti C
- Tomic D, *see* Badros AZ
- Tomita Y, *see* Sakane-Ishikawa E
- Tomlinson G, *see* Cheung AM  
*see* Grundy PE  
*see* Rebbeck TR
- Tomlinson GE, *see* Patterson AR
- Tomlinson GE, Breslow NE, Dome J, Guthrie KA, Norkool P, Li S, Thomas PRM, Perlman E, Beckwith JB, D'Angio GJ, Green DM. Rhabdoid Tumor of the Kidney in The National Wilms' Tumor Study: Age at Diagnosis As a Prognostic Factor, 7641
- Tomlinson JS, Ferrone CR
- Toney MO, *see* Auethavekiat P
- Tong RT, *see* Willett CG
- Tong W, *see* Kelly WK  
*see* Kortmansky J
- Tonini G, *see* Vincenzi B
- Tonin G, *see* Graziano F
- Top LE, *see* Carbone DP
- Topalian SL, *see* Attia P  
*see* Dudley ME
- Topaloglu O, *see* Hoque MO
- Torjman L, *see* Abdelkefi A
- Török H-P, *see* Glas J
- Torre SD, *see* Bajetta E
- Torres A, *see* Roman-Gomez J
- Torri V, *see* Buda A
- Torrisi R, *see* Colleoni M
- Tortochaux J, *see* Baselga J
- Toschi L, *see* Cappuzzo F
- Tosi P, *see* Greipp PR
- Tossen G, *see* Chacón R
- Tostain J, *see* Patard J-J
- Toubis M, *see* Georgoulas V
- Touijer AK, *see* Saranchuk JW
- Tourani J-M, *see* Scotté F
- Tournigand C, *see* Taïieb J
- Touroutoglou N, *see* Treon SP
- Tourt-Uhlig S, *see* Quinn JA
- Town A, *see* Corless CL
- Townsley C, Pond GR, Peloza B, Kok J, Naidoo K, Dale D, Herbert C, Holowaty E, Straus S, Siu LL. Analysis of Treatment Practices for Elderly Cancer Patients in Ontario, Canada, 3802
- Townsley CA, Selby R, Siu LL. Systematic Review of Barriers to the Recruitment of Older Patients With Cancer Onto Clinical Trials, 3112
- Toze CL, *see* Forrest DL
- Trabacchi E, *see* Soverini S  
*see* Vallisa D
- Traina TA, Leonard GD, Tang L, Paty PB, Maki RG. Problems in Colon Cancer and a Child With Renal Lymphoma. Metastatic Colon Cancer to the Ovaries in a Krukenberg-Like Pattern, 5255
- Tralongo P, Di Mari A, Ferrau' F. Cognitive Impairment, Aromatase Inhibitors, and Age (correspondence), 4243
- Tran H, *see* Herbst RS
- Tran HT, *see* Herbst RS
- Tran NV, *see* Frost MH
- Trauth JM, Jernigan JC, Siminoff LA, Musa D, Neal-Ferguson D, Weissfeld J. Factors Affecting Older African American Women's Decisions to Join the PLCO Cancer Screening Trial, 8730
- Trautvetter S, *see* Weber RW
- Travaglino E, *see* Malcovati L
- Travis P, *see* Belani CP
- Travis WD, Garg K, Franklin WA, Wistuba II, Sabloff B, Noguchi M, Kakinuma R, Zakowski M, Ginsberg M, Padera R, Jacobson F, Johnson BE, Hirsch F, Brambilla E, Flieder DB, Geisinger KR, Thunnissen F, Kerr K, Yankelevitz D, Franks TJ, Galvin JR, Henderson DW, Nicholson AG, Hasleton PS, Roggli V, Tsao M-S, Cappuzzo F, Vazquez M. Evolving Concepts in the Pathology and Computed Tomography Imaging of Lung Adenocarcinoma and Bronchioloalveolar Carcinoma, 3279
- Trehu E, *see* Goy A  
*see* O'Connor OA
- Treish I, *see* Ezzo J
- Trelle S, *see* Elter T
- Tremblay A, *see* Gaudreau J-D
- Trent RJA, *see* Kohonen-Corish MRJ
- Treon SP, *see* Dimopoulos MA
- Treon SP, Hansen M, Branagan AR, Verselis S, Emmanouilides C, Kimby E, Frankel SR, Touroutoglou N, Turnbull B, Anderson KC, Maloney DG, Fox EA. Polymorphisms in FcγRIIIA (CD16) Receptor Expression Are Associated With Clinical Response to Rituximab in Waldenström's Macroglobulinemia, 474
- Trepel JB, *see* Ryan QC
- Tresgallo ME, *see* Saroyan JM
- Tretter CPG, *see* McDermott DF
- Treuner J, *see* Carli M  
*see* Kempf-Bielack B  
*see* Koscielniak E
- Treusson I, *see* Greipp PR
- Trèves ST, *see* Adams MJ
- Tricot G, *see* Mahfouz T

## AUTHOR INDEX

- see* Talamo G  
 Trieu V, *see* Nyman DW  
 Trieu Y, *see* Jaksic W  
 Trigo JM, *see* Baselga J  
 Tripcony L, *see* Paramasivan S  
 Trivett M, *see* Southey MC  
 Trock BJ, *see* Petricoin EF III  
 Trott KR, *see* Bentzen SM  
 Trotti A, *see* Ang KK  
 Trudeau M, *see* Dark GG  
     *see* Verma S  
 Trudeau ME, *see* Goodwin PJ  
     *see* Parulekar WR  
 Trudel S, *see* Jaksic W  
 Trunzo JJ, *see* Pinto BM  
 Truong M, *see* Lu C  
 Truong MT, *see* Herbst RS  
 Truong PT, *see* Olivotto IA  
     *see* Panades M  
 Tsai M-F, *see* Chen JJW  
 Tsang K-Y, *see* Marshall JL  
 Tsang KY, *see* Correale P  
 Tsang R, *see* Shankier TN  
 Tsao A, *see* Herbst RS  
 Tsao M-S, *see* Travis WD  
 Tsavaris N, *see* Bonovas S  
 Tse A, *see* Chung KY  
 Tse J, *see* Dressler LG  
 Tseng J, *see* Robert F  
 Tseng JF, *see* Yao JC  
 Tsiafaki X, *see* Georgoulas V  
 Tsien CI, *see* Cao Y  
 Tsimelzon A, *see* Chang JC  
 Tsodikov A, *see* Florell SR  
 Tsuchida M, *see* Igarashi S  
 Tsuchiya K, *see* Gotoh T  
 Tsuji M, *see* Yokote T  
 Tsukaguchi M, *see* Sakane-Ishikawa E  
 Tsuta K, *see* Takano T  
 Tu D, *see* Brundage M  
     *see* Leighl NB  
     *see* Levine MN  
     *see* Singh S  
     *see* Whelan TJ  
 Tu P-h, Giannini C, Judkins AR, Schwab JM, Burack R, O'Neill BP, Yachnis AT, Burger PC, Scheithauer BW, Perry A. Clinicopathologic and Genetic Profile of Intracranial Marginal Zone Lymphoma: A Primary Low-Grade CNS Lymphoma That Mimics Meningioma, 5718  
 Tu S-M, Kim J, Pagliaro LC, Vakar-Lopez F, Wong FC, Wen S, General R, Podoloff DA, Lin S-H, Logothetis CJ. Therapy Tolerance in Selected Patients With Androgen-Independent Prostate Cancer Following Strontium-89 Combined With Chemotherapy, 7904  
 Tubiana-Hulin M, *see* Marty M  
 Tucker MA, *see* Kleinerman RA  
     *see* Strouse JJ  
 Tucker RW, *see* Williamson SK  
 Tucker SL, *see* Clayman GL  
     *see* Gonzalez-Angulo A  
 Tulpule A, *see* Lim S-T  
     *see* Lim ST  
     *see* Noy A  
 Tummala M, Thomas L, Gocke C, Heyman MR, Gojo I. Unusual Leukemia Presentations: Granulocytic Sarcoma of the Colon, 5840  
 Tung SY, *see* Lee AWM  
 Tunon De Lara C, *see* MacGrogan G  
 Turetschek K, *see* Raderer M  
 Turkina AG, *see* O'Brien SM  
 Turnbull B, *see* Treon SP  
 Turner B, *see* Mack JW  
 Turner RR, *see* Kim J  
     *see* Lyman GH  
 Turrell C, *see* Lara PN Jr  
 Turrisi AJ, *see* Sartor CI  
 Turrisi AT III. Creeping Phase II-ism and the Medical Pharmaceutical Complex: Weapons of Mass Distraction in the War Against Lung Cancer, 4827  
 Tursz T, *see* Dòmont J  
 Tutic M, *see* Lardinois D  
 Tyc VL, *see* Mulhern RK  
 Tynninen O, *see* Sihto H  
 Tyson LB, *see* Shah NT  
 Tzekova V, *see* Zielinski C
- ## U
- Ubel PA, *see* Armstrong K  
 Uchino J, *see* Noguchi S  
 Uchitomi Y, *see* Morita T  
 Uebelhart D, *see* Knols R  
 Ueda Y, *see* Yamamoto N  
 Ueno M, *see* Huang C-I  
 Ueno N, *see* Iwao-Koizumi K  
 Ueno NT, *see* Hamaoka T  
 Ueoka H, *see* Hotta K  
     *see* Matsuo K  
 Ugurel S, *see* Mian S  
 Ullmann AJ, *see* Hess G  
 Ullmer L, *see* Stearns V  
 Ulusakarya A, Gumus Y, Brahim N, Delmas-Marsalet B, Almohamad W, Misra SC, Goldschmidt E, Haydar M, Machover D. Symptoms in Cancer Patients and an Unusual Tumor: Regression of Hypertrophic Pulmonary Osteoarthropathy Following Chemotherapy for Lung Metastases of a Nasopharyngeal Carcinoma, 9422  
 Umetani N, *see* Koyanagi K  
     *see* Mori T  
 Umezue H, *see* Ogose A  
 Umutyan A, *see* Lara PN Jr  
 Unger JM, *see* Fisher RI  
 Unterhalt M, Hiddemann W, *see* Hiddemann WL  
     *see* Lenz G  
     *see* Rohatiner AZS  
 Upponi S, *see* Purushotham AD  
 Urba SG, Moon J, Giri PGS, Adelstein DJ, Hanna E, Yoo GH, LeBlanc M, Ensley JF, Schuller DE. Organ Preservation for Advanced Resectable Cancer of the Base of Tongue and Hypopharynx: A Southwest Oncology Group Trial, 88  
 Urba WJ, *see* Jones SE  
     *see* McDermott DF  
 Urrea P, *see* Ajani JA  
 Urruticoechea A, Smith IE, Dowsett M. Proliferation Marker Ki-67 in Early Breast Cancer, 7212  
 Urtasun R, *see* Roa W  
 Uscinska B, *see* Langley RE  
 Utkan G, Yalçin B, Büyükcelik A, Yalçin S. Neoadjuvant Chemotherapy Followed by Extrapleural Pneumonectomy in Malignant Pleural Mesothelioma: Is It Safe? (correspondence), 655  
 Uzieblo A, Badger J

## V

- vab der Velden PA, *see* van Doorn R
- Vacca A, Scavelli C, Montefusco V, Di Pietro G, Neri A, Mattioli M, Biccato S, Nico B, Ribatti D, Dammacco F, Corradini P. Thalidomide Downregulates Angiogenic Genes in Bone Marrow Endothelial Cells of Patients With Active Multiple Myeloma, 5334
- Vaishampayan UN, *see* Hussain M
- Vakaet LAML. Computer Modeling Is No Substitute for Randomized Clinical Trials for Decision Making in Early Breast Cancer Hormonal Therapy (correspondence), 8543
- Vakar-Lopez F, *see* Tu S-M
- Valagussa P, *see* Corradini P  
*see* Gianni L
- Valcárcel F, *see* Zapatero A
- Valdimarsdóttir HB, *see* Madalinska JB
- Valdimarsdóttir U, *see* Kreicbergs U
- Valentí V, *see* Hitt R
- Valentin L, *see* Timmerman D
- Valentin V, *see* Colomer R
- Valentino D, *see* Eisenbeis CF
- Valero V, *see* Cristofanilli M  
*see* Ewer MS  
*see* Gonzalez-Angulo A  
*see* Green MC  
*see* Hennessy BT  
*see* Rouzier R
- Valk PJM, *see* Bullinger L
- Vallabhajosula S, *see* Bander NH  
*see* Leonard JP
- Valladares M, *see* Sastre J
- Vallböhmer D, Zhang W, Gordon M, Yang DY, Yun J, Press OA, Rhodes KE, Sherrod AE, Iqbal S, Danenberg KD, Groshen S, Lenz H-J. Molecular Determinants of Cetuximab Efficacy, 3536
- Valle JW, *see* Jayson GC
- Vallieres E, *see* Gaspar LE
- Vallisa D, Bernuzzi P, Arcaini L, Sacchi S, Callea V, Marasca R, Lazzaro A, Trabacchi E, Anselmi E, Arcari AL, Moroni C, Bertè R, Lazzarino M, Cavanna L. Role of Anti-Hepatitis C Virus (HCV) Treatment in HCV-Related, Low-Grade, B-Cell, Non-Hodgkin's Lymphoma: A Multi-center Italian Experience, 468
- Vallisa D, Bernuzzi P, Lazzaro A, Trabacchi E, Anselmi E, Arcari AL, Moroni C, Bertè R, Cavanna L. In Reply (correspondence), 4471
- Valls C, *see* Poston GJ
- Valsecchi MG, *see* Pession A
- Valteau-Couanet D. Event-Free Survival of Patients With High-Risk Neuroblastoma Treated With an N6-Like Induction Treatment (correspondence), 6262
- Valteau-Couanet D, Michon J, Boneu A, Rodary C, Perel Y, Bergeron C, Rubie H, Coze C, Plantaz D, Bernard F, Chastagner P, Bouzy J, Hartmann O. Results of Induction Chemotherapy in Children Older Than 1 Year With a Stage 4 Neuroblastoma Treated With the NB 97 French Society of Pediatric Oncology (SFOP) Protocol, 532
- Valuckas K, *see* Leyland-Jones B
- Valverde S, *see* Tabernero J
- van Baren N, Bonnet M-C, Dréno B, Khammari A, Dorval T, Piperno-Neumann S, Liénard D, Speiser D, Marchand M, Brichard VG, Escudier B, Négrier S, Dietrich P-Y, Maraninchi D, Osanto S, Meyer RG, Ritter G, Moingeon P, Tartaglia J, van der Bruggen P, Coulié PG, Boon T. Tumor and Immunologic Response After Vaccination of Melanoma Patients With an ALVC Virus Encoding MAGE Antigens Recognized by T Cells, 9008
- Van Becelaere K, *see* LoRusso PM
- Van Belle P, *see* Gimotty PA
- van Besien K, Artz A, Smith S, Cao D, Rich S, Godley L, Jones D, Del Cerro P, Bennett D, Casey B, Odenike O, Thirman M, Daugherty C, Wickrema A, Zimmerman T, Larson RA, Stock W. Fludarabine, Melphalan, and Alemtuzumab Conditioning in Adults With Standard-Risk Advanced Acute Myeloid Leukemia and Myelodysplastic Syndrome, 5728
- van Beurden M, *see* Madalinska JB
- Van Calster B, *see* Timmerman D
- Van Criekinge W, *see* Hoque MO
- Van Cutsem E, *see* Ajani JA  
*see* Lutz MP
- van Cutsem E, *see* Köhne C-H
- van de Kastele WF, *see* Luiten RM
- van de Rijn M, *see* Li FP
- van de Velde CJH, *see* Hartgrink HH  
*see* Jansen EPM  
*see* Jansen SJT  
*see* Marijnen CAM  
*see* Nagtegaal ID  
*see* Peeters KCMJ  
*see* van den Brink M
- van de Vijver MJ, *see* Hannemann J
- Van de Wiele C, *see* Van Den Bossche B
- van den Bent M, *see* Abrey LE
- van den Berg MP, *see* Nuver J
- van den Berk PCM, *see* Luiten RM
- Van Den Bossche B, Van de Wiele C. In Reply (correspondence), 3171
- van den Bout J, *see* van der Lee ML
- van den Brink M, *see* Marijnen CAM
- van den Brink M, van den Hout WB, Stiggelbout AM, Kievit J, van de Velde CJH. What You May Learn From the Dutch Experience (correspondence), 3632
- Van den Broecke C, *see* Vandesompele J
- van den Broek WJM, *see* Brouwers AH
- van den Hout WB, *see* Kramer GWPM  
*see* van den Brink M
- van den Wijngaard A, *see* Gómez-García EB
- van der Bom JG, *see* van der Lee ML
- van der Bruggen P, *see* van Baren N
- van der Does A, *see* Pession A
- van der Gaast A, *see* Hoekstra R
- van der Graaf, WTA, *see* Nijhuis CO
- van der Graaf WTA, *see* Nieboer P  
*see* Nuver J
- van der Heide A, *see* Voogt E
- van der Holt B, *see* van Imhoff GW
- van der Lee ML, van der Bom JG, Swarte NB, Heintz APM, de Graeff A, van den Bout J. Euthanasia and Depression: A Prospective Cohort Study Among Terminally Ill Cancer Patients, 6607
- Van der Lelie J, *see* Breems DA
- van der Maas PJ, *see* Voogt E
- van der Meer FJM, *see* van Rooden CJ
- van der Meer J, *see* Nuver J
- van der Putten H, *see* Madalinska JB
- van der Rijt CCD, *see* Voogt E
- van der Velden J, *see* Reesink-Peters N
- van der Velden K, *see* Madalinska JB
- van der Velden PC, *see* Bontenbal M
- van der Wall E, *see* Baak JPA  
*see* Nieboer P
- van der Zee AGJ, *see* Reesink-Peters N
- van Diest PJ, *see* Baak JPA
- van Doorn R, Zoutman WH, Dijkman R, de Menees RX, Commandeur S, Mulder AA, van der Velden PA, Vermeer MH, Willemze R, Yan PS, Huang TH, Tensen CP. Epigenetic Profiling of Cutaneous T-Cell Lym-

- phoma: Promoter Hypermethylation of Multiple Tumor Suppressor Genes Including *BCL7a*, *PTPRG*, and *p73*, 3886
- van Dorst EBL, *see* Madalinska JB
- van Eijck CH, *see* Kwekkeboom DJ
- van Eijk R, *see* Sieben NLG
- van Engeland M, *see* Sieben NLG
- van Gessel AI, *see* Nuver J
- van Gestel K, *see* Voogd A
- Van Glabbeke M, *see* Le Cesne A
- Van Glabbeke M, Verweij J, Casali PG, Le Cesne A, Hohenberger P, Ray-Coquard I, Schlemmer M, van Oosterom AT, Goldstein D, Sciot R, Hogendoorn PCW, Brown M, Bertulli R, Judson IR. Initial and Late Resistance to Imatinib in Advanced Gastrointestinal Stromal Tumors Are Predicted by Different Prognostic Factors: A European Organisation for Research and Treatment of Cancer–Italian Sarcoma Group–Australasian Gastrointestinal Trials Group Study, 5795
- Van Heijzen K, *see* Bhatia R
- van Herpen CML, *see* Hendrickx BW
- Van Hoof A, *see* Feugier P
- van Houwelingen HC, *see* Kramer GWPM
- Van Huffel S, *see* Timmerman D
- van Imhoff GW, van der Holt B, MacKenzie MA, van't Veer MB, Wijermans PW, Ossenkoppele GJ, Schouten HC, Sonneveld P, Steijaert MMC, Kluin PM, Kluin-Nelemans HC, Verdonck LF. Impact of Three Courses of Intensified CHOP Prior to High-Dose Sequential Therapy Followed by Autologous Stem-Cell Transplantation As First-Line Treatment in Poor-Risk, Aggressive Non-Hodgkin's Lymphoma: Comparative Analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40, 3793
- Van Klaveren RJ, *see* van Meerbeeck JP
- van Kouwen MCA, Nagengast FM, Jansen JBMJ, Oyen WJG, Drenth JPH. 2-<sup>18</sup>F)-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Detects Clinically Relevant Adenomas of the Colon: A Prospective Study, 3713
- van Krieken JHJM, *see* Nagtegaal ID
- Van Laethem J-L, *see* Lutz MP
- van Leeuwen AF, *see* Voogt E
- Van Marck EA, *see* van Meerbeeck JP
- van Meerbeeck JP, Gaafar R, Manegold C, Van Klaveren RJ, Van Marck EA, Vincent M, Legrand C, Bottomley A, Debruyne C, Giaccone G. Randomized Phase III Study of Cisplatin With or Without Raltitrexed in Patients With Malignant Pleural Mesothelioma: An Intergroup Study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada, 6881
- van Merkesteyn R, Bakker DJ. Comment on "Hyperbaric Oxygen Therapy for Radionecrosis of the Jaw: A Randomized, Placebo-Controlled, Double-Blind Trial From the ORN96 Study Group" (correspondence), 4465
- van Nederveen FH, *see* Dannenberg H
- Van Oosterom A, *see* Le Cesne A
- van Oosterom A, *see* McArthur GA
- van Oosterom AT, *see* Aass N
- see* Soepenberg O
- see* Van Glabbeke M
- van Poppel H, *see* Aass N
- Van Putten WLJ, *see* Breems DA
- van Rooden CJ, Schippers EF, Barge RMY, Rosendaal FR, Guiot HFL, van der Meer FJM, Meinders AE, Huisman MV. Infectious Complications of Central Venous Catheters Increase the Risk of Catheter-Related Thrombosis in Hematology Patients: A Prospective Study, 2655
- van Roon AM, *see* Nuver J
- Van Roy N, *see* De Preter K
- see* Vandesompele J
- van Staveren IL, *see* Jansen MPH
- van Tienhoven G, *see* Klerk CPW
- van Tinteren H, *see* Hoekstra CJ
- see* Nieboer P
- van Tinteren H, Smit EF, Hoekstra OS. FDG-PET in Addition to Conventional Work-Up in Non-Small-Cell Lung Cancer (correspondence), 1591
- van Unnik A, *see* Orbach D
- see* Stevens MCG
- Van Vreckem A, *see* Tabernero J
- van Wering ER, *see* Pession A
- van Zandwijk N, *see* Hoekstra CJ
- van Zuylen L, *see* de Jong FA
- Vanderwerker LC, Laff RE, Kadan-Lottick NS, McColl S, Prigerson HG. Psychiatric Disorders and Mental Health Service Use Among Caregivers of Advanced Cancer Patients, 6899
- Vandesompele J, *see* De Preter K
- Vandesompele J, Baudis M, De Preter K, Van Roy N, Ambros P, Bown N, Brinkschmidt C, Christiansen H, Combaret V, Lastowska M, Nicholson J, O'Meara A, Plantaz D, Stallings R, Brichard B, Van den Broecke C, De Bie S, De Paep A, Laureys G, Speleman F. Unequivocal Delineation of Clinicogenetic Subgroups and Development of a New Model for Improved Outcome Prediction in Neuroblastoma, 2280
- Vanhenhennik V, *see* De Paep P
- Vanhoefer U, *see* Köhne C-H
- see* Lutz MP
- see* Pink D
- Vansteenkiste J, *see* Hedenus M
- see* Hoekstra CJ
- van't Veer L, *see* Rebbeck TR
- van't Veer LJ, Paik S, Hayes DF. Gene Expression Profiling of Breast Cancer: A New Tumor Marker, 1631
- van't Veer MB, *see* van Imhoff GW
- Vara JAF, *see* Espinosa E
- Vardiman JW, *see* Farag SS
- see* Marcucci G
- Vardy J, Clarke SJ. In Reply (correspondence), 5850
- Vardy J, Clarke SJ, Yarrow PM, Lin BPC. In Reply (correspondence), 7762
- Vardy J, Joshua AM, Clarke SJ, Yarrow PM, Lin POC. Small Blue Cell Tumors of the Rectum. Ewing's Sarcoma of the Rectum, 910
- Varella-Garcia M, *see* Cappuzzo F
- see* Hirsch FR
- Vargas C, *see* Colomer R
- Vargas HI. Blue Dye of Choice for Lymphatic Mapping (correspondence), 3648
- Varma S, *see* Ghadimi BM
- Varni JW, *see* Bhat SR
- Varterasian M, *see* LoRusso PM
- Varterasian ML, *see* Campos S
- Varvarigou AD, *see* Scopinaro F
- Vasen H, *see* Bian Y
- Vasey P, *see* Dark GG
- Vasey PA, *see* Crawford SC
- Vasile V, *see* Goetz MP
- Vass S, *see* Bairati I
- Vauthey J-N, *see* Dômont J
- Vauthey NJ-N, *see* Poston GJ
- Vazina A, *see* Lotan Y
- Vázquez F, *see* Tabernero J
- Vázquez M, *see* Travis WD
- Veeder M, *see* Belani CP
- Vega ME, *see* Hitt R
- Velardi A, *see* Aversa F
- Velazquez IA, *see* Kramer JL
- Velds A, *see* Hannemann J

- Velich N, *see* Timár J
- Velji K, *see* Brundage M
- Vellenga E, *see* Breems DA  
*see* Nijhuis CO
- Velu T, *see* Keilholz U
- Veness MJ. Merkel Cell Carcinoma: Improved Outcome With the Addition of Adjuvant Therapy (correspondence), 7235
- Veninga T, *see* Rades D
- Venkatraman ES, *see* Zelefsky MH
- Ventura GJ. Cardiotoxicity of Epirubicin Versus Doxorubicin: Cost and Clinical Results (correspondence), 2873
- Venturini M, *see* Bruzzi P
- Verbruggen MP, *see* ten Tije AJ
- Vercammen E, *see* Leyland-Jones B
- Verdeguer A, *see* Ortega JJ
- Verdelli D, *see* Agnelli M
- Verderio P, *see* Frattini M
- Verdonck LF, *see* Breems DA  
*see* van Imhoff GW
- Vergidis D, *see* Butts C
- Vergnenégre A, *see* Fournel P
- Vergote I, *see* Timmerman D
- Vergouwe Y, Steyerberg EW. Minimal Residual Tumor Masses in Non-seminomatous Testicular Cancer: Surgery or Surveillance? (correspondence), 3653
- Verheij M, *see* Jansen EPM
- Verheijen RHM, *see* Madalinska JB
- Verhoef G, *see* De Paepe P
- Verhoef GEG, *see* Breems DA
- Verhofstad AA, *see* Dannenberg H
- Verigos C, *see* Athanassiou H
- Verma S, Trudeau M, Dranitsaris G, Clemons M, Joy AA, MacKey JR. What Is the Best Chemotherapy Treatment Option for Anthracycline and Taxane Pretreated Metastatic Breast Cancer? (correspondence), 6260
- Vermeer MH, *see* van Doorn R
- Vermeulen KM, *see* Nijhuis CO
- Vermorken JB, *see* Baak JPA
- Vernon CB, *see* Hawkins DS
- Vernon SW, *see* Gritz ER
- Veronesi P, *see* Colleoni M
- Verselis S, *see* Treon SP
- Verso M, Agnelli G, Bertoglio S, Di Somma FC, Paoletti F, Ageno W, Bazzan M, Parise P, Quintavalla R, Naglieri E, Santoro A, Imberti D, Sorarú M, Mosca S. Enoxaparin for the Prevention of Venous Thromboembolism Associated With Central Vein Catheter: A Double-Blind, Placebo-Controlled, Randomized Study in Cancer Patients, 4057
- Versteegh MI, *see* Annema JT
- Verstovsek S, *see* Issa J-PJ
- Verweij J, *see* Bontenbal M  
*see* de Jong FA  
*see* de Jonge M  
*see* Hoekstra R  
*see* Le Cesne A  
*see* Soepenberg O  
*see* Sparreboom A  
*see* ten Tije AJ  
*see* Van Glabbeke M
- Verweij J. Ecteinascidin-743 (ET-743): Early Test or Effective Treatment in Soft Tissue Sarcomas? (editorial), 5420
- Veselić M, *see* Annema JT
- Vey N, *see* Jourdan E
- Viale G, *see* Colleoni M  
*see* Pruneri G
- Viarengo G, *see* Massa M
- Vicent J-M, *see* Feliu J
- Vicent JM, *see* Sastre J
- Vici P, *see* Papaldo P
- Vicini FA, *see* Arthur DW  
*see* Hayman JA
- Vickers A, *see* Ezzo J
- Vickers AJ, *see* Cassileth BR
- Vickers KS, Hathaway JC, Patten CA, Clark MM, Britt TL, Looker SA, Johnson PT, Loprinzi CL. Cancer Patients' and Patient Advocates' Perspectives on a Novel Information Source: A Qualitative Study of *The Art of Oncology, When the Tumor Is Not the Target*, 4013
- Vidal PM, *see* Ravasco P
- Vietti-Ramus G, *see* Montemurro F
- Viganó A, *see* Maltoni M
- Vigneault E, *see* Bairati I
- Vignot S, *see* Andre F
- Villa E, *see* Ferreri AJM
- Villá S, *see* Zapatero A
- Villafuerte J, *see* Mankin HJ
- Villalona-Calero M, *see* Weber F
- Villamor N, *see* López-Guillermo A  
*see* Moreno C
- Villanueva J, *see* Robbins RJ
- Villanueva L, *see* Gallardo J
- Villari P, *see* Mercadante S
- Villegas A, *see* Marchioli R
- Vincent M, *see* van Meerbeek JP
- Vincenzi B, Santini D, Tonini G. Thymidylate Synthase Expression in Colorectal Cancer: The Never-Ending Story (correspondence), 2108
- Vinchon M, *see* Oyharcabal-Bourden V
- Vinciguerra V, *see* Schwartz GK
- Viney RC, *see* Fulham MJ
- Viret F, *see* Ducreux M
- Virgo KS, *see* Desch CE
- Visscher DW, *see* Goetz MP
- Visser AP, *see* Voogt E
- Vitellas KM, *see* Hricak H
- Vitolo U, *see* Gobbi PG
- Vlastos G, *see* Bouchardy C
- Voest EE, *see* Nieboer P
- Vogel CL, Tan-Chiu E. Trastuzumab Plus Chemotherapy: Convincing Survival Benefit or Not? (editorial), 4247
- Vogel CL, Wojtukiewicz MZ, Carroll RR, Tjulandin SA, Barajas-Figueroa LJ, Wiens BL, Neumann TA, Schwartzberg LS. First and Subsequent Cycle Use of Pegfilgrastim Prevents Febrile Neutropenia in Patients With Breast Cancer: A Multicenter, Double-Blind, Placebo-Controlled Phase III Study, 1178
- Vogel VG, *see* Tan-Chiu E
- Vogel VG. Can Statin Therapy Reduce the Risk of Breast Cancer? (editorial), 8553
- Vogelsang GB, *see* Bolaños-Meade J
- Vogelzang NJ, *see* Halabi S
- Vogt T, *see* Kaufmann R
- Voi M, *see* Leighl NB  
*see* Tabernero J
- Voigt P, *see* Annema JT
- Voigtmann R, *see* Köhne C-H  
*see* Strumberg D
- Voit C, Kron M, Rademaker J, Schwürzer-Voit M, Sterry W, Weber L, Özdemir C, Proebstle T, Keilholz U. Molecular Staging in Stage II and III Melanoma Patients and Its Effect on Long-Term Survival, 1218
- Vokes EE, *see* Herbst RS  
*see* Hotte SJ

## AUTHOR INDEX

*see* Kindler HL  
*see* Niell HB  
 Vokes EE. Optimal Therapy for Unresectable Stage III Non–Small-Cell Lung Cancer (editorial), 5853  
 Volc-Platzer B, *see* Richtig E  
 Voliotis D, *see* Strumberg D  
 Voloch A, *see* Ray-Coquard I  
 Voltz R, *see* Schmid C  
 von den Driesch P, *see* Kaufmann R  
 von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, Moore MJ, Zimmermann A, Arning M. Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer, 4602  
 von Gerstenberg-Hellendorf B, *see* Hofheinz R-D  
 von Grünhagen U, *see* Rummel MJ  
 Von Hoff, DD, *see* Nyman DW  
 Von Hoff DD, *see* Schrag D  
 von Mehren M. Targeted Therapy With Imatinib: Hit and Misses? (editorial), 8  
 von Minckwitz G, *see* Kaufman M  
 von Minckwitz G, Raab G, Caputo A, Schütte M, Hilfrich J, Blohmer JU, Gerber B, Costa SD, Merkle E, Eidtmann H, Lampe D, Jackisch C, du Bois A, Kaufmann M. Doxorubicin With Cyclophosphamide Followed by Docetaxel Every 21 Days Compared With Doxorubicin and Docetaxol Every 14 Days as Preoperative Treatment in Operable Breast Cancer: The GERARDUO Study of the German Breast Group, 2676  
 von Pawel J, *see* Bissett D  
 von Rahden BHA, Stein HJ, Feith M, Becker K, Siewert JR. Lymphatic Vessel Invasion As a Prognostic Factor in Patients With Primary Resected Adenocarcinomas of the Esophagogastric Junction, 874  
 Von Roenn J, *see* Muss HB  
 von Schulthess GK, *see* Lardinois D  
 von Stackelberg A, *see* Einsiedel HG  
     *see* Wu S  
 von Weikersthal LF, *see* Schuette W  
 Vondeling H, *see* Aabom B  
 Vonk EJA, *see* Kramer GWPM  
 Voog E, *see* Oudard S  
 Voogd A, van Gestel K, Ernst MF. Trends in Survival of Patients With Metastatic Breast Cancer (correspondence), 2116  
 Voogt E, van der Heide A, Rietjens JAC, van Leeuwen AF, Visser AP, van der Rijt CCD, van der Maas PJ. Attitudes of Patients With Incurable Cancer Toward Medical Treatment in the Last Phase of Life, 2012  
 Vooletich MT, *see* Ewer MS  
 Voorhorst FJ, *see* Baak JPA  
 Vordermark D, Seufert I, Schwab F, Flentje M, Kung M, Angermann C. Cardiac Toxicity of Mediastinal Radiotherapy: Which Are the Critical Structures? (correspondence), 3634  
 Vos A, *see* Aronson DC  
 Vose JM, *see* Czuczman MS  
     *see* Fisher RI  
     *see* Juweid ME  
 Vose JM, Bierman PJ, Enke C, Hankins J, Bociek G, Lynch JC, Armitage JO. Phase I Trial of Iodine-131 Tositumomab With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation for Relapsed Non-Hodgkin's Lymphoma, 461  
 Voss NJ, *see* Forrest DL  
 Vourlekis B, *see* Ell K  
 Voznyi E, *see* Leyland-Jones B  
 Vrbancic D, *see* Zielinski C  
 Vredenburgh JJ, *see* Peters WP  
     *see* Quinn JA  
     *see* Petros WP

*see* Reardon DA  
 Vrionis F, *see* Chamberlain MC  
 Vu HT, *see* Ahn PH  
 Vu VD, *see* Mori T  
 Vuillermoz-Blas S, *see* Arpin D  
 Vujaskovic Z, *see* Jones EL  
 Vukov AM, *see* Davidson NE  
     *see* Witzig TE

## W

Wada H, *see* Hamada C  
 Wade M, *see* Samlowski WE  
 Wagener T, *see* Lutz MP  
 Wagman LD, *see* Faynsod M  
 Wagner H, *see* Belani CP  
     *see* Manon R  
 Wagner P, *see* Rouzier R  
 Wagner T, *see* Eisen A  
     *see* Rebbeck TR  
 Wagnerova M, *see* Zielinski C  
 Wahl P, *see* Gimotty PA  
 Wahl R, *see* Lyman GH  
 Wahl RL, *see* Fisher RI  
     *see* Kaminski MS  
 Wakahara K, *see* Matsuzaki H  
 Wakelee HA, *see* Kuo T  
 Wale C, *see* Dowsett M  
 Walewski J, *see* Johnson PWM  
 Walgren RA, Meucci MA, McLeod HL. Pharmacogenomic Discovery Approaches: Will the Real Genes Please Stand Up? 7342  
 Walker AP, *see* Mamounas EP  
 Walker J, *see* Stirling D  
 Walker MJ, *see* Eisenbeis CF  
 Walker R, *see* Mahfouz T  
 Walker RC, *see* Ghobrial IM  
     *see* Talamo G  
 Walker S, *see* Ben-Josef E  
 Wall L, *see* Dahele M  
 Wallace D, *see* Fouladi M  
     *see* Mulhern RK  
     *see* Tekautz TM  
 Wallen H, Gooley TA, Deeg HJ, Pagel JM, Press OW, Appelbaum FR, Storb R, Gopal AK. Ablative Allogeneic Hematopoietic Cell Transplantation in Adults 60 Years of Age and Older, 3439  
 Waller D, *see* Brown J  
     *see* Welsh TJ  
 Wallerstedt DB, *see* Calzone KA  
 Walmsley S, *see* Noy A  
 Walsh D, *see* Davis MP  
     *see* Yavuzsen T  
 Walsh DJ, *see* Galanis E  
 Walsh G, *see* Dowsett M  
     *see* Smith IE  
 Walsh GL, *see* Lu C  
 Walsh MD, *see* Southey MC  
 Walsh W, *see* Dark GG  
 Walton M, *see* Banerji U  
 Waltzer U, *see* Ghilmini M  
 Walz MK, *see* Stahl M  
 Walz P, *see* Lehmann J  
 Wan TS, *see* Au WY  
 Wanders SL, *see* Kramer GWPM  
 Wandt H, *see* Lenz G

AUTHOR INDEX

- Wanek LA, *see* Kang JC  
Wang C-X, *see* Mohsin SK  
Wang H, *see* Berger AC  
Wang H-J, *see* Kim J  
    *see* Mori T  
Wang HJ, *see* Koyanagi K  
Wang M, *see* Goy A  
    *see* Romaguera JE  
Wang Q, *see* Smith MR  
Wang W, *see* Belani CP  
Wang Y, *see* Le Q-T  
    *see* Leibovici D  
Wang Y-C, *see* Wang Y-C  
Wang Y-C, Lin R-K, Tan Y-H, Chen J-T, Chen C-Y, Wang Y-C. Wild-Type p53 Overexpression and Its Correlation With MDM2 and p14ARF Alterations: An Alternative Pathway to Non-Small-Cell Lung Cancer, 154  
Ward C, *see* Marty M  
Ward JH, *see* Phillips K-A  
Warde P, *see* Lukka H  
Wardelmann E, *see* Kuhl CK  
Wardwell WA, *see* Rock CL  
Warnke PH, Sherry E, Russo PA Sprengel M, Açil Y, Bredee JP, Schubert S, Wiltfang J, Springer IN. Antibacterial Essential Oils Reduce Tumor Smell and Inflammation in Cancer Patients (correspondence), 1588  
Warr DG, Hesketh PJ, Gralla RJ, Muss HB, Herrstedt J, Eisenberg PD, Raftopoulos H, Grunberg SM, Grunberg SM, Gabriel M, Rodgers A, Bohidar N, Klinger G, Hustad CM, Horgan KJ, Skobieranda F. Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer After Moderately Emetogenic Chemotherapy, 2822  
Warren KE, Aikin AA, Libucha M, Widemann BC, Fox E, Packer RJ, Balis FM. Phase I Study of O<sup>6</sup>-Benzylguanine and Temozolomide Administered Daily for 5 Days to Pediatric Patients With Solid Tumors, 7646  
Warshaw AL, Ferrone CR  
Wascher RA. Pitfalls in the Use of RT-PCR As a Prognostic Indicator in Melanoma (correspondence), 3863  
Washington MK, *see* Rothenberg ML  
Wasi P, *see* Couban S  
Wassef M, *see* Duet M  
Wasserman T, *see* Movsas B  
Wassmann B, *see* Hess G  
Watanabe T, *see* Kohno N  
Watanabe T, Kanazawa T, Kazama Y, Tanaka J, Tanaka T, Ishihara S, Nagawa H. TP53 Mutation and Microsatellite Instability Status for the Prediction of Survival in Adjuvant-Treated Colon Cancer Patients (correspondence), 9031  
Waters L, *see* Stebbing J  
Watkins, PB, *see* Dees EC  
Watson D, *see* Gianni L  
Watson DM, *see* Lilenbaum RC  
    *see* Niell HB  
Watson P, *see* Bian Y  
    *see* Lynch HT  
Watson Y, *see* Jayson GC  
Watterson J, *see* Mack JW  
Watts BG, *see* Gritz ER  
Waxman A, *see* Garcia-Carbonero R  
Wayne AS, *see* Strouse JJ  
Weathers B, *see* Halbert CH  
Weaver DL, *see* Lyman GH  
Weber A, Imisch P, Bergmann E, Christiansen H. In Reply (correspondence), 3168  
Weber B, *see* Armstrong K  
    *see* DeMichele A  
    *see* Eisen A  
Weber BL, *see* Rebbeck TR  
Weber F, Fukino K, Villalona-Calero M, Eng C. Limitations of Single-Strand Conformation Polymorphism Analysis As a High-Throughput Method for the Detection of EGFR Mutations in the Clinical Setting (correspondence), 5847  
Weber J, *see* Sanderson K  
Weber J-C, *see* Dômont J  
Weber L, *see* Voit C  
Weber RS, *see* Ang KK  
Weber RW, O'Day S, Rose M, Deck R, Ames P, Good J, Meyer J, Allen R, Trautvetter S, Timmerman M, Cruickshank S, Cook M, Gonzalez R, Spittle LE. Low-Dose Outpatient Chemobiotherapy With Temozolomide, Granulocyte-Macrophage Colony Stimulating Factor, Interferon- $\alpha$ 2b, and Recombinant Interleukin-2 for the Treatment of Metastatic Melanoma, 8992  
Weber T, Hokschi B, Körner M, Jüngling F, Schmid RA. Positive Positron Emission Tomography Scan in Sarcoidosis and Two Challenging Cases of Metastatic Cancer: Hoarseness Caused by Cancer Metastasis to the Vagus Nerve, 8909  
Weber WA, *see* Amendola MA  
    *see* Avril N  
Webster WS, Small EJ, Rini BI, Kwon ED. Prostate Cancer Immunology: Biology, Therapeutics, and Challenges, 8262  
Wedam, SB, *see* Low JA  
Wedam SB, Swain SM. Contralateral Breast Cancer: Where Does It All Begin? 4585  
Wedel N, *see* Feldman EJ  
Weder P, *see* Luiten RM  
Weder W, *see* Lardinois D  
Weder W. In Reply (correspondence), 655  
Wee J, *see* Cheung Y-B  
Wee J, Tan EH, Tai BC, Wong HB, Leong SS, Tan T, Chua ET, Yang E, Lee KM, Fong KW, Tan HSK, Lee KS, Loong S, Sethi V, Chua EJ, Machin D. Randomized Trial of Radiotherapy Versus Concurrent Chemoradiotherapy Followed by Adjuvant Chemotherapy in Patients With American Joint Committee on Cancer/International Union Against Cancer Stage III and IV Nasopharyngeal Cancer of the Endemic Variety, 6730  
Weeden W, *see* Koon HB  
Weeks JC, *see* Emmons KM  
    *see* Lilenbaum RC  
    *see* Mack JW  
    *see* Punglia RS  
    *see* Steyerberg EW  
Wegener WA, *see* Leonard JP  
    *see* Liersch T  
Wei JT, *see* Miller DC  
Weidekamm E, *see* Camidge R  
Weigert O, *see* Hiddemann W  
Weil RJ, Lonser RR, Quezado MM. CNS Manifestations of Malignancies. Skull and Brain Metastasis From Tibial Osteosarcoma, 4226  
Weil RJ, Lonser RR. Selective Excision of Metastatic Brain Tumors Originating in the Motor Cortex With Preservation of Function, 1209  
Weiner L, *see* Berger AC  
Weiner M, *see* Meyers PA  
Weingard T, *see* Quinn JA  
Weining C, *see* Lehmann J  
Weinstein HJ, *see* Laver JH  
Weintjes MG, *see* Bolaños-Meade J  
Weir L, *see* Panades M  
Weisdorf DJ, *see* Baker KS  
    *see* Pavletic SZ  
Weisenburger D, *see* Lynch HT

## AUTHOR INDEX

- Weiser M, *see* Rengan R  
*see* Schrag D
- Weiser MR, *see* Guillem JG
- Weisman R, *see* Robbins KT
- Weiss GR, *see* McDermott DF  
*see* Poplin EA
- Weiss H, *see* Chang JC
- Weiss HL, *see* Arpino G  
*see* Mohsin SK
- Weissfeld J, *see* Trauth JM
- Weitzel JN, *see* Palomares MR
- Weitzen R, Pfeffer R, Mandel M. Benign Lesions in Cancer Patients. Vitiligo After Radiotherapy for Breast Cancer in a Woman With Depigmentation Disorder, 644
- Weitzman A, *see* Schwartz GK
- Weitzman S, *see* Laver JH
- Welker DA, *see* Witzig TE
- Wellek S, *see* Lehmann J
- Weller M, *see* Wick W
- Wells R, *see* Meyers PA
- Wells WA, *see* Meyer RM
- Welnicka-Jaskiewicz M, *see* Zielinski C
- Welsh TJ, Green RH, Richardson D, Waller DA, O'Byrne KJ, Bradding P. Macrophage and Mast-Cell Invasion of Tumor Cell Islets Confers a Marked Survival Advantage in Non-Small-Cell Lung Cancer, 8959
- Welslau M, *see* Rummel MJ
- Welte K, *see* Seidemann K
- Wen P, *see* Cloughesy TF
- Wen S, *see* Tu S-M  
*see* Wierda W
- Weng L, *see* Schöder H
- Wenz F, *see* Hofheinz R-D  
*see* Thönnessen D
- Wenzel L, Huang HQ, Monk BJ, Rose PG, Cella D. Quality-of-Life Comparisons in a Randomized Trial of Interval Secondary Cytoreduction in Advanced Ovarian Carcinoma: A Gynecologic Oncology Group Study, 5605
- Wernecke K-D, *see* Budach V
- Werner M, *see* Amendola MA  
*see* Avril N
- Werner-Wasik M, *see* Manon R  
*see* Movsas B
- Wessels LFA, *see* Hannemann J
- West DW, *see* Ayanian JZ
- West H, *see* Hirsch FR
- West P, *see* Brown J
- Westberg R, *see* Sederholm C
- Westerman F, *see* Bilke S
- Westin J, *see* Greipp PR
- Weston CL, *see* Ellison DW
- Westra JL, Hofstra RMW, Schaapveld M, Plukker JTM. In Reply (correspondence), 9032
- Westra JL, Schaapveld M, Hollema H, de Boer JP, Kraak MMJ, de Jong D, ter Elst A, Mulder NH, Buys CHCM, Hofstra RMW, Plukker JTM. Determination of *TP53* Mutation Is More Relevant Than Microsatellite Instability Status for the Prediction of Disease-Free Survival in Adjuvant-Treated Stage III Colon Cancer Patients, 5635
- Westra WH, *see* Hoque MO
- Weverling GJ, *see* Aronson DC
- Wexler LH, *see* Huang H-Y
- Weyerbacher A, *see* Kortmansky J
- Weymuller E, *see* Robbins KT
- Whalen SG, *see* DiGiovanna MP
- Whang-Peng J, *see* Chan ATC
- Wharton JT, *see* Frumovitz M
- Wheatley K, *see* Hancock B
- Wheeler J, *see* Kimmick GG
- Wheeler R, *see* Samlowski WE
- Whelan T, Levine M. In Reply (correspondence), 6267
- Whelan T, Levine M. Radiation Therapy and Tamoxifen: Concurrent or Sequential? That Is the Question (editorial), 1
- Whelan TJ, *see* Winer EP
- Whelan TJ, Goss PE, Ingle JN, Pater JL, Tu D, Pritchard K, Liu S, Shepherd LE, Palmer M, Robert NJ, Martino S, Muss HB. Assessment of Quality of Life in MA.17: A Randomized, Placebo-Controlled Trial of Letrozole After 5 Years of Tamoxifen in Postmenopausal Women, 6931
- Whelan TJ, Loprinzi C. Physician/Patient Decision Aids for Adjuvant Therapy, 1627
- Whelan TJ. Use of Conventional Radiation Therapy As Part of Breast-Conserving Treatment, 1718
- White DE, *see* Dudley ME
- White DR, *see* Davidson NE
- White JD, *see* Buchanan DR
- White M, *see* Astrow AB
- White WL, *see* Witzig TE
- Whitlock J, *see* Berg SL
- Whitlock JA, Krailo M, Reid JM, Ruben SL, Ames MM, Owen W, Reaman G. Phase I Clinical and Pharmacokinetic Study of Flavopiridol in Children With Refractory Solid Tumors: A Children's Oncology Group Study, 9179
- Whitman CG, *see* McCaskill-Stevens W
- Whitman SP, *see* Marcucci G
- Whitton J, *see* Castellino SM
- Whitty J, *see* Southey MC
- Wick W, Weller M. How Lymphotoxic Is Dose-Intensified Temozolomide? The Glioblastoma Experience (correspondence), 4235
- Wickerham DL, *see* Mamounas EP
- Wickerman DL, *see* Dunn BK
- Wickrema A, *see* van Besien K
- Widemann BC, *see* Warren KE
- Wieand HS, *see* Sargent DJ
- Wieand HS. Chemotherapy Sensitivity and Response Assays: Are the ASCO Guidelines for Clinical Trial Design Too Restrictive? (correspondence), 3643
- Wieand HS. Randomized Phase II Trials: What Does Randomization Gain? (editorial), 1794
- Wiede T, *see* Ferrari S
- Wiemers C, *see* Lehmann J
- Wiens BL, *see* Vogel CL
- Wierda W, *see* Keating MJ
- Wierda W, O'Brien S, Wen S, Faderl S, Garcia-Manero G, Thomas D, Do K-A, Cortes J, Koller C, Beran M, Ferrajoli A, Giles F, Lerner S, Albitar M, Kantarjian H, Keating M. Chemoimmunotherapy With Fludarabine, Cyclophosphamide, and Rituximab for Relapsed and Refractory Chronic Lymphocytic Leukemia, 4070
- Wierda WG, Kipps TJ, Keating MJ. Novel Immune-Based Treatment Strategies for Chronic Lymphocytic Leukemia, 6325
- Wiernik P, *see* Baker KS
- Wiernik PH, *see* Lynch HT
- Wiggers T, *see* Marijnen CAM  
*see* Peeters KCMJ
- Wiggins C, *see* Florell SR
- Wijermans PW, *see* van Imhoff GW
- Wijnen J, *see* Bian Y  
*see* Stormorken AT
- Wilding G, *see* Liu G  
*see* Rugo HS

- Wilding G, Remington P. Period Analysis of Prostate Cancer Survival (editorial), 407
- Wildt L, *see* Behringer K
- Wileyto EP, *see* Halbert CH
- Wilke H, *see* Stahl M
- Willeke F, *see* Hofheinz R-D
- Willemze R, *see* van Doorn R
- Willet CG, *see* Suntharalingam M
- Willett CG, Boucher Y, Duda DG, di Tomaso E, Munn LL, Tong RT, Kozin SV, Petit L, Jain RK, Chung DC, Sahani DV, Kalva SP, Cohen KS, Scadden DT, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Shellito PC, Mino-Kenudson M, Lauwers GY. Surrogate Markers for Antiangiogenic Therapy and Dose-Limiting Toxicities for Bevacizumab With Radiation Chemotherapy: Continued Experience of a Phase I Trial in Rectal Cancer patients (correspondence), 8136
- Willett CG, Czito BG, Bendell JC, Ryan DP. Locally Advanced Pancreatic Cancer, 4538
- Willett WC, *see* Meyerhardt JA
- Willey J, *see* Bruera E
- Willey S, *see* Peshkin BN
- Williams CI, *see* Frost MH
- Williamson D, Lu Y-J, Gordon T, Sciort R, Kelsey A, Fisher C, Poremba C, Anderson J, Pritchard-Jones K, Shipley J. Relationship Between *MYCN* Copy Number and Expression in Rhabdomyosarcomas and Correlation With Adverse Prognosis in the Alveolar Subtype, 880
- Williamson SK, Crowley JJ, Lara PN Jr, McCoy J, Lau DHM, Tucker RW, Mills GM, Gandara DR. Phase III Trial of Paclitaxel Plus Carboplatin With or Without Tirapazamine in Advanced Non-Small-Cell Lung Cancer: Southwest Oncology Group Trial S0003, 9097
- Willich NA, *see* Koch P
- Wilner S, *see* Madhusudan S
- Wils J, *see* Köhne C-H  
*see* Lutz MP  
*see* Praga C
- Wilschut FA, Timmer-Bonte JN
- Wilsgaard T, *see* Sagstuen H
- Wilson GD, *see* Bentzen SM
- Wilson KS, *see* Sehn LH
- Wilson LD, *see* Floyd SR  
*see* Smith BD
- Wilson LD, Housman D, Smith BD. Merkel Cell Carcinoma: Improved Outcome With the Addition of Adjuvant Therapy (correspondence), 7236
- Wilson P, *see* Shamash J
- Wilson RH, *see* Grem JL
- Wilson W, *see* Robbins KT
- Wilson WH, *see* Kreitman RJ
- Wiltfang J, *see* Warnke PH
- Wiltschke C, *see* Zielinski C
- Windschitl HE, *see* Ma CX
- Winer EP, *see* Burstein HJ  
*see* Krop IE  
*see* Lyman GH  
*see* Meyerhardt JA  
*see* Partridge AH  
*see* Punglia RS
- Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J, Cobleigh MA, Mamounas EP, Goldstein LJ, Whelan TJ, Powles TJ, Bryant J, Perkins C, Perotti J, Braun S, Langer AS, Browman GP, Somerfield MR. American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Status Report 2004, 619
- Winer EP. Optimizing Endocrine Therapy for Breast Cancer (editorial), 1609
- Wingard JR, *see* Andrykowski MA
- Winkler K, *see* Kempf-Bielack B
- Winkler P, *see* Koscielniak E
- Winnie J, *see* Goodin S
- Winqvist E, *see* Canil CM  
*see* Hotte SJ
- Winter JN, *see* Meyer RM
- Winter K, *see* Lawton CA
- Winters M, *see* Petricoin EF III
- Wirth LJ, Haddad RI, Lindeman NI, Zhao X, Lee JC, Joshi VA, Norris CM Jr, Posner MR. Phase I Study of Gefitinib Plus Celecoxib in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck, 6976
- Wirths S, *see* Lengerke C
- Wischnowsky M, *see* Schmid P
- Wiseman GA, *see* Juweid ME
- Wisoff JH, *see* Beebe DW
- Wist E, *see* Mykletun A  
*see* Sagstuen H
- Wistuba II, *see* Travis WD
- Wittekind C, *see* Rödel C
- Witzig TE, *see* Czuczman MS  
*see* Kumar S  
*see* Martin WG
- Witzig TE. Current Treatment Approaches for Mantle-Cell Lymphoma, 6409
- Witzig TE, Geyer SM, Ghobrial I, Inwards DJ, Fonseca R, Kurtin P, Ansell SM, Luyun R, Flynn PJ, Morton RF, Dakhil SR, Gross H, Kaufmann SH. Phase II Trial of Single-Agent Temsirolimus (CCI-779) for Relapsed Mantle Cell Lymphoma, 5347
- Witzig TE, Silberstein PT, Loprinzi CL, Sloan JA, Novotny PJ, Mailliard JA, Rowland KM, Alberts SR, Krook JE, Levitt R, Morton RF. Phase III, Randomized, Double-Blind Study of Epoetin Alfa Compared With Placebo in Anemic Patients Receiving Chemotherapy, 2606
- Witzig TE, Vukov AM, Habermann TM, Geyer S, Kurtin PJ, Friedenberg WR, White WL, Chalchal HI, Flynn PJ, Fitch TR, Welker DA. Rituximab Therapy for Patients With Newly Diagnosed, Advanced-Stage, Follicular Grade I Non-Hodgkin's Lymphoma: A Phase II Trial in the North Central Cancer Treatment Group, 1103
- Wlodarska I, *see* De Paepe P
- Wöhler S, *see* Raderer M
- Wojtukiewicz MZ, *see* Vogel CL
- Wolchok JD, *see* Su YB
- Wold L, *see* Meyers PA
- Wolf IH, *see* Richtig E
- Wolf MK, *see* Cella D
- Wolf MS, Fitzner KA, Powell EF, McCaffrey KR, Pickard AS, McKoy JM, Lindenberg J, Schumock GT, Carson KR, Ferreira MR, Dolan NC, Bennett CL. Costs and Cost Effectiveness of a Health Care Provider-Directed Intervention to Promote Colorectal Cancer Screening Among Veterans, 8877
- Wolfe J, *see* Mack JW
- Wolff AC, *see* Lyman GH  
*see* Winer EP
- Wolffenbutter BHR, *see* Nuver J
- Woll MM, *see* Peoples GE
- Wolmark N, *see* Mamounas EP  
*see* O'Connell MJ  
*see* Sargent DJ  
*see* Tan-Chiu E
- Womer R, *see* Meyers PA
- Wong AF, *see* Russo C
- Wong C-Y, *see* Chan W-M

AUTHOR INDEX

Wong FC, *see* Tu S-M  
 Wong H, *see* Chang JC  
     *see* Mok TSK  
 Wong HB, *see* Wee J  
 Wong LC, *see* Chan YW  
 Wong N, *see* Gross CP  
 Wong WD, *see* Guillem JG  
     *see* Rengan R  
 Wood BJ, *see* Pingpank JF  
 Wood CG, *see* Patard J-J  
 Wood L, *see* Mekhail TM  
 Wood WG, *see* Johnston DL  
 Woods JE, *see* Frost MH  
 Woods ML, *see* Ewer MS  
 Wooldridge JE, *see* Juweid ME  
     *see* Swenson WT  
 Woolf S, *see* Sartor CI  
 Woolfrey AE, *see* Baron F  
 Wooten EC, *see* Chang JC  
 Worah S, *see* Yao JC  
 Worden FP, Taylor JMG, Biermann JS, Sondak VK, Leu M, Chugh R, McGinn CJ, Zalupski MM, Baker LH. Randomized Phase II Evaluation of 6 g/m<sup>2</sup> of Ifosfamide Plus Doxorubicin and Granulocyte Colony-Stimulating Factor (G-CSF) Compared With 12 g/m<sup>2</sup> of Ifosfamide Plus Doxorubicin and G-CSF in the Treatment of Poor-Prognosis Soft Tissue Sarcoma, 105  
 Workman P, *see* Banerji U  
 Workman P, Johnston PG. Genomic Profiling of Cancer: What Next? (editorial), 7253  
 Wörmann B, *see* Lenz G  
 Wray L, *see* DeMichele A  
 Wright J, *see* Cloughesy TF  
     *see* Cortes J  
     *see* Hamilton AL  
     *see* O'Connor OA  
 Wright J, Fairclough L, Manzo J, Phippard L, Smuck B, Lacourciere J. The Metrics of Clinical Trials (correspondence), 1589  
 Wright WE, *see* Ayanian JZ  
 Wu J, *see* Gianni L  
 Wu LYF, *see* Chan YW  
 Wu S, Geßner R, Taube T, von Stackelberg A, Henze G, Seeger K. Expression of *Interleukin-10* Splicing Variants Is a Positive Prognostic Feature in Relapsed Childhood Acute Lymphoblastic Leukemia, 3038  
 Wu S-X, *see* Zhang L  
 Wu TT, *see* Ajani JA  
     *see* Yao JC  
 Wu X, *see* Leibovici D  
     *see* Spitz MR  
 Wun T, *see* Lara PN Jr  
 Wunder JS, Gokgoz N, Parkes R, Bull, Eskandarian S, Davis AM, Beauchamp CP, Conrad EU, Grimer RJ, Healey JH, Malkin D, Mangham DC, Rock MJ, Bell RS, Andrulis IL. TP53 Mutations and Outcome in Osteosarcoma: A Prospective, Multicenter Study, 1483  
 Wunderlich JR, *see* Dudley ME  
 Wündisch T, Thiede C, Morgner A, Dempfle A, Günther A, Liu H, Ye H, Du M-Q, Kim TD, Bayerdörffer E, Stolte M, Neubauer A. Long-Term Follow-up of Gastric MALT Lymphoma After *Helicobacter Pylori* Eradication, 8018  
 Wust P, *see* Budach V  
 Wyatt GE, Loeb TB, Desmond KA, Ganz PA. Does a History of Childhood Sexual Abuse Affect Sexual Outcomes in Breast Cancer Survivors? 1261  
 Wynne C, *see* Smith MR

X

Xavier AC, *see* Hirsch FR  
 Xia W, *see* Spector NL  
 Xie D, *see* Herbst RS  
 Xie K, *see* Yao JC  
 Xing Y, *see* Cormier JN  
 Xu L, *see* Lee AWM  
 Xu R, *see* Hoang T  
 Xu X, *see* Gimotty PA  
 Xu Y, *see* Bueso-Ramos C

Y

Yabe H, *see* Igarashi S  
 Yachnis AT, *see* Tu P-h  
 Yagyu T, *see* Matsuzaki H  
 Yahalom J, *see* Noy A  
 Yalamanchili A, *see* Lu C  
 Yalçin B, *see* Utkan G  
 Yalçin S, *see* Utkan G  
 Yamada J, *see* D'Adamo DR  
 Yamaguchi K, *see* Kanazawa S  
 Yamamoto K, *see* Mizutani Y  
 Yamamoto N, *see* Takano T  
 Yamamoto N, Tamura T, Murakami H, Shimoyama T, Nokihara H, Ueda Y, Sekine I, Kunitch H, Ohe Y, Kodama T, Shimizu M, Nishio K, Ishizuka N, Saijo N. Randomized Pharmacokinetic and Pharmacodynamic Study of Docetaxel: Dosing Based on Body-Surface Area Compared With Individualized Dosing Based on Cytochrome P450 Activity Estimated Using a Urinary Metabolite of Exogenous Cortisol, 1061  
 Yamamoto S, *see* Takano T  
 Yamano T, *see* Yokote T  
 Yamshchikov G, *see* Slingsluff CL Jr  
 Yan PS, *see* van Doorn R  
 Yang C-Y, *see* Chen C-N  
 Yang DY, *see* Vallböhmer D  
 Yang E, *see* Wee J  
 Yang I, *see* Eschrich S  
 Yang JC, *see* Attia P  
     *see* Dudley ME  
 Yang P-C, *see* Chen JJW  
 Yang SX, *see* Karlin JD  
     *see* Low JA  
 Yankelevitz D, *see* Travis WD  
 Yannucci J, *see* Floyd SR  
 Yao JC, *see* Ajani JA  
 Yao JC, Tseng JF, Worah S, Hess KR, Mansfield PF, Crane CH, Schnirer II, Reddy S, Chiang SS, Najam A, Yu C, Giacco GG, Xie K, Wu T-T, Feig BW, Pisters PWT, Ajani JA. Clinicopathologic Behavior of Gastric Adenocarcinoma in Hispanic Patients: Analysis of a Single Institution's Experience Over 15 Years, 3094  
 Yao M, Funk GF, Goldstein DP, DeYoung BR, Graham MM. Benign Lesions in Cancer Patients. Sarcoidosis After Chemoradiation for Head and Neck Cancer, 640  
 Yao P-L, *see* Chen JJW  
 Yap J, *see* Chuba PJ  
 Yarnold JR, *see* Bentzen SM  
 Yarrow PM, *see* Vardy J  
 Yasui Y, *see* Bowers DC  
 Yatabe Y, *see* Mitsudomi T  
 Yataghene K, *see* Kushner BH  
 Yates P, Aranda S, Hargraves M, Mirolo B, Clavarino A, McLachlan SA, Skerman H. Randomized Controlled Trial of an Educational Interven-

AUTHOR INDEX

tion for Managing Fatigue in Women Receiving Adjuvant Chemotherapy for Early-Stage Breast Cancer, 6027

Yau K, *see* Hon C

Yau TK, *see* Lee AWM

Yavuzsen T, Davis MP, Walsh D, LeGrand S, Lagman R. Systematic Review of the Treatment of Cancer-Associated Anorexia and Weight Loss, 8500

Ychou M, *see* Ducreux M  
*see* Kramer A

Ye D, *see* Chen S

Ye H, *see* Wündisch T

Ye J, *see* Ryan QC

Yeap BY, *see* Mamon HJ

Yeatman TJ, *see* Eschrich S

Yeckes H, *see* Brown JR

Yee H, *see* Hamilton AL

Yeh BM, *see* Liu G

Yeh E, *see* Taghian AG

Yeh R, *see* Soetikno R

Yeilding AL, *see* Grote T

Yellin M, *see* Sanderson K

Yellin MJ, *see* Attia P

Yellowlees A, *see* Evans TRJ

Yeo CJ, *see* Hansel DE

Yeo W, *see* Mok TSK

Yeshaya A, *see* Stojadinovic A

Yeung H, *see* Akhurst T

Yeung HWD, *see* Schöder H

Yi Q-L, *see* Mar Fan HG

Yi S, *see* Kortmansky J

Yiannoutsos C, *see* Li J

Yildirim Y, Akcali Z, Ozyilkan O. Controversy in Folinic Acid Administration After Fluorouracil (correspondence), 3862

Yokomise H, *see* Huang C-I

Yokote T, Akioka T, Hara S, Oka S, Miyamoto H, Yamano T, Sugino M, Tsuji M, Hanafusa T. Patients With Malignancy Requiring Urgent Therapy. Bilateral Renal Swelling Induced by Adult T-Cell Leukemia/Lymphoma, 6793

Yoo BC, *see* Rhee J-Y

Yoo GH, *see* Urba SG

Yoon YS, *see* Oh SW

Yoshida T, *see* Takano T

Yost KJ, *see* Ayanian JZ

Yothers G, *see* Mamounas EP  
*see* Tan-Chiu E

Younes A, *see* Czuczman MS  
*see* Goy A  
*see* Horning SJ  
*see* Khouri IF  
*see* Romaguera JE

Younes M. Is Immunohistochemistry for Epidermal Growth Factor Receptor Expression a Poor Predictor of Response to Epidermal Growth Factor Receptor-Targeted Therapy? (correspondence), 923

Young AM, *see* Bower M

Young DC, *see* Eisenbeis CF  
*see* Raval A

Young JP, *see* Southey MC

Young L, *see* Petricoin EF III

Young NA, *see* Austin RM

Young RC, *see* Brady MF

Young S, *see* Chang J

Younger J, *see* Burstein HJ

Yu C, *see* Yao JC

Yu D, *see* Jones EL

Yu H, *see* Baker KS

Yu L, *see* Chen S

Yu M, *see* Taylor JMG

Yu O, *see* Herrinton LJ

Yu S, *see* Mok TSK

Yuan A, *see* Chen JJW

Yubero A, *see* Feliu J

Yun J, *see* Vallböhmer D

Yung A, *see* Cloughesy TF

Z

Zach O, Lutz D. Mammaglobin Remains a Useful Marker for the Detection of Breast Cancer Cells in Peripheral Blood (correspondence), 3160

Zacharia BE, *see* Komotar RJ

Zaentz SD, *see* Stadler WM

Zahrieh D, *see* Colleoni M

Zahurak ML, *see* Santillan A

Zain J, *see* Molina A

Zakowski M, *see* Travis WD

Zallio F, *see* Corradini P

Zaloudek CJ, *see* Hansen EK  
*see* Powell CB

Zalupski MM, *see* Chugh R  
*see* Worden FP

Zambetti M, *see* Gianni L

Zamora P, *see* Espinosa E

Zampino G, *see* DePas T

Zampino MG, *see* Louvet C

Zanaboni F, *see* Sessa C

Zander AR, *see* Baker KS

Zanetti I, *see* Carli M

Zangari M, *see* Talamo G

Zaniboni A, *see* Louvet C

Zapatero A, Valcárcel F, Calvo FA, Algás R, Béjar A, Maldonado J, Villá S. Risk-Adapted Androgen Deprivation and Escalated Three-Dimensional Conformal Radiotherapy for Prostate Cancer: Does Radiation Dose Influence Outcome of Patients Treated With Adjuvant Androgen Deprivation? A GICOR Study, 6561

Zaretsky L, *see* Noy A

Zaslavsky AM, *see* Ayanian JZ

Zatloukel P, *see* Giaccone G

Zattoni F, *see* Boccardo F.

Zee B, *see* Mok TSK

Zeiser R, Hackanson B, Bley TA, Finke J, Bertz H. Unusual Cases in Multiple Myeloma and a Dramatic Response in Metastatic Lung Cancer. Multiple Myeloma Relapse Presenting As Malignant Pericardial Effusion, 230

Zelevsky MJ, Ben-Porat L, Scher HI, Chan HM, Fearn PA, Fuks ZY, Liebel SA, Venkatraman ES. Outcome Predictors for the Increasing PSA State After Definitive External-Beam Radiotherapy for Prostate Cancer, 826

Zelenetz AD, *see* Fisher RI  
*see* Noy A  
*see* O'Connor OA

Zeleniuch-Jacquotte A, *see* Hamilton AL

Zelger B, *see* Richtig E

Zell JA, Ou S-HI, Ziogas A, Anton-Culver H. Epidemiology of Bronchioloalveolar Carcinoma: Improvement in Survival After Release of the 1999 WHO Classification of Lung Tumors, 8396

Zeltzer LK, *see* Castellino SM

Zemplén B, *see* Tímár J

Zetes-Zanatta L, *see* Brundage M

Zhai J, *see* Ziari M

Zhai S, *see* Pingpank JF

Zhang B, *see* Badros AZ

## AUTHOR INDEX

- Zhang DD, *see* Pratt DA
- Zhang G, *see* Ezzo J
- Zhang H-T, Zhao J, Zheng S-Y, Chen X-F. Is *TGFBR1\*6A* Really Associated With Increased Risk of Cancer? (correspondence), 7743
- Zhang J, *see* Knox JJ
- Zhang L, Zhao C, Peng P-J, Lu L-X, Huang P-Y, Han F, Wu S-X. Phase III Study Comparing Standard Radiotherapy With or Without Weekly Oxaliplatin in Treatment of Locoregionally Advanced Nasopharyngeal Carcinoma: Preliminary Results, 8461
- Zhang MH, *see* Bissett D
- Zhang T, *see* Nayak S
- Zhang W, *see* Vallböhmer D
- Zhang YR, *see* Eberhard DA
- Zhao C, *see* Zhang L
- Zhao J, *see* Zhang H-T
- Zhao M, *see* Rudek MA
- Zhao S, *see* Le Q-T
- Zhao X, *see* Wirth LJ
- Zhao Y, *see* Chen S
- Zhao Z, *see* Huang H-Y
- Zheng M, *see* Coleman RE  
*see* Smith MR
- Zheng S-Y, *see* Zhang H-T
- Zhou P, Chen M-H, McLeod D, Carroll PR, Moul JW, D'Amico AV. Predictors of Prostate Cancer-Specific Mortality After Radical Prostatectomy or Radiation Therapy, 6992
- Zhou X, *see* Clayman GL
- Zhu AX, *see* Thomas MB  
*see* Willett CG
- Zia MI, Siu LL, Pond GR, Chen EX. Comparison of Outcomes of Phase II Studies and Subsequent Randomized Control Studies Using Identical Chemotherapeutic Regimens, 6982
- Ziari M, Sonpavde G, Shen S, Teh BS, Shu T, Lerner SP. Patients With Unusual Bladder Malignancies and a Rare Cause of Splenomegaly. Small-Cell Carcinoma of the Urinary Bladder, 4458
- Ziari M, Sonpavde G, Shen S, Zhai J, Teh BS, Lerner SP. Patients With Unusual Bladder Malignancies and a Rare Cause of Splenomegaly. Rhabdomyosarcoma of the Urinary Bladder in an Adult, 4459
- Ziegler H, *see* Arndt V
- Ziegler M, *see* Powell CB
- Zielinski C, Beslija S, Mrcsic-Krmpotic Z, Welnicka-Jaskiewicz M, Wiltschke C, Kahan Z, Grgic M, Tzekova V, Inbar M, Cervek J, Chernoziemsky I, Szanto J, Spanik S, Wagnerova M, Ghilezan N, Pawlega J, Vrbanec D, Khamtsov D, Soldatenkova V, Brodowicz T. Gemcitabine, Epirubicin, and Paclitaxel Versus Fluorouracil, Epirubicin, and Cyclophosphamide As First-Line Chemotherapy in Metastatic Breast Cancer: A Central European Cooperative Oncology Group International, Multicenter, Prospective, Randomized Phase III Trial, 1401
- Zielinski CC, *see* Filipits M  
*see* Raderer M
- Zilembo N, *see* Bajetta E
- Zimmerman T, *see* van Besien K
- Zimmermann A, *see* von der Maase H
- Zimmermann M, *see* Seidemann K
- Zinkewich-Péotti K, *see* Jayson GC
- Zinner NR, *see* Smith MR
- Zinzindohoué F, *see* Lièvre A
- Ziogas A, *see* Zell JA
- Ziotopoulos P, *see* Georgoulas V
- Zisman A, *see* Patard J-J
- Zivanovic O, *see* Tasci S
- Zola P, Gadducci A, *see* Buda A
- Zone JJ, *see* Florell SR
- Zorzi D, *see* Dômont J
- Zoubek A, *see* Kempf-Bielack B
- Zoutman WH, *see* van Doorn R
- Zucca E, *see* Abrey LE  
*see* Bertoni F  
*see* Martrinelli G
- Zucca E, Bertoni F. Another Piece of the MALT Lymphomas Jigsaw, 4832
- Zucker J-M, *see* Guibout C
- Zuley M, *see* Stojadinovic A
- Zwiebel J, *see* Badros AZ  
*see* Marcucci G  
*see* Ryan QC